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Resistance to chemotherapy is a major obstacle to the successful treatment of 
breast cancer. In order to optimise treatment regimens and identify novel drug 
targets, it is important first to understand the molecular mechanisms that can 
lead to chemoresistance. In this thesis, I have investigated mRNA and miRNA 
expression profiles of tumour samples taken from patients with oestrogen 
receptor positive primary breast cancers treated with neoadjuvant 
chemotherapy (NAC) who displayed only a partial response. Samples were 
analysed before and after chemotherapy treatment. Gene expression profiles 
post-NAC suggested that the MAPK and PI3K-AKT pathways were activated. 
MiRNA expression profiles demonstrated three miRNAs that were consistently 
deregulated post-NAC. Further in vitro studies revealed that the increased 
expression of miR-26b and miR-195 contributed to significant increases in 
chemoresistance (p<0.05). 
Pulldown assays using mimics of miR-26b and miR-195 as bait, together with 
RNA-Seq, led to the identification of possible mRNA targets of these two 
miRNAs. Further in vitro studies confirmed REEP4 and SEMA6D as targets of 
miR-26b and miR-195 respectively. As targets of these miRNAs, decreased 
expression of these mRNAs would be expected to contribute to 
chemoresistance. Chemosensitivity assays suggested a consistent but not 
significant increase in resistance when REEP4 was silenced, and a significant 
increase in resistance when SEMA6D was silenced (p<0.05). Investigations 
were performed to determine whether the expression of either of the 
corresponding proteins had any prognostic value. Results suggested that 
REEP4 expression was significantly related to disease free survival, although 
the precise relationship was unclear. 
The effect of increased expression of the xenobiotic drug pump BCRP induced 
by endocrine therapy on chemoresistance was also investigated. Results 
suggested that increased BCRP expression led to significant increases in 
chemoresistance (p<0.05), thus suggesting that a treatment regimen of 
endocrine therapy followed by chemotherapy may not be beneficial. 
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I have identified in this thesis several molecular changes that are induced by 
chemotherapy or endocrine therapy that contribute to chemoresistance, 
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Chapter 1: Introduction 
1.1 Introduction to breast cancer 
1.1.1 Incidence of breast cancer 
Breast cancer is the second-leading cause of cancer death in women 
worldwide after lung cancer, and accounted for a quarter of all cancers 
diagnosed in women in 2012 worldwide (Ferlay et al., 2015). It is currently 
estimated that one in seven women in the UK will be diagnosed with breast 
cancer sometime in their lifetime, amounting to approximately 50 000 
diagnoses per year (CRUK.Available:https://www.cancerresearchuk.org/health-
professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/risk-
factors#heading-Zero). However, with ongoing research into novel treatments 
and the advancement of technologies that allow earlier detection of cancer, a 
greater proportion of patients are surviving longer post-diagnosis. This is 
reflected in the fact that female breast cancer death rates (European age-
standardised) have fallen by 40% in the UK since the mid-1980s (CRUK. 
Available: https://www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/breast-cancer/risk-factors#heading-Zero). 
1.1.2 Classifying breast tumours 
Breast tumours are classified using a variety of systems in order to assess the 
extent to which they have spread, their relative growth rates, their aggressive 
potential, and to some extent the likelihood of them responding to specific 
therapies.  
The extent to which the cancer has progressed or spread is commonly 
classified using the TNM staging system (Classification of Malignant Tumours) 
(Gospodarowicz et al., 2017). The ‘T’ indicates the size of the primary tumour 
and the extent of invasion of surrounding tissues (if any). The ‘N’ indicates if 
and how many lymph nodes are involved and the ‘M’ indicates whether any 
distant metastasis has occurred and if so, to what extent. Each classification 
and their stages are shown in Table 1.1.1. 
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Table 1.1.1: Parameters and classifications used to classify breast 
tumours (Senkus et al., 2015, Giuliano et al., 2017) 
Parameter Classification Description 
T 
Tis Carcinoma in situ 
T1, T2, T3, T4 Size of primary tumour (T4 is the largest) 
N 
N0 No evidence of regional lymph node 
metastasis 
N1-3 Extent/location of metastases present in lymph 
nodes (N3 is the largest number of nodes, or 
more distant nodes) 
M 
M0 No distant metastasis 
M1 Metastasis to distant organs 
Depending on their TNM classification, tumours are subsequently divided into 
stages. These categories give a summarised overview of the extent of the 
disease and are shown in Table 1.1.2. 
Table 1.1.2: Stages of breast tumours (Senkus et al., 2015) 
Stage TNM classifications 
0 Tis N0 M0 
IA T1 N0 M0 
IB T0/1 N1 M0 
IIA T0/1 N1 M0 
T2 N0 M0 
IIB T2 N1 M0 
T3 N0 M0 
IIIA T0/1/2 N2 M0 
T3 N1/2 M0 
IIIB T4 N0/1/2 M0 
IIIC T0/1/2/3/4 N3 M0 
IV T0/1/2/3/4 N1/2/3 M1 
Tumours are also classified according to their grade. This is based on the 
appearance of the tumour cells. Tumours are given grades of 1, 2 or 3, with ‘1’ 
designated to tumours where cells appear to be relatively normal, ‘2’ 
designated to tumours where cells appear to be slightly bigger than normal and 
vary more in shape, and ‘3’ designated to tumours where cells are very 
different to normal cells due to poor differentiation (Bloom and Richardson, 
1957). It has been noted that tumours with lower grades have better outcomes 
3 
 
than higher grade tumours, which tend to recur and metastasise much earlier 
after initial diagnosis (Rakha et al., 2010). 
Growing evidence has shown that earlier detection of cancer when tumours are 
of lower stages leads to better outcomes than late diagnoses (Hiom, 2015). 
This is likely due to fewer incidences of metastasis and involvement of lymph 
nodes at earlier stages of the disease (Saadatmand et al., 2015).  
1.1.2.1 Molecular subtypes of breast cancer and associated survival 
statistics 
Breast cancer is a heterogeneous disease that can be further classified into 
several different molecular subtypes. The subtypes that are used clinically were 
initially defined using hierarchical clustering of the gene expression profiles of 
breast tumours (Perou et al., 2000, Sorlie et al., 2001), but in clinical practice 
this classification is made using surrogate markers, based around three 
receptors (Onitilo et al., 2008). The expression of these receptors is determined 
at diagnosis and, importantly, partially determines what treatment regimens 
would be the most effective (see section 1.2). The three receptors used by 
pathologists to determine subtype are the oestrogen receptor (ER), the 
progesterone receptor (PR) and the human epidermal growth factor receptor 2 
(HER2). The presence and absence of the various combinations of expression 
of these receptors largely determines into which subtype of breast cancer the 
tumour is defined (Brenton et al., 2005, Voduc et al., 2010), although the 
proliferation marker Ki67 is also sometimes used (Hugh et al., 2009, Keam et 
al., 2011). 
The four main subtypes of breast cancer used clinically in the UK are luminal A, 
luminal B, HER2 and triple negative, sometimes referred to as basal, although 
it should be noted that the terms actually describe different groups of tumours 
(Brenton et al., 2005, Onitilo et al., 2008, Voduc et al., 2010). A summary of 
marker expression for each subtype is shown in Table 1.1.3. In brief, as the 
name suggests triple negative breast tumours do not express any of the three 
receptors, HER2 subtype breast tumours only express the HER2 receptor, 
luminal B breast tumours express ER and may express PR and HER2 




Table 1.1.3: Molecular subtype classifications of breast cancers showing 






ER PR HER2 
Luminal A + +/- - Low 
Luminal B + +/- +/- High 
Triple Negative - - - High 
HER2 - - + High 
The prevalence of each subtype of breast cancer is largely weighted towards 
those expressing the oestrogen receptor, therefore luminal A and luminal B 
subtypes, with 65-75% of all breast cancers being diagnosed expressing this 
receptor (Voduc et al., 2010, Ignatiadis and Sotiriou, 2013). Breast cancers that 
express the HER2 receptor (both the HER2 subtype and HER2 positive luminal 
B subtypes) account for roughly 15% of all breast cancers (Loibl and Gianni, 
2017), and triple negative breast cancers account for the remaining proportion. 
Long-term survival and risk of metastasis are just some of the factors that differ 
between these subtypes. Response to therapies also differs between subtypes 
(Rouzier et al., 2005). 
Different molecular subtypes of breast cancer are associated with different 
prognoses. Despite the fact that luminal A and luminal B subtypes both largely 
express the ER, the former generally has a better prognosis associated with it 
than the latter. Luminal A breast cancers have a ten-year survival rate of 
roughly 85% whereas luminal B breast cancers have a ten-year survival rate of 
just over 65% (Haque et al., 2012). However, luminal A breast cancers have 
been noted to have a tendency to lay dormant for many years and can recur 
beyond a decade after initial diagnosis (Di Leo et al., 2012, Haque et al., 2012). 
It is therefore important for this particular subgroup of patients to be carefully 
monitored for any recurrences well beyond the first five years post-initial 
diagnosis. Luminal A breast tumours generally have higher expression of ER 
related genes whereas luminal B tumours tend to have higher expression of 
genes involved in cell proliferation (Brenton et al., 2005). 
Basal-like breast cancers are associated with an initial poor prognosis as they 
typically have an aggressive nature and suffer relapses rapidly (Toft and Cryns, 
2010). However, survival rates ten years post-initial diagnosis tend to stabilise 
at roughly 75% in this subtype with later recurrences being relatively rare 
5 
 
(Haque et al., 2012). HER2 positive breast cancers are similar to triple negative 
breast cancers in that they are also associated with an initial poor diagnosis 
and aggressive nature (Voduc et al., 2010). Over-expression of this receptor 
correlates with numerous poor prognostic features including large tumour size 
and high nuclear grade (Nielsen et al., 2009). Ten-year survival rates of HER2-
positive breast cancer are just below 65%. However, unlike with basal-like 
breast cancer, the survival probability of the HER2 molecular subtype continues 
to decrease beyond ten years post-initial diagnosis (Haque et al., 2012). The 
poor prognoses associated with ER negative tumour subtypes has been 
hypothesised to be linked to their resistance to the ER-targeted treatments that 
are routinely used with ER positive tumours (Dai et al., 2015). 
1.2 Therapies in the treatment of Breast Cancer 
1.2.1 Local and systemic therapies are available for the treatment of 
breast cancer 
There are multiple treatment options available for primary breast cancer. 
However, viable treatment options for individual patients depend on a number 
of factors. The majority of treatment strategies include surgery to remove the 
primary tumour (Miller et al., 2016). This involves either breast conserving 
surgery (BCS), where a minimal amount of breast tissue is removed including 
the tumour mass and a margin of normal tissue (Park et al., 2000), or a 
mastectomy in which all of the breast tissue is removed (Shimkin et al., 1961). 
However, unfortunately, not all patients are eligible for surgery for a number of 
reasons. Some of these reasons include frailty, particularly in elderly patients 
who would not be able to tolerate the stress of undergoing a major procedure, 
and comorbidities that may cause an increased risk to the procedure (Chou et 
al., 2016, Ethun et al., 2017).  
Another available treatment option, almost always used in conjunction with 
surgery is radiotherapy. This involves the use of accelerated particles, usually 
photons, to create therapeutic, high energy beams. The energy and the focus 
of these beams are calculated to target the site of the tumour mass, whilst 
minimising the reach of these beams to surrounding normal tissue (Pereira et 
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al., 2014). The aim of post-surgery radiotherapy is to target any tumour cells 
remaining within the breast or local tissues that were outside the main tumour 
mass that was resected. The resultant ionising radiation causes clusters of 
DNA damage sites, in particular double strand breaks. These clusters refer to 
multiple sites of damage within one or two helical turns of DNA. Sites of DNA 
damage clusters are more difficult to repair than naturally occurring DNA 
damage sites (Lomax et al., 2013). Successful radiotherapy causes clusters of 
DNA damage to such an extent that cells are unable to repair the damage and 
apoptosis is induced (Roos and Kaina, 2013). Less successful radiotherapy 
causes clusters of DNA damage such that cell cycle arrest is induced in order 
to allow the sites of DNA damage to be repaired (Wang et al., 2000). A 
disadvantage of using radiotherapy in the treatment of breast cancer is the 
associated increased risk of toxicities that sometimes do not appear until over 
15 years post-treatment (Poortmans, 2013). The most concerning toxicity that 
does not appear until many years later is cardiac toxicity. Studies have shown 
that ionising radiation used in the treatment of breast cancer also exposes the 
heart to this radiation. This exposure increases the rate of subsequent ischemic 
heart disease. It was also shown that this increased rate was proportional to 
the mean dose of ionising radiation to which the heart was exposed (Darby et 
al., 2013). 
A third treatment option is the use of systemic therapies, also often used in 
conjunction with surgery. The advantage of this treatment type is that it is not 
targeted to a specific region of the body and is therefore able to target cancer 
cells that have left the local environs of the primary tumour as well, in particular 
sub-clinical micro-metastases. Targeting these cells, if present, is critical since 
it is the full metastatic recurrences that grow from these cells that lead to 
patient deaths in almost all cases. There are several different types of systemic 
therapies routinely used for the treatment of primary breast cancer. The type 
used depends on a number of factors including the molecular subtype of the 
tumour (Higgins and Baselga, 2011), and the overall health of the patient 
(Barroso-Sousa et al., 2016). I have divided the relevant systemic therapies 
into endocrine therapy, HER2-targeted therapy, cytotoxic chemotherapy and 




Systemic therapies are also typically used in conjunction with radiotherapy with 
or without surgery (Miller et al., 2016). The various combinations of treatment 
options that can be used in the treatment of breast cancer partly depend on 
stage, with lower stage tumours more frequently being treated by local 
treatments alone, while increasing proportions of patients with the higher stage 
tumours receive systemic treatments in addition. These are the proportions of 
patients treated with different combinations of therapies, broken down by stage 
- according to the National Cancer Data Base statistics from 2013 (Miller et al., 
2016); of all patients with either stage I or II breast cancer, the largest 
proportion (34%) underwent BCS and ionising radiation with no systemic 
therapy. The next two treatment options of equal proportions (17%) were BCS 
with both ionising radiation and systemic therapy and mastectomy alone. In 
contrast, of patients with stage III breast cancer, nearly 50% underwent 
mastectomies with both ionising radiation and systemic therapy. The next two 
largest proportions of patients were treated with BCS and both ionising 
radiation and systemic therapy (15%) and a mastectomy and systemic therapy 
(13%). Patients with stage IV breast cancer usually do not undergo surgery as 
distant metastasis has already occurred, therefore surgery is often not thought 
to have any overall benefits (Blanchard et al., 2008). Therefore, the largest 
proportion of patients (48%) receive ionising radiation and/or systemic therapy. 
The next largest proportion of patients (28%) did not receive any treatment, 
likely due to the conditions indicating no benefits would be gained from any 
treatments. As these statistics indicate, systemic therapies are a major 
component of therapy regimens in the treatment of breast cancer and have the 
advantage of being able to reach all areas of the body, unlike ionising radiation.  
1.2.2 Systemic therapies in the treatment of breast cancer 
1.2.2.1 Endocrine therapy 
Endocrine therapy is a form of targeted systemic therapy that can be used to 
treat breast cancer by targeting the oestrogen responsive component of 
tumours. This means that endocrine therapy can only be used to treat a subset 
of breast cancers – the luminal A and B breast cancers that express the 
oestrogen receptor (Table 1.1.3). It is important to note, however, that 
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endocrine therapies are not always used alone to treat these subtypes of 
breast cancer, since these can also be treated with non-targeting, cytotoxic 
chemotherapies (see section 1.2.2.3) (Colleoni and Montagna, 2012). 
However, some of the criteria that are taken into consideration when making 
the choice concerning whether to include chemotherapy with (or – rarely – 
instead of) endocrine therapy is the patients’ health and choice. Endocrine 
therapies are more well tolerated than chemotherapies and so endocrine 
therapies are sometimes the only appropriate treatment option available for 
patients who are frail and/or elderly (Barroso-Sousa et al., 2016). 
There are multiple classes of endocrine therapies available for the treatment of 
breast cancer. Anti-oestrogens, also known as selective oestrogen receptor 
mediators (SERMs), such as tamoxifen block the ER (Figure 1.2.1), thus 
preventing oestrogen from binding and activating the receptor (Nass and 
Kalinski, 2015). Tamoxifen has long been used to treat ER positive breast 
cancers in both premenopausal and postmenopausal women (MacCallum et 
al., 2000, Davies et al., 2011, Dowsett et al., 2015), and trials have even shown 
that breast cancer incidence is decreased in healthy women with a high risk of 
developing breast cancer that take tamoxifen (Rutqvist et al., 1995, Kisanga et 
al., 2004, Cuzick et al., 2015). However, there are several worries associated 
with the use of this drug. Several studies have shown that whilst tamoxifen can 
be used successfully to treat ER positive breast cancers, patients who have 
been administered this treatment also have an increased risk of developing 
second primary cancers, most notably endometrial cancer (Curtis et al., 1996, 
Bernstein et al., 1999). There has also been a suggestion that tamoxifen may 
increase the risk of developing gastrointestinal cancers (Rutqvist et al., 1995). It 
is thought that this increased risk is due to tamoxifen having partial oestrogenic 
effects rather than anti-oestrogenic effects in specific tissues including in the 
endometrium (Shang, 2006). 
A second drug that can be used to treat ER positive breast cancers is 
fulvestrant, a selective oestrogen receptor degrader (SERD) (Figure 1.2.1) 
(McDonnell et al., 2015). As with tamoxifen and other SERMs, fulvestrant 
competitively binds the ER, however it has a much higher binding affinity to the 
ER than tamoxifen (89% that of oestradiol (the prototypical endogenous ligand) 
vs 2.9% that of oestradiol respectively) (Osborne et al., 2004). Tamoxifen binds 
9 
 
to the ER and induces a conformational change, reducing the ability of the 
receptor to interact with coactivators. However, alterations in the cell such as 
increased expression of these coactivators can lead to the inhibition by 
tamoxifen being overcome and activation of the ER to occur (McDonnell and 
Wardell, 2010). Fulvestrant however, accelerates the degradation of ER protein 
without affecting ER transcript levels, ultimately preventing ER function 
influencing oncogenesis (Nicholson et al., 1995, Osborne et al., 2004). It has 
also been noted that fulvestrant does not have oestrogenic properties in other 
tissues such as endometrial tissues as tamoxifen does (Carlson, 2005). 
Finally, aromatase inhibitors (AIs) can also be used to treat ER positive breast 
cancers (Figure 1.2.1), although their use is limited to postmenopausal patients 
(Maughan et al., 2010). Instead of targeting the ER as SERMs and SERDs do, 
AIs target oestrogen production by blocking its conversion from androgens. By 
blocking this process, oestrogen levels fall to virtually undetectable levels in 
plasma, leading to less activation of the ER by oestrogens (Howell and 
Dowsett, 2004, Dowsett et al., 2015). Oestrogen is largely produced by the 
ovaries in premenopausal women (Goss and Strasser, 2001, Miller, 2003). In 
this subset of patients, inhibition of oestrogen synthesis by AIs activates a 
pathway involving gonadotrophin that ultimately leads to signals to the ovaries 
that stimulate aromatase levels, thus limiting the efficacy of the AIs. In 
postmenopausal women, however, after ovarian failure, oestrogen is largely 
synthesised in peripheral tissues and circulates at lower levels. In these 
circumstances, ovarian stimulation no longer plays a role, resulting in AIs 
remaining effective in this subset of patients. Studies comparing AIs with anti-
oestrogens, usually tamoxifen, have revealed that AIs are the superior 
endocrine therapy in terms of response rates, durations of response, and 
recurrence rates (Howell and Dowsett, 2004, Dowsett et al., 2015). However, 
tamoxifen and AIs are often both used to treat different groups of patients 





Figure 1.2.1: Endocrine therapy targets of the ER pathway 
Aromatase inhibitors (AI) target aromatase enzymes involved in the 
conversion of androgens to oestrogen. Selective oestrogen receptor 
modulators (SERM) and degraders (SERD) competitively bind the 
oestrogen receptor (ER), thus preventing binding of oestrogen to the 
receptor, and consequently inhibiting the transcription of oestrogen-
regulated genes. 
1.2.2.2 HER2-targeted therapy 
Since the development of endocrine therapies that target the hormonal 
component of luminal type breast cancers, other targeted therapies have also 
been developed that work on a similar principle of attempting to inhibit the 
action of a specific receptor. In breast cancer therapy, the most widely used of 
these novel targeted therapies are the HER2-targeted therapies. These were 
developed after it was discovered that overexpression of HER2 protein was 
observed in almost a quarter of all breast cancers and was associated with a 
particularly aggressive subtype (Gschwind et al., 2004, Ross et al., 2009). 
HER2 is a tyrosine kinase receptor (Nielsen et al., 2009). It has been shown to 
form heterodimers with HER1 (also known as EGFR) and HER3, leading to 
activation of the PI3K pathway. Numerous clinical trials investigating the effects 
of HER2 targeting therapies on HER2 positive breast cancers in both the 
preoperative and postoperative settings have revealed significant benefits 
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associated with HER2 targeted therapies in terms of overall survival and 
disease free survival (Dent et al., 2013, Mendes et al., 2015).  
The first HER2-targeted therapy was trastuzumab, a monoclonal antibody still 
in use today (Nielsen et al., 2009, Higgins and Baselga, 2011). A newer 
monoclonal antibody, pertuzumab, has since been developed. These 
monoclonal antibodies function by inhibiting the dimerization of the receptors, 
thus inhibiting the activation of downstream pathways. There is also evidence 
that monoclonal antibodies including trastuzumab also function by stimulating 
elements of the immune system such as natural killer cells to target cancer 
cells (Clynes et al., 2000, Arnould et al., 2006). Trastuzumab has, however, 
been associated with cardiotoxicity although newer HER2-targeted therapies 
are associated with a significantly lower risk of cardiac dysfunction (Sendur et 
al., 2013). Evidence has suggested that treatment regimens consisting of a 
combination of trastuzumab and one of the newer agents do not have 
significantly worse cardiotoxicity than trastuzumab alone. However, considering 
that HER2-targeted therapies are often administered together with cytotoxic 
chemotherapy and cardiotoxicity is associated with both trastuzumab and the 
widely used class of therapeutics, the anthracyclines (see section 1.2.2.3.1), it 
has been suggested that anthracyclines should not be administered in 
combination with trastuzumab (Popat and Smith, 2008). Small molecule 
tyrosine kinase inhibitors also exist to treat HER2 positive breast cancers 
including lapatinib, which has been shown to inhibit both HER1 and HER2, 
leading to inhibition of the downstream AKT and MAPK pathways (Nielsen et 
al., 2009). It has been shown that this agent is even able to restore sensitivity 
to tamoxifen in tamoxifen resistant tumours. There is even modest evidence 
that lapatinib may be able to cross the blood brain barrier (Lin et al., 2008), 
providing hope that it could be effective at targeting sub-clinical brain 
metastases. 
1.2.2.3 Cytotoxic chemotherapy 
Cytotoxic chemotherapy was the first chemical means of treating cancers 
(DeVita and Chu, 2008) and is still used today to treat a large proportion of 
primary breast cancers. According to a study that calculated various statistics 
associated with a number of cancers, including breast cancer, in the USA, 40% 
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of patients with stage I or II breast cancer were treated with a therapeutic 
regimen including chemotherapy (DeSantis et al., 2014). For the higher stages 
of breast cancer, approximately 70% of patients were treated with a regimen 
including chemotherapy. Cytotoxic chemotherapy drugs have the ability to kill 
cancer cells using multiple mechanisms. In general, these drugs target various 
mechanisms used by cells to proliferate. The inhibition of proliferation can lead 
to activation of other pathways that ultimately lead to cell death (Waldman et 
al., 1997, Pucci et al., 2000). As such, chemotherapeutic drugs largely target 
highly proliferative cells, as is often the case for tumour cells, but also target 
other proliferating cells in the body that are completely healthy. This leads to 
off-target toxicities that can have adverse effects on patients (Cheok, 2012, Liu 
et al., 2015a). This is a disadvantage of chemotherapy as it is administered 
systemically and not targeted specifically to tumour cells. There is however an 
advantage to this systemic administration. As mentioned previously, unlike 
surgical interventions and radiotherapy, chemotherapy as well as other 
systemic therapies have the benefit of being able to target cells that have 
disseminated from the primary tumour. This is therefore the primary choice of 
treatment in the context of metastatic disease (Liu et al., 2015a), although 
palliative radiotherapy may be indicated in specific circumstances such as 
cases of bone metastases that may cause fractures and/or neurological 
complications, extensive brain metastases, and fungating tissue masses 
(Cardoso et al., 2012). 
Chemotherapy also has the advantage of being able to treat all subtypes of 
breast cancer as it is not targeted to any specific molecules present in only 
certain subtypes of breast cancer (see Table 1.1.3, for example, since these 
receptors provide targets for endocrine therapy and HER2 targeted therapy). 
Instead, chemotherapeutic drugs target various generic cell processes such as 
DNA replication and mitotic segregation during cell division (Siddik, 2002). It is 
for this reason that chemotherapy is the only form of systemic treatment that 
can be used to treat triple negative breast cancers (Foulkes et al., 2010). 
However, cytotoxic chemotherapy can also be used alone or in conjunction with 
targeted therapies to treat receptor positive breast cancers (Gnant et al., 2015). 
For patients with ER positive tumours – luminal A or luminal B-type breast 
cancers – endocrine therapies are often sufficient (see section 1.2.2.1). In 
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these patients, chemotherapy can, however, be recommended for patients with 
large or node-positive tumours, and is commonly recommended for luminal B-
type tumours (Gnant et al., 2015), which are more highly proliferative and may 
also receive chemotherapy in combination with trastuzumab if HER2 positive. 
Interestingly, it has previously been noted that despite the fact that both luminal 
A-type tumours and luminal B-type tumours express the oestrogen receptor, 
luminal A-type tumours are generally less responsive to chemotherapy drugs 
than luminal B-type tumours (Ignatiadis and Sotiriou, 2013, Gnant et al., 2015), 
which probably relates to the difference in proliferation rate. Chemotherapy is 
also generally administered to patients with HER2 subtype tumours in 
conjunction with HER2-targeted therapies (see section 1.2.2.2) (Arteaga et al., 
2012). It has previously been noted that when administered preoperatively, 
triple negative and HER2 subtype breast tumours are more sensitive to 
anthracycline and taxane-containing chemotherapies (see section 1.2.2.3.1) 
than the luminal breast tumours, although gene expression profiles obtained 
from the triple negative or HER2 subtype tumours following chemotherapy 
suggest that the molecular mechanisms employed that contribute to this 
sensitivity vary between them (Rouzier et al., 2005). 
1.2.2.3.1 Multiple classes of chemotherapy drugs with different mechanisms of 
action are used in the treatment of breast cancer 
Different classes of chemotherapeutic drugs can be used, each of which 
primarily target different cellular processes. One of the first classes of drug 
developed, which is still commonly used today, is alkylating agents (Ralhan and 
Kaur, 2007). These directly target DNA using three different mechanisms. 
Alkylating agents have the ability to cross-link DNA, resulting in the inability of 
the double strands to unwind during replication and transcription. Secondly, 
alkylating agents can cause the mispairing of nucleotides leading to mutations. 
The final mechanism involves the drug adding alkyl groups to DNA bases. 
When DNA repair enzymes attempt to replace these alkylated bases, the DNA 
is fragmented. The most commonly used alkylating agent in the treatment of 
breast cancer is cyclophosphamide (Stoll, 1970, Wisinski et al., 2013). 
Anthracyclines are another class of chemotherapy drug frequently used in the 
treatment of breast cancers. These antibiotics have been used to treat breast 
cancer for half a century, although more recent retrospective studies have 
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suggested that this class of chemotherapeutic drug should be used less 
frequently in favour of newer classes of drug that have fewer associated 
toxicities (Robson and Verma, 2009). The most commonly used anthracyclines 
in the treatment of breast cancer are doxorubicin and epirubicin. There appear 
to be multiple possible mechanisms of action used by anthracyclines to kill 
tumour cells. However, the two most prominent mechanisms are through the 
inhibition of topoisomerase II and the production of free radicals (Bonadonna et 
al., 1993, Gewirtz, 1999). Topoisomerase II is an enzyme required for the 
unwinding of DNA during replication and transcription by creating double strand 
DNA breaks (Nitiss, 2009a). Anthracyclines function by intercalating with the 
topoisomerase II:DNA covalent complex and inhibit the DNA from being re-
ligated (Nitiss, 2009b). Anthracyclines can also be oxidised and then converted 
back in a reaction that releases reactive oxygen species, which can activate a 
number of processes such as apoptosis and cause membrane damage as well 
as DNA damage (Thorn et al., 2011). A particular disadvantage of 
anthracyclines is associated toxicities, in particular cardiotoxicities as 
anthracycline-induced cardiomyopathy is largely irreversible (Hortobagyi, 1997, 
Thorn et al., 2011), although evidence suggests that epirubicin is less toxic 
than doxorubicin (Khasraw et al., 2012). 
Taxanes are a newer class of chemotherapeutic drug that have been 
suggested to be less toxic in terms of side effects than anthracyclines and it 
has therefore been suggested that these be used preferentially (Robson and 
Verma, 2009). These chemotherapeutic drugs target microtubule dynamics, 
preventing chromosome segregation, and thereby causing mitosis to halt 
(Risinger et al., 2009). They have also been shown to promote apoptosis; 
paclitaxel is a common taxane used in the treatment of breast cancer and has 
been shown to activate the apoptosis signal-regulating kinase (ASK1), leading 
to the inactivation of the anti-apoptotic protein Bcl2 (McGrogan et al., 2008). 
Docetaxel is also commonly used to treat breast cancers (Baselga and 
Tabernero, 2001). Finally, taxanes have also been shown to inhibit 
angiogenesis by reducing cell motility. This inhibition was associated with 
decreased activity of Rac1 and Cdc42 activity, thought to be caused by 
cytoskeletal changes induced by the drugs observed in endothelial cells 
(Bijman et al., 2006). 
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The final class of chemotherapeutic drugs used to treat breast cancers are 
platinum-based drugs such as cisplatin (Decatris et al., 2004). Clinically, this 
class of drugs has been limited to the triple negative subtype of breast cancers 
as studies have shown significant benefits associated with these drugs when 
administered in this subtype (Guan et al., 2015, Zhang et al., 2015). Their 
primary mechanism of action is very similar to that of alkylating agents in that 
they too form intra-strand adducts and inter-strand crosslinks in DNA. Cisplatin 
has also been shown to bind RNA and cellular proteins. Interestingly, platinum-
based chemotherapy has been shown to be particularly effective in patients 
with BRCA1 mutations or silencing of BRCA1 (Stefansson et al., 2012). 
1.2.2.4 Other targeted therapies 
Other targeted therapies also exist that can be used to treat breast cancers. 
Cyclin dependent kinases (CDKs) are essential for cell cycle progression and it 
has previously been shown that CDK4 and CDK6 in particular are 
overexpressed in breast cancer and may play a particular role in hormone 
receptor positive and HER2 positive breast cancers (Malumbres and Barbacid, 
2009, Finn et al., 2009, DeMichele et al., 2015). These two CDKs are required 
for transition from G1 to S phase of the cell cycle, and several drugs have been 
developed to target these kinases, including palbociclib (O'Leary et al., 2016). 
This agent has been shown to be well tolerated by patients with significant 
increases in progression free survival (PFS) in hormone receptor positive 
breast cancer resistant to endocrine therapies compared with hormone 
receptor negative breast cancers (DeMichele A et al., 2015). In pre-clinical 
models, CDK4/6 inhibitors have also been shown to work well in combination 
with HER2-targeted therapies in a bid to overcome resistance to the latter 
therapy (Witkiewicz et al., 2014). These two kinases function downstream of 
the HER2 receptor and simultaneous inhibition of these kinases and the 
receptor should lead to increased cell cycle arrest. Similarly, inhibition of PI3K 
has also been shown to be successful in the treatment of breast cancers with 
mutant PIK3CA as well as those with resistance to HER2-targeted therapies, 
and treatments consisting of combinations of CDK4/6 inhibitors with PI3K 
inhibitors have been shown to work synergistically (Vora et al., 2014, Wilks, 
2015). However, these targeted inhibitors have not yet entered standard 
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practice, with PI3K inhibitors still undergoing clinical trials and further 
development (Massacesi et al., 2016). Palbociclib has been approved by the 
Food and Drug Administration, but only for the treatment of hormone receptor 
positive, metastatic breast cancer when given in combination with the 
endocrine therapy letrozole (Vidula and Rugo, 2016). Further clinical trials in 
breast cancer are ongoing. 
Another promising targeted therapy is poly(ADP-ribose) polymerase (PARP) 
inhibitors (Lord and Ashworth, 2017). PARP enzymes are DNA damage 
sensors and signal transducers that bind damaged DNA and recruit DNA repair 
enzymes. As such, PARP inhibitors have been of particular interest in the 
context of BRCA mutations, as these mutations adversely affect DNA repair 
capabilities (Livraghi and Garber, 2015). Multiple clinical trials investigating the 
efficacy of various PARP inhibitors such as olaparib have been performed in 
breast cancers, the majority of which only included breast cancers with BRCA 
mutations (Livraghi and Garber, 2015, Kaufman et al., 2015, Michalarea et al., 
2016). These clinical trials have showed promising results in terms of a 
favourable response of the tumours to the inhibitors and limited off-target 
toxicities. Olaparib has been approved for the treatment of ovarian cancer, but 
clinical trials are still ongoing for the treatment of breast cancer (Lord and 
Ashworth, 2017, Yamaguchi et al., 2018). 
1.2.2.5 Therapeutic drugs can be administered as single agents or in 
combination 
Systemic therapies can be administered as single agents or as combination 
therapies. Not only can multiple chemotherapeutic agents be administered 
together for example, but chemotherapeutic agents can also be administered in 
combination with endocrine therapies or other targeted therapies (Bergh et al., 
2001, Slamon et al., 2001). There are multiple advantages associated with 
administering polytherapies. These include increased rates of survival, higher 
rates of overall response and longer durations of response. Another potential 
benefit of administering multiple therapies is a greater chance of overcoming 
resistance or preventing its development (Masui et al., 2013). A well-known 
example of this is in HER2-targeted therapies. Addition of a HER2 targeting 
agent such as trastuzumab to chemotherapy led to increased patient response 
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rates compared with chemotherapy or HER2 targeting therapies alone (see 
section 1.2.2.2).  
There are, however, disadvantages to administering multiple therapeutic 
agents as opposed to only single agents. Administration of polytherapies is also 
associated with increased toxicities such as leukopenia and anaemia. For 
example, when the HER2-targeted therapy trastuzumab was given in 
combination with a chemotherapy regimen consisting of an anthracycline and 
cyclophosphamide, when compared with chemotherapy alone, 27% versus 8% 
of patients experienced some cardiac dysfunction. For patients who were 
administered paclitaxel alone, 1% experienced cardiac dysfunction whereas 
13% experienced this side effect when administered a combination of paclitaxel 
and trastuzumab (Slamon et al., 2001, Beslija et al., 2003). As such, 
recommendations have been made regarding the use of single agent therapies 
versus polytherapies. In metastatic breast cancer, these involve taking into 
consideration patient prognosis, symptom control and toxicity profiles with the 
ultimate goal being optimising the quality and quantity of life (Beslija et al., 
2003). It has been suggested that in metastatic breast cancer, single agent 
therapies are a reasonable option when the primary goals are to limit drug 
toxicity whilst maximising the quality of life. This was considered particularly 
relevant for those patients with tumours that are ER negative and whose 
disease is only slowly progressive. 
There are two main approaches that can be taken when administering 
polytherapies, and the use of these is partly dependent on the patient (Miles et 
al., 2002, Beslija et al., 2003, Bergh et al., 2001). Therapeutic drugs can be 
administered simultaneously or sequentially. Studies comparing the efficacies 
of these two methods of administration have not discovered any significant 
differences between the two in terms of overall survival (Bergh et al., 2001). 
However, trends have been noticed specifically in patients with liver 
metastases that they had better survival rates when administered simultaneous 
combination therapies as opposed to sequential therapies (Joensuu et al., 
1998). It was also noticed that in the former approach, the response and time to 
progression tended to be better, but these benefits were accompanied by 
increased toxicity. Therefore, as with the decision between administering single 
agents versus polytherapies, the choice between administering combination 
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therapies simultaneously or sequentially is partially dependent on the patient 
(Miles et al., 2002). It has been suggested that in the context of metastatic 
breast cancer, administration of therapeutic agents simultaneously may be 
preferable to administering them sequentially if an urgent reduction in tumour 
burden is required. In contrast, sequential therapies may be especially 
appropriate in patients who are frail and/or elderly and may not be able to 
tolerate the toxicity associated with simultaneous administration of the 
therapies. This second approach may also be beneficial for those patients with 
slow growing tumours as this method also allows optimal delivery of each 
single drug and therefore potentially reduces the risk of toxicity, which may 
improve the quality of life (Miles et al., 2002).  
The issue of sequential or simultaneous treatments is of particular relevance to 
my work here, since in Chapter 6 I have attempted to study the consequences 
of initial treatment with one therapy (endocrine) on response to a subsequent 
therapy (cytotoxic chemotherapy). In addition, the remainder of my work 
involves identification of changes in expression within tumour cells that are 
induced by chemotherapy – and it would be possible to consider the 
implications of these changes on any subsequent therapies (in the case of my 
work, this would most likely be adjuvant endocrine therapy). 
1.2.2.6 Adjuvant therapies versus neoadjuvant therapies 
Traditionally, systemic therapies are administered post-surgery in the hope of 
eradicating any tumour cells remaining locally after removal of the main tumour 
mass, as well as any distant sub-clinical metastatic cells (Sonnenblick and 
Piccart, 2015). This therapy is known as adjuvant therapy (Zhang et al., 
2013a). However, in more recent years, the administration of systemic therapy 
prior to surgery, known as neoadjuvant therapy, has increased (Kaufmann et 
al., 2012, Kesmodel, 2016). Chemotherapy and endocrine therapy as well as 
other targeted therapies can be administered in the neoadjuvant setting 
although chemotherapy is the most commonly administered neoadjuvant option 




1.2.2.6.1 The advantages of neoadjuvant systemic therapies 
There are several potential advantages to neoadjuvant therapies. The first is 
that the response of the tumour to the administered drug can be monitored 
using non-invasive imaging (Kaufmann et al., 2012, Park et al., 2015). This 
allows clinicians to observe whether the tumour is sensitive or resistant to the 
therapy and allows the opportunity to change the treatment regimen if the 
tumour is non-responsive (Porkka et al., 1994, Polyzos et al., 2009). This of 
course is not possible when administering adjuvant therapies, since the primary 
tumour is not present, and assessments of therapy response can only be made 
subsequently based on whether recurrences occur or not (Gonzalez-Angulo et 
al., 2007, Sotgia et al., 2017), at which point it is already too late to avoid these 
recurrences. 
A benefit of being able to monitor tumour response in the neoadjuvant setting is 
that there is a high correlation between response and change in tumour size 
(Gajdos et al., 2002, Samuel et al., 2018). It is inferred that a good response in 
the primary tumour likely indicates a good response in any disseminated 
tumour cells as well. Therefore, if there is a large degree of shrinkage of the 
primary tumour post-neoadjuvant therapy, it is likely that any disseminated 
tumour cells will also have responded very well to the therapy. The association 
between incidences of pathological complete response (pCR) and the 
associated improved survival of these patients supports this (Mieog et al., 
2007, Gianni et al., 2014). The term pCR broadly refers to the absence of the 
primary tumour, although various groups use differing specific definitions. Two 
of the definitions used to define pCR are where no residual cancer at all is left 
and where no invasive cancer is detected with various degrees of residual 
cancer in axillary nodes and non-invasive cancer cells (von Minckwitz et al., 
2012). 
Neoadjuvant therapies are also beneficial in cases where the tumour is 
responsive to the treatment and results in tumour shrinkage (Goble and Bear, 
2003). At diagnosis, some tumours are deemed inoperable due to advanced 
lymph node involvement (El-Charnoubi et al., 2012). Neoadjuvant therapy may 
successfully treat affected lymph nodes, thus rendering the tumour operable. 
Similarly, a tumour that once required a complete mastectomy could only 
require breast-conserving surgery following neoadjuvant treatment (Mauri et al., 
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2005). In the best cases, neoadjuvant therapies can sometimes even result in 
pCR. This occurs in 3-18% of cases. The likelihood of pCR depends on a large 
number of factors such as tumour subtypes, stage of disease, the patient and 
definition of pCR used (Cortazar et al., 2012, von Minckwitz et al., 2012).  
A third advantage for administering systemic therapies in the neoadjuvant 
setting does not have immediate clinical benefits, but rather benefits the 
research community. It is clear that the administration of systemic therapies 
leads to alterations in gene expression (Magbanua et al., 2015, Klintman et al., 
2016). Some of these alterations cause the tumour to be more sensitive to the 
treatment whereas others can cause the tumour to be more resistant (Kim et 
al., 2013a, Magbanua et al., 2015). The combinations of all these changes put 
together results in tumours responding to the treatment to various degrees or 
not responding at all. These changes in gene expression can be investigated 
only in the neoadjuvant setting as samples from both pre-treatment (biopsy 
taken for initial diagnosis) and/or post-treatment (resection from surgical 
removal of the tumour) are available, in cases where pCR is not achieved 
(Gonzalez-Angulo et al., 2012, Bhola et al., 2013).  
The ability to determine gene expression changes associated with systemic 
therapies has many advantages. Together with clinical follow-up data, different 
gene expression changes can be used as signatures to determine what 
changes are associated with numerous factors such as disease free survival, 
overall survival and response to subsequent therapies if any (Ayers et al., 
2004, Magbanua et al., 2015). As such, the molecular response of tumours can 
be correlated with the observed clinical response and give a greater 
understanding of phenomenons such as how resistance is acquired and what 
combinations of therapies result in the best outcomes (Rouzier et al., 2005, 
Colleoni and Montagna, 2012). Understanding how resistance occurs could 
also lead us to strategies that can be used to overcome this resistance such 
that more cancers can be treated more successfully. 
1.2.2.6.2 Comparing neoadjuvant and adjuvant systemic therapies in the clinical 
setting 
Several clinical trials have been performed to analyse whether there were any 
significant differences between adjuvant and neoadjuvant administration of 
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systemic therapies for primary breast cancer. In one of these studies, 
chemotherapy administered to premenopausal patients with tumours too large 
for BCS was compared in these two settings (Scholl et al., 1994). In this study, 
patients also received radiation therapy and also underwent surgery if tumour 
masses remained post-irradiation, irrespective of whether systemic therapies 
were administered in the adjuvant or neoadjuvant settings. Where tumour 
masses remained post-treatment, surgery was aimed to be as conservative as 
possible. Results showed a statistically significant difference in overall survival 
of patients between the two treatment arms, with patients who received NAC 
having better outcomes than those who received adjuvant chemotherapy. 
However, there was no difference in disease free survival (DFS) or rates of 
local recurrence. 
A meta-analysis published in 2005 (Mauri et al.) considered results from nine 
separate randomised trials, including the study described above (Scholl et al., 
1994), in which breast cancer patients were treated either in the neoadjuvant or 
adjuvant settings with the same regimen. This study concluded that there were 
no significant statistical differences between these two settings in terms of rates 
of death, disease progression or recurrences in the form of distant disease. 
However, it was noted that neoadjuvant therapies were statistically significantly 
associated with an increased risk of loco-regional disease recurrences 
compared to adjuvant therapies. This was noted to be of particular importance 
if patients received radiation therapy but no surgery. The results from this meta-
analysis could therefore lead to the conclusion that administering systemic 
therapies in the adjuvant setting may be superior in terms of disease control, 
than in the neoadjuvant setting. It is important to note however, that a treatment 
regimen for breast cancer that does not involve surgery is very rare (between 
1% and 4% in stages I, II and III) and usually only occurs in stage IV breast 
cancer when distant metastasis is present (Miller et al., 2016). 
However, another meta-analysis published two years later (Mieog et al., 2007) 
that included data from fourteen randomised trials comparing neoadjuvant and 
adjuvant systemic therapies had slightly different conclusions. This meta-
analysis included the studies that were in the former meta-analysis (Mauri et 
al., 2005). As with the previous meta-analysis, overall survival was equivalent 
in both treatment groups (Mieog et al., 2007). It was noted though, that rates of 
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mastectomy were lower in the neoadjuvant group than in the adjuvant group 
and that this had no effect on the ability to control local recurrences. NAC was 
also associated with fewer side effects such as infectious complications and 
cardiotoxicity. When comparing loco-regional recurrences between the two 
groups, this meta-analysis excluded trials where it was deemed that patients 
received inadequate loco-regional treatment. In the first meta-analysis (Mauri et 
al., 2005), data from these trials were included (see above). However, in the 
latter meta-analysis (Mieog et al., 2007), data from these trials were removed 
from the analysis. Data from the remaining eight studies that reported data on 
loco-regional recurrences demonstrated no difference in the rate of loco-
regional recurrences between the neoadjuvant and adjuvant groups. The 
results from this meta-analysis could therefore lead to the conclusion that 
administering systemic therapies in the neoadjuvant setting may be superior to 
the adjuvant setting when considering patient psycho-social outcomes in terms 
of increased rates of BCS in the former setting – an outcome usually preferred 
by patients. Combining these data with the advantage of being able to monitor 
tumour response to the administered therapy in the neoadjuvant setting, 
allowing the regimen to be changed if necessary (Porkka et al., 1994, 
Kaufmann et al., 2006), it seems there are numerous advantages to 
neoadjuvant therapies compared to adjuvant therapies. 
1.3 An introduction to microRNAs 
MicroRNAs (miRNAs) are short, non-coding RNA sequences typically between 
20 and 24 nucleotides in length (Chekulaeva and Filipowicz, 2009). These 
single stranded RNA sequences were first identified in 1993 in Caenorhabditis 
elegans (Wightman et al., 1993, Lee et al., 1993) and have since been 
discovered to regulate gene expression post-transcriptionally (Ambros, 2001). 
MiRNAs are now known to repress gene function by inhibiting the translation of 
messenger RNAs (mRNAs) and/or targeting mRNAs for degradation (Fabian et 
al., 2010, Meijer et al., 2013). However, in more recent years, evidence has 
suggested that miRNAs may also be able to up-regulate gene expression 
(Ørom et al., 2008). 
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1.3.1 MiRNAs are expressed as primary transcripts and are 
processed to form mature miRNAs 
Genes encoding miRNAs have been located in transcription units containing 
clusters of distinct miRNAs as well as transcription units that also encode 
proteins (Carthew and Sontheimer, 2009). MiRNA genes can be found in the 
introns of protein-coding genes and both introns and exons of non-coding 
genes (Rodriguez et al., 2004). MiRNA genes can also be found in intergenic 
regions (Kim and Nam, 2006). Genes are typically transcribed by RNA 
polymerase II, and transcripts are capped and polyadenylated and form double-
stranded structures known as primary miRNAs (pri-miRNAs) (Carthew and 
Sontheimer, 2009). These products are processed by the Drosha-DGCR8 
complex (Han et al., 2004). Drosha is a nuclear RNase III enzyme that cleaves 
the pri-miRNA to form precursor mRNAs (pre-miRNAs) that form hairpin 
structures. DGCR8 is an essential component of the complex: it contains two 
double-stranded RNA binding sites. The pre-miRNAs are exported from the 
nucleus in a Ran-GTP dependent manner, mediated by Exportin-5 (Murchison 
and Hannon, 2004).  
Once in the cytoplasm, the pre-miRNAs are further cleaved by a second RNase 
III enzyme known as Dicer, to form the mature miRNA duplex. As with the 
Drosha-DGCR8 complex, the involvement of TRBP, known to contain three 
double-stranded RNA binding domains, has been shown to be essential in this 
process (Chendrimada et al., 2005). One strand of the duplex (the guide 
strand) is designated to be loaded onto the RNA-induced silencing complex 
(RISC) to form the miRISC, whilst the second strand (the passenger strand) is 
degraded (Winter et al., 2009). There is a bias present as to which strand is 
selected as the guide strand. This bias has been shown to be influenced by the 
thermodynamic properties of the two strands of the pre-miRNA duplex 
(Khvorova et al., 2003).  




Figure 1.3.1: Biogenesis of miRNAs 
MiRNAs are transcribed by RNA polymerase (Pol) II and capped and 
polyadenylated. They are then processed by the Drosha-DGCR8 complex 
before being exported from the nucleus in a process mediated by Exportin 
5. The mature miRNA duplex is formed by the Dicer enzyme before the 
guide strand is loaded into the RISC. This complex containing the mature 
miRNA strand can then target mRNA transcripts. 
1.3.1.1 MiRNA nomenclature 
When the guide and passenger strands of miRNAs were first identified, the 
standard nomenclature used to differentiate between the two strands was a ‘*’ 
symbol following the miRNA name to denote the passenger strand (Griffiths-
Jones, 2004). However, after it was discovered that different strands were used 
as a passenger or guide in different tissues (Bhayani et al., 2012), the ‘*’ 
system was found to be unhelpful. Therefore, the ‘-5p’ and ‘-3p’ suffix system 
was put in place to denote the 5’ strand and the 3’ strand of the duplex 
respectively (Kozomara and Griffiths-Jones, 2014). 
MiRNA nomenclature is further complicated by the fact that some mature 
miRNAs derived from different genes can differ at only one or two positions in 
their sequence (Griffiths-Jones, 2004). These miRNAs are differentiated by a 
letter suffix, for example miR-26a and miR-26b. Alternatively, some identical 
mature miRNAs have different genomic origins. These are differentiated by a 
25 
 
number suffix, for example miR-19b-1 and miR-19b-2 (Moreno-Moya et al., 
2014). 
Finally, miRNA families also exist. A family refers to a group of miRNAs that 
derive from a common evolutionary ancestor and normally have similar 
physiological functions (Zou et al., 2014). However, their primary sequence is 
not always conserved, nor is their secondary structure. 
1.3.1.2 MiRNAs identify their targets via a seed sequence 
The miRISC complex, composed in part by argonaute proteins (Ago) (Liu et al., 
2005), recognises the 3’ UTR of target mRNAs by virtue of the seed sequence 
of the miRNA (the sequence of nucleotides in positions 2-8 numbering from the 
5’ end) (Brennecke et al., 2005, Wilczynska and Bushell, 2015). More recently, 
miRNAs have also been shown to recognise sequences in the 5’ UTR (Ørom et 
al., 2008) as well as the coding region (Hausser et al., 2013). Evidence also 
exists of miRNAs binding their targets via their central regions rather than the 
seed region (Martin et al., 2014). However, most binding is still thought to occur 
between the seed sequence of the miRNA and the 3’UTR of the target mRNA. 
Because sequence complementarity between a miRNA and its target mRNA is 
only required in a limited number of positions (the prototype being the seven 
positions in the seed region), each miRNA has many potential targets in terms 
of complementarity alone (Wilczynska and Bushell, 2015). It has previously 
been noted however, that a surprising number of miRNA genes are located 
under the transcriptional control of their target genes (Carthew and Sontheimer, 
2009). The location and transcription of miRNA genes could therefore provide 
clues as to some of their mRNA targets beyond simple sequence 
complementarity. 
1.3.2 MiRNAs post-transcriptionally regulate gene expression 
Translational repression of target mRNAs by miRNAs is still a relatively poorly 
understood process. However, evidence has shown that this step is essential 
for mRNA degradation (Meijer et al., 2013), but that not all mRNAs are 
ultimately degraded – some miRNA-repressed mRNAs can be translationally 
reactivated (Wilczynska and Bushell, 2015). Inhibition of translation involves 
miRNAs preventing the formation of the eIF4F initiation complex. This is 
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achieved by the binding of the RNA helicase eIF4A2 to the CCR4:NOT 
deadenylase complex (Meijer et al., 2013). This process requires not only the 
presence of the miRNA target site in the 3’ UTR of the mRNA, but also 
secondary structures in the 5’ UTR. These secondary structures are hairpin 
loops, the complexity of which seems to contribute to the efficiency of miRNA-
mediated repression of mRNAs (Ricci et al., 2013). In some cases, translational 
repression is followed by the deadenylation and eventual degradation of the 
mRNA (Djuranovic et al., 2012). This process occurs in specific processing 
bodies (P bodies) and the complex is directed to these sites by the Ago 
proteins (Behm-Ansmant et al., 2006). The degradation of mRNAs by miRNAs 
requires the GW182 protein, which has been shown to interact with the Ago 
proteins, as well as the decapping DCP1:DCP2 complex and the CCR4:NOT 
deadenylase complex. It has previously been shown that a switch can be made 
between translational repression and degradation of mRNAs when bound by 
miRNAs (Horman et al., 2013). Phosphorylation of Ago2 at S387 was shown to 
facilitate the interaction of this protein with GW182, resulting in increased 
localisation of miRNA:mRNA complexes to P bodies. This phosphorylation, by 
Akt3, increased translational repression of target mRNAs and decreased 
degradation. 
1.3.3 MiRNAs in cancer 
1.3.3.1 Differential expression of miRNAs in breast cancer 
Dysregulation of miRNA expression has been observed in multiple cancer 
types including chronic lymphocytic leukaemia, lung cancer and breast cancer 
(Calin and Croce, 2006). Despite the thousands of miRNAs that we now know 
exist, we still know relatively little about what role individual miRNAs play in the 
pathogenesis of cancers (Palanichamy and Rao, 2014). However, individual 
miRNAs have been labelled as oncogenic, as their expression is generally 
increased compared to normal levels and are known as oncomiRs (Esquela-
Kerscher and Slack, 2006). Other miRNAs have been labelled as tumour 
suppressors, with their expression generally decreased compared to normal 
levels. The functions of these miRNAs are presumed to be the results of the 
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miRNAs acting through their mRNA targets: either tumour suppressors or 
oncogenes respectively. 
In breast cancer, many different miRNAs have been implicated in influencing 
tumour progression, either by promoting or by inhibiting metastasis and by 
increasing sensitivity or resistance to systemic therapies (Corcoran et al., 
2011). Numerous miRNAs have been associated with breast cancer including 
increased expression of miR-21 and miR-155 (Volinia et al., 2006), and 
decreased expression of let-7 and miR-10b (Iorio et al., 2005) relative to non-
cancerous expression. Interestingly, specific miRNAs have been associated 
with the differential receptor expression used for subtyping breast cancer (Iorio 
et al., 2005). These include the miR-26 and miR-30 families with increased 
expression in ER positive tumours compared to ER negative tumours, and let-
7c and specific members of the miR-30 family with increased expression in PR 
positive tumours compared to PR negative tumours. It is important to note that 
in both of these profiling studies, total RNA was isolated from whole tumour 
samples containing all cell types, therefore these differential expressions 
cannot confidently be assigned to the tumour epithelial cells alone. 
MiRNA expression profiling studies have also been performed on breast 
tumours that have taken into consideration which cellular components of 
tumours express the dysregulated miRNAs. In one of the first of such studies, 
whole tumour samples initially underwent miRNA expression profiling 
compared with normal tissue as described above (Sempere et al., 2007). This 
led to the identification of numerous dysregulated miRNAs in the tumour tissue 
including increased expression of miR-21 and decreased expression of miR-
145 and miR-451 relative to normal tissue expression. In situ hybridisation 
(ISH) experiments were then performed on tissue microarrays (TMAs) 
containing breast tissue cores. The miRNAs of interest were targeted in order 
to view their localisation. MiR-21 was expressed primarily in luminal epithelial 
cells and was occasionally detected in fibroblasts. In contrast, miR-145 was 
expressed primarily in myoepithelial cells of lobules and ducts and in the 
smooth muscle cells within blood vessels. Of significance, miR-451 was 
exclusively expressed in erythrocytes and not in any cancer cells. It was 
hypothesised that the significant down-regulation of this miRNA observed in the 
whole tumour sample may have simply reflected the fact that tumour 
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vasculature is inherently different to normal vasculature. This observation 
underscored the importance of assessing not only miRNA expression but also 
the localisation of this expression within the tumour mass. 
More recent profiling studies have taken the observation of the importance of 
miRNA localisation into consideration. In a study investigating whether 
circulating miRNA profiles were reflective of miRNA expression profiles in the 
breast tumour, miRNA microarrays were performed using RNA extracted from 
plasma samples and tumour tissue samples that had been macro-dissected for 
areas enriched for tumour epithelial cells (Cookson et al., 2012). This led to the 
identification of let-7b, let-7g and miR-18b as potential biomarkers, with higher 
expression levels associated with breast tumours to normal breast tissue. In a 
separate study investigating the different miRNA expression profiles associated 
with breast cancers in different ethnic backgrounds, RNA was also extracted 
from tumours that had been macro-dissected for areas enriched for tumour 
epithelial cells (Pollard et al., 2018). Nine miRNAs were differentially expressed 
across the four ethnic groups. Tumour epithelial cells taken from patients of 
Nigerian origins had increased expression of miR-140-5p, miR-194 and miR-
423-5p relative to other ethnic groups, whereas increased expression of miR-
101 was observed in the Indian group. It may, however, be worth emphasising 
that although macro-dissection was performed to select areas of tumour 
enriched for epithelial cells, other cells present in these areas were also 
included in the analyses and may therefore skew some results. 
It has been noted that many miRNA genes are located in fragile chromosome 
locations and cancer-associated genomic regions (Calin et al., 2004), and that 
this may contribute to aberrant expression of miRNAs. For example, miR-335, 
located at 7q32.2, is commonly genetically deleted in breast cancers (Png et 
al., 2011). However, it was also observed that the promoter also underwent 
hypermethylation in every metastatic derivative obtained from the patients’ 
malignant cell populations (Png et al., 2011). Since then, polymorphisms in the 
miRNAs themselves have been identified, such as in miR-196a2, where a 
specific single nucleotide polymorphism (SNP) was observed to increase the 
risk of breast cancer in individuals who were homozygous for this allele (Gao et 
al., 2011). However, evidence linking specific polymorphisms in miRNAs with 
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breast cancer risk is controversial as meta-analyses and confirmatory studies 
often do not obtain the same results (Mulrane et al., 2013). 
Polymorphisms in miRNA target binding sites have also been identified. A SNP 
in ITGB4 at a potential binding site of miR-34a correlated with decreased 
survival in ER negative breast cancers (Brendle et al., 2008). Interestingly, 
polymorphisms in genes coding for proteins required in the miRNA biogenesis 
pathway, as well as other causes leading to aberrant expression and/or 
function of proteins, such as DICER1 and AGO2 have also been associated 
with breast cancer risk (Blenkiron et al., 2007, Sung et al., 2012). It is evident 
that aberrant miRNA expression contributes to numerous processes in cancer 
and evidence has shown that regulation of miRNA expression is complex. This 
involves genetic and epigenetic factors of not only the miRNAs themselves but 
also the genes required for miRNA processing and function. Further study is 
clearly required to understand the exact mechanisms behind miRNA function in 
cancer, with a view to identifying novel therapeutic targets (Corcoran et al., 
2011, Liu, 2012, Mulrane et al., 2013). 
1.3.3.2 Functions of dysregulated miRNAs in breast cancer 
Some miRNAs function as suppressors of metastasis, including miR-335 
(Tavazoie et al., 2008). Expression of this miRNA was absent in the majority of 
breast cancer patients who suffered relapses and this loss of expression was 
associated with poor metastasis-free survival. Investigations into the 
mechanism by which miR-335 supresses metastasis led to the identification of 
two mRNA targets. These were the products of the metastasis-associated 
genes SOX4 and TNC. 
Other miRNAs are oncomiRs, including miR-155 (Jiang et al., 2010). 
Expression of this miRNA has been shown to be increased in a number of 
cancer types including breast. As such, a search for mRNA targets of this 
miRNA resulted in the identification of SOCS1. Investigating miR-155 and 
SOCS1 expression in both breast cancer cell lines and primary breast tumours 
showed an inverse correlation in expression of these two RNAs. In vitro studies 
showed that increased expression of miR-155 led to increased cell proliferation. 
Similar results were observed when SOCS1 was knocked down. Interestingly, 
in tumours from two patients, increased expression of both miR-155 and 
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SOCS1 was observed. Further investigations revealed a SNP in the 3’-UTR of 
SOCS1 at the miR-155 binding site, thus demonstrating that although miRNA 
expression may be dysregulated, expression of target mRNAs may not be 
affected if binding by the miRNA is inhibited. 
However, dysregulation of miRNA can be complex. Although miR-10b had 
previously been shown to have decreased expression in breast cancer relative 
to normal breast tissue (Iorio et al., 2005), subsequent studies revealed that 
this miRNA acts as a promoter of metastasis, with over-expression resulting in 
non-metastatic breast cancer cells converting to a metastatic phenotype (Ma et 
al., 2007). This phenotype was a result of miR-10b targeting HOXD10, leading 
to increased expression of the pro-metastatic gene RHOC. In the initial profiling 
study where decreased expression of miR-10b was observed relative to normal 
tissue, RNA was extracted from whole tumour tissues (Iorio et al., 2005). 
However, the subsequent functional study was performed only in tumour 
epithelial cells (Ma et al., 2007). This again highlights the importance of 
performing miRNA expression profiling studies on RNA extracted from specific 
tumour components, such as tumour epithelial cells. 
1.4 Mechanisms of resistance to systemic therapies 
Resistance to systemic therapies accounts for 90% of cases of treatment 
failure in metastatic breast cancer (Hodges, 2011). The origins of resistance 
are not fully understood, although there are two over-arching categories to this 
phenomenon. These are the principles of de novo resistance, where tumour 
cells are intrinsically resistant to the administered drugs (Li et al., 2008), and 
acquired resistance, which refers to tumours where cells initially respond to the 
administered therapy but gradually respond less over time. This is due to the 
tumours modifying their reliance on the function of the drug targets in order to 
escape death, ultimately leading to increased chances of recurrence and can 
also cause tumours to become more aggressive (Pogribny et al., 2010, Higgins 
and Baselga, 2011, Hazlehurst et al., 2003).  
One aspect of de novo resistance is the phenomenon of clonal selection. This 
relates to intra-tumour heterogeneity: the fact that tumours are composed of 
different populations of cells and that even within cell populations, there are 
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differences between cells (Navin et al., 2011, Gerlinger, 2012, Tudoran et al., 
2016). The hypothesis is that within a tumour, certain clones are intrinsically 
resistant to the administered therapy, thus surviving and preventing a complete 
response to treatment (Burrell and Swanton, 2014). A contributing factor to 
both de novo resistance as well as acquired resistance is the presence of 
cancer stem cells, which are often resistant to therapies, and cells that undergo 
the epithelial-to-mesenchymal transition (EMT) process (Liu and Wicha, 2010, 
Giatromanolaki et al., 2011, Jia et al., 2017). The EMT process has been 
proposed to be a highly dynamic process, with cells able to pause the process 
such that they exhibit properties of both states and can switch back and forth. 
This cellular plasticity mediated by EMT allows cells to switch between drug 
resistant and sensitive states dynamically (Jia et al., 2017). 
Some other contributors to the development of acquired resistance are therapy-
induced changes in gene expression, alternative splicing events, and 
mutagenesis of genes with numerous possible consequences including 
alterations of target sites and changes in expression (Poulikakos et al., 2011, 
Wood, 2015, Nakazawa et al., 2018). These events can lead to altered gene 
function, altered drug binding sites, and/or activation and repression of 
molecular pathways that contribute to cell survival and cell death respectively. 
These therapy-induced changes ultimately lead to increased cell survival, as a 
result of acquired resistance to the administered therapy. 
Another important mechanism of acquired resistance is therapy-induced up-
regulation of xenobiotic drug transporter expression (Di Nicolantonio et al., 
2005, Kim et al., 2015). Expression of these pumps can be increased in 
response to presence of the therapeutic drug. This is a result of the therapeutic 
drug inducing expression of drug pumps that then function to pump out any 
drugs in the cell, thus preventing the drug from reaching its target (Vasiliou et 
al., 2009). Considering the heterogeneous nature of tumours, it seems likely 
that acquired resistance is the result of both intrinsic resistant features and 
acquired resistance mechanisms. 
1.4.1 Molecular effectors of therapy resistance 
Alterations in gene expression are a possible mechanism cells use to avoid 
destruction by systemic therapies. One example of this is decreased 
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expression of the breast cancer susceptibility gene 1 (BRCA1). This gene 
contributes to the double strand DNA break repair mechanism (Scully et al., 
1999). Decreased expression of this gene leads to different responses 
depending on the treatment administered. For several drugs, deficiencies in 
BRCA1 expression results in hypersensitivity, whereas for microtubule-
targeting drugs, such as paclitaxel, resistance is encountered (Chabalier et al., 
2006). Deficiencies in BRCA1 are found in many cases of familial breast cancer 
and are also found in a small percentage of sporadic breast cancer cases 
(Kennedy et al., 2004). In some cases this is due to epigenetic changes where 
hyper-methylation of the promoter has occurred, and in other cases is due to 
genomic changes where copy number deletions and loss of heterozygosity 
occur (Rice et al., 2000, Staff et al., 2003, Chabalier et al., 2006). Determining 
BRCA1 status of patients is therefore important when deciding which systemic 
therapies should be administered in suspected cases of familial breast cancer. 
However, since BRCA1 aberrations are only found in a small percentage of 
sporadic breast cancer cases (Ford et al., 1995), patients diagnosed with this 
breast cancer type are not routinely tested (Levy et al., 2011, Grindedal et al., 
2017). 
Another example of altered gene expression conferring resistance is the 
increased expression of the transcription factor FOXM1 in endocrine therapy 
resistance in ER positive breast cancer (Bergamaschi et al., 2014). In this case, 
the increased expression of FOXM1 is a result of altered transcription rates. A 
previous study had noted that increased expression of 14-3-3ζ (gene name 
YWHAZ) in primary tumours was associated with earlier time to recurrence and 
metastasis in breast cancer (Bergamaschi et al., 2013) and increased 
expression following tamoxifen treatment was found to be a marker of poor 
prognosis (Frasor et al., 2006). 14-3-3ζ was subsequently observed to regulate 
FOXM1, acting upstream of this transcription factor (Bergamaschi et al., 2011). 
14-3-3ζ has also been previously shown to influence expression of other genes 
that contribute to chemoresistance such as the xenobiotic drug transporter 
ABCB1 (protein name P-glycoprotein) (Liang et al., 2014). Increased FOXM1 
protein expression was correlated with significantly reduced survival in ER 
positive breast cancer patients and was also associated with an expansion of 
the cancer stem-like cell population as well as resistance to endocrine 
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therapies (Bergamaschi et al., 2014). FOXM1 regulates the expression of 
genes involved in cell proliferation, metastasis and stem cell-like properties, 
implying several mechanisms by which tumour cells would be able to overcome 
tamoxifen-induced death. 
A more indirect mechanism of conferring resistance to therapeutic drugs is 
altered expression and function of enzymes that metabolise the drugs. These 
include cytochrome P450 enzymes, which are predominantly expressed in the 
liver but have also been shown to be expressed in tumour tissues including 
breast (Oyama et al., 2004, van Schaik, 2008). These enzymes are responsible 
for converting pro-drugs to active drugs and active drugs to their inactive 
metabolites. Increased expression of several of these metabolic enzymes has 
been observed in breast cancers, including CYP1B1 (Husbeck and Powis, 
2002) and CYP2E1 (Kapucuoglu et al., 2003). Evidence shows a role for 
CY1B1 in the metabolism of the anti-oestrogen tamoxifen (Crewe et al., 2002), 
whereas CYP2E1 has been shown to contribute to the metabolism of the 
chemotherapy agents cyclophosphamide and etoposide (Kawashiro et al., 
1998, Huang et al., 2000). Numerous polymorphisms in the genes encoding 
these enzymes have also been identified. The consequences of these 
polymorphisms on enzyme function vary. For example, CYP2D6, another 
enzyme involved in tamoxifen metabolism (Coller et al., 2002) has numerous 
alleles with different functions (van Schaik, 2008). Patients administered 
tamoxifen who were carriers of the alleles with reduced or no activity (examples 
include CYP2D6*9, *10, *41 and CYP2D6*3, *4, *5 respectively) had shorter 
times to recurrence compared with patients administered tamoxifen who were 
carriers of alleles with normal functionality (examples include CYP2D6*1, *2, 
*35) (Bonanni et al., 2006, Goetz et al., 2007, Schroth et al., 2007). This was 
proposed to be due to the decreased ability of the poor metabolisers to 
metabolise tamoxifen into its more active forms, such as endoxifen. 
A further mechanism by which cells can become resistant to chemotherapeutic 
agents is by expressing xenobiotic efflux pumps, which pump out substrates 
such as cytotoxic drugs. A well-known family of proteins that perform this 
function is the ABC transporter family (Sharom, 2008). These proteins actively 
transport substrates across the plasma membrane against the concentration 
gradient. The ABC protein family has a wide variety of substrates, although 
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there are many overlaps in substrate specificity between individual members 
(Massey et al., 2014). These genes are regulated by a number of mechanisms 
including epigenetic changes (Reed et al., 2008, Spitzwieser et al., 2016), 
genomic changes (Reed et al., 2008, O'Brien et al., 2008) and transcriptional 
changes (Ee et al., 2004, Wang et al., 2008). 
1.4.1.1 The role of ABC transporters in multi-drug resistance 
The ATP-Binding Cassette (ABC) proteins are membrane bound proteins 
involved in the efflux of many compounds across the cell membrane. 
Substrates include amino acids, metal ions, and sugars, demonstrating the 
important role these transporters play in normal cell function. There are forty-
nine known human ABC genes (Vasiliou et al., 2009, Hodges et al., 2011). The 
ABC family is subdivided into seven subfamilies, designated A-G, each of 
which has specific characteristics. For example, ABCA subfamily members are 
predominantly expressed in the central nervous system and several members 
of the ABCB subfamily facilitate intracellular peptide transport (Robey et al., 
2009, Fletcher et al., 2010).  
However, in cancer, the presence of the ABC transporters can pose a major 
problem during systemic treatment as some of the many substrates that can be 
transported across the cell membrane by these pumps include 
chemotherapeutic drugs (Eckford and Sharom, 2009). This can lead to multi-
drug resistance as these drug pumps lead to an efflux of drug from the cell, 
resulting in lower intracellular drug concentrations and increasing the ability of 
the cell to overcome damage-induced cell death (Hazlehurst and Dalton, 2006, 
Zahreddine and Borden, 2013). Three ABC genes in particular have been 
shown to contribute to multi-drug resistance in breast cancer. These are 
ABCB1, known also as MDR1 or P-glycoprotein (Pgp), ABCC1, also known as 
MRP1, and ABCG2, known also as MXR or Breast Cancer Resistance Protein 
(BCRP) (Eckford and Sharom, 2009, Fletcher et al., 2010). 
ABCB1 has numerous chemotherapeutic substrates that include 
anthracyclines, taxanes, mitoxantrone and irinotecan. ABCC1 also has several 
chemotherapeutic substrates, some of which are in common with ABCB1 such 
as anthracyclines and others that are unique such as antifolate antineoplastic 
agents. As with the previous two ABC family members, ABCG2 substrates 
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include anthracyclines, mitoxantrone and etoposide (Staud and Pavek, 2005, 
Gillet et al., 2007, Fletcher et al., 2010). Of these, ABCG2 / BCRP is of 
particular relevance to my work since I study its expression and potential 
importance in Chapter 6.  
1.4.2 Molecular pathways with indirect influence on resistance to 
systemic therapies 
Resistance to systemic therapies can also be conferred indirectly by altered 
activity of molecular pathways. One such pathway is the mitogen-activated 
protein kinases (MAPK) pathway, increased activity of which has been 
implicated in resistance to numerous systemic therapies. This pathway is 
involved in multiple cellular processes including cell proliferation (Zhang and 
Liu, 2002). Some of the effectors activated by this pathway that contribute to 
this function are c-fos, c-myc and c-jun (Sanchez et al., 1994, Price et al., 1996, 
Zhu et al., 2008). Increased expression of these proteins has previously been 
observed in breast cancer cells (Walker and Cowl, 1991, Berns et al., 1992, 
Zajchowski et al., 2001). Molecular profiling of residual breast tumours post-
NAC identified decreased expression of DUSP4, which was associated with 
high rates of cell proliferation post-NAC and the basal-like subtype of breast 
cancers (Balko et al., 2012). The DUSP4 protein (MKP2) is a dual-specificity 
MAPK phosphatase, which dephosphorylates ERK1/2, p38 and JNK (Lake et 
al., 2016). Reduced expression of MKP2 led to increased activation of the 
MAPK pathway and reduced response to chemotherapy (Balko et al., 2012). 
Further investigations revealed that in the basal-like subtype of breast cancer, 
the DUSP4 promoter is more highly methylated than in other breast cancer 
subtypes, suggesting one mechanism, an epigenetic change, for the decreased 
expression of this protein post-NAC. Increased activity of the MAPK pathway 
has also been associated with endocrine therapy resistance (Haagenson and 
Wu, 2010). 
Another dysregulated pathway implicated in systemic therapy resistance is the 
activation of the PI3K pathway, attributed in part to the over-expression and 
activation of growth factor receptors and their coactivators, including integrin 
receptors and JAK proteins (Garcia-Becerra et al., 2013, Martz et al., 2014). 
Similarly to the MAPK pathway, the PI3K pathway also contributes to the 
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regulation of cell proliferation, and also aids in the process of evasion of 
apoptosis (Ghebeh et al., 2014). Genomic changes involving mutations in 
PIK3CA have been observed in breast cancer, mostly consisting of SNPs 
(Isakoff et al., 2005). Several of the most studied mutations result in increased 
PI3K activity (Altomare and Testa, 2005), thus providing another possible 
mechanism by which PI3K pathway activity can be increased, leading to 
resistance to systemic therapies.  
1.4.2.1 Molecular pathways as novel therapeutic targets 
Identification of these dysregulated pathways and understanding the 
mechanisms behind the activities of these pathways that lead to 
chemoresistance, potentially allows the identification of novel therapeutic 
targets. Specific inhibitors of these molecular pathways have already been 
developed, although it has been observed that targeting only one pathway can 
result in another pathway being activated instead, resulting in continued 
resistance to therapies (Mirzoeva et al., 2009). This was reflected when 
inhibitors of the MAPK pathway tested in clinical trials yielded limited positive 
results in multiple cancers including breast cancer (Rinehart et al., 2004), and 
this has since been attributed to tumours being able to circumvent the effects of 
these inhibitors on their target expression (Duncan et al., 2012). Simultaneous 
administration of inhibitors of the MAPK and PI3K pathways had a synergistic 
effect, increasing apoptosis and cell cycle arrest (Mirzoeva et al., 2009). A 
more recent phase Ib clinical trial investigating the efficacy of alpelisib, an 
inhibitor of the PI3K catalytic subunit p110α (PI3KCA), in combination with the 
endocrine therapy letrozole, showed promising results, particularly in patients 
with a mutation in PIK3CA (Mayer et al., 2017). Phase II and III trials are 
ongoing and will hopefully show limited ability of tumours to circumvent the 
inhibition of the PI3K pathway. 
1.4.3 Altered miRNA expression in systemic therapy resistance 
MiRNAs are regulators of gene expression that act at post-transcriptional levels 
(see section 1.3.2). A wide range of miRNAs have also been implicated in 
therapeutic resistance, typically through their roles in controlling expression of 
protein-coding targets that themselves have roles in resistance, although the 
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specific targets have not always been identified for each miRNA. MiR-487a was 
down-regulated in a variant of the ER positive, breast cancer cell line MCF7 
that was resistant to mitoxantrone (Ma et al., 2013). These resistant cells had 
increased expression of the drug efflux pump breast cancer resistance protein 
(BCRP), which confers multidrug resistance (see section 1.4.1.1). Several 
validation experiments demonstrated that miR-487a was able to down-regulate 
BCRP expression by binding to the 3’UTR of the transcript, therefore that the 
down-regulation of miR-487a in the resistant cells was contributing to the 
resistance by leading to up-regulation of BCRP. 
MiRNAs also influence chemosensitivity via other less direct mechanisms such 
as evasion of apoptosis and epithelial-mesenchymal transition (EMT) (Kutanzi 
et al., 2011, Wang et al., 2015). One of the mechanisms the chemotherapeutic 
doxorubicin uses to kill tumour cells is by increased production of reactive 
oxygen species (ROS) (see section 1.2.2.3.1). Increased expression of let-7a 
increased the chemosensitivity of doxorubicin resistant triple negative breast 
cancer cells, an effect that was attenuated when cells were pre-treated with an 
antioxidant (Serguienko et al., 2015). This implicated let-7a in ROS production, 
although the precise molecular mechanisms were not identified. In a slightly 
different mechanism of inhibition of apoptosis, decreased expression of miR-
149 in doxorubicin resistant ER positive breast cancer cells led to increased 
expression of its target NDST1 (He et al., 2014a). This increased expression 
led to activation of a heparan sulphate pathway that triggered inhibition of 
apoptosis.  
An example of a miRNA that influences EMT is miR-125b, which was observed 
to be down-regulated in paclitaxel resistant ER positive MCF7 and HER2 
positive SKBR3 breast cancer cells (Yang et al., 2015). This down-regulation 
resulted in mesenchymal features, apparently including drug resistance, due to 
increased expression of the miR-125b target SEMA4C. 
Interestingly, multiple miRNAs can target the same transcript. PTEN is a 
tumour suppressor gene and over-expression of this gene sensitises ER 
positive breast cancer cells to doxorubicin by enhancing caspase-3-dependent 
apoptosis (Wang et al., 2011). Both miR-19 (Liang et al., 2011) and miR-21 
(Wang et al., 2011) have been shown to mediate chemoresistance via PTEN. 
Altogether, over sixty miRNA families have been identified as mediators of 
38 
 
resistance to systemic therapies in breast cancer (Kutanzi et al., 2011). This 
emphasises the vast network of small RNAs that could have a major impact on 
breast cancer response to systemic treatments that could be exploited when 
searching for novel therapeutic targets. 
1.5 Hypothesis and Aims 
The hypothesis of this project is that the specific molecular changes that occur 
during systemic therapy can lead to resistance to chemotherapy. There are two 
main aims to this project: 
1. To identify molecular changes that occur during neoadjuvant 
chemotherapy and determine which of these changes contributes to 
chemoresistance and what their mechanisms of function are. 
2. To determine whether the up-regulation of the Breast Cancer Resistance 
Protein (BCRP) post-neoadjuvant endocrine therapy could lead to 




Chapter 2: Materials & Methods 
2.1 Ethical considerations and patient samples 
Ethical approval was obtained from the Leeds (East) Research Ethics 
Committee, reference 06/Q1206/180. Tumour samples were available for 
research in the form of formalin-fixed paraffin-embedded (FFPE) cancer tissue 
blocks archived as part of routine clinical management at St James’ University 
Hospital, Leeds (Leeds Teaching Hospitals NHS Trust). Tissue was available 
for two patient cohorts: 1) 5 patients diagnosed with ER positive and HER2 
negative primary breast cancer at St James’s University Hospital, and who 
were treated with a combination of epirubicin and cyclophosphamide (EC) in a 
neoadjuvant setting and showed partial resistance to this treatment, as defined 
by MRI assessments during treatment and histopathology assessment of the 
resection samples. Matched tissues representing diagnostic core biopsies (pre-
neoadjuvant chemotherapy (NAC)) and resections (post-NAC) were available. 
2) 305 patients diagnosed with primary breast cancers of all molecular 
subtypes at St James’s University Hospital. Patients were diagnosed with 
primary breast cancer between 2005 and 2010. Tumour samples were taken 
from patients during surgical resection of the tumour without prior systemic 
therapies. Patients with incomplete follow-up data including time of recurrence 
(if any) and/or death were excluded. Areas of tumour enriched for tumour 
epithelial cells were marked by a breast histopathologist (Dr Eldo Verghese, 
project supervisor and consultant pathologist at Leeds Teaching Hospitals NHS 
Trust) and three cores with a diameter of 0.6mm were taken from each sample 
to construct tissue microarrays (TMAs). 
2.2 Tissue sectioning and staining of tissues with 
Haematoxylin and Eosin (H&E) 
Sectioning procedures were different for samples destined for Laser Capture 
Microdissection (LCM), or for immunohistochemistry. For LCM, samples were 
sectioned at 10μm and placed on MembraneSlide NF 1.0 PEN (415190-9211-
000; Carl Zeiss; Oberkochen, Germany) slides. Samples (whole tissue blocks 
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for optimisation or tissue microarrays) for immunohistochemistry were 
sectioned at 5µM and placed on SuperFrost Plus™ Adhesion Slides 
(12625336; Fisher Scientific; Hampton, USA). Following sectioning, slides were 
placed on a hot plate at 70oC for 15 minutes to ensure tissue attachment.  
Slides to be Haematoxylin and Eosin (H&E) stained were placed in xylene 
three times for 3 minutes each. Tissues were then rehydrated using dilutions of 
ethanol (100%, 75% and 50%) for 1 minute each followed by distilled water. 
Slides were then placed in filtered Mayer’s haematoxylin (008011; Thermo 
Fisher Scientific; Waltham, USA) for 2 minutes followed by washing with 
distilled water until excess haematoxylin had been removed. This was followed 
by staining with 1% eosin for 2 minutes and washing again to remove excess 
eosin. Tissues were dehydrated again using dilutions of ethanol (75% and 2x 
100%) for 2 minutes each and then xylene for a total of 5 minutes. 
2.3 Isolation of tumour epithelial cells using Laser Capture 
Micro-dissection (LCM) 
All samples were viewed by breast histopathologists (Dr Eldo Verghese, 
consultant breast histopathologist at Leeds Teaching Hospitals NHS Trust and 
co-supervisor for this work, or Professor Andrew Hanby, consultant breast 
histopathologist at Leeds Teaching Hospitals NHS Trust) and areas containing 
cancer cells were identified. LCM was performed using the PALM® Robot 
Microbeam laser microdissection system (P.A.L.M. Microlaser Technologies 
GmbH; Bernried, Germany) using the PALM RoboSoftware 3.2, or the 
ArcturusXT™ Laser Capture Microdissection System (Thermo Fisher Scientific; 
Waltham, USA). Two approaches were used to isolate epithelial cancer cells. 
When samples consisted predominantly of epithelial cancer cells, any 
unwanted elements such as stroma or Ductal Carcinoma In Situ (DCIS) were 
removed from the slides by LCM (Figure 2.3.1A and B) and tumour cells were 
later macro-dissected from the slides into micro-centrifuge tubes using a 
scalpel. When samples contained smaller patches of epithelial cancer cells, 
dissection occurred using LCM directly (Figure 2.3.1C and D) into an Adhesive 
Cap 500 clear (415190-9211-000; Carl Zeiss; Oberkochen, Germany) (for use 
with the PALM system, or an Arcturus® CapSure® Macro LCM Cap (10284-04; 
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Applied Biosystems; Foster City, USA) (for use with the Arcturus system). For 
most samples, 10 to 15 sections were used except where very few cells were 
present, in which case up to 25 sections were used. When samples contained 
smaller patches of epithelial cancer cells, the total areas of tissue that were 
LCM dissected were 7-54mm2. 
  
  
Figure 2.3.1: Isolation of tumour epithelial cells using two different LCM 
approaches 
Two approaches were taken when performing LCM to isolate tumour 
epithelial cells – representative pairs of images for each approach are 
shown. (A) An example section of tissue highly enriched with tumour 
epithelial cells with only small areas of unwanted elements, in this case 
stroma. (B) The same section of tissue shown in (A) after removal of 
stroma by LCM – the epithelial cancer cells left behind were collected 
manually for RNA extraction. (C) An example section of tissue with small 
groups of tumour epithelial cells interspersed with many areas of 
unwanted elements. (D) The same section of tissue shown in (C) after 
direct isolation of the tumour epithelial cells by LCM; RNA was extracted 





2.4 Extraction of total RNA from isolated tumour cells from 
patient samples 
RNA was extracted from cells using the AllPrep DNA/RNA FFPE Kit (80234; 
Qiagen; Venlo, the Netherlands). In brief, cells were re-suspended in Buffer 
PKD with proteinase K and incubated at 56oC for 15 minutes followed by a 3 
minute incubation on ice. Samples were centrifuged for 15 minutes at 20000g 
and the supernatant incubated for a further 15 minutes at 80oC. Buffer RLT was 
added together with ethanol before applying the sample to an RNeasy 
MiniElute spin column. The spin column was washed with Buffer FRN before a 
mixture of DNaseI and Buffer RDD was added directly to the membrane and 
allowed to incubate at room temperature for 15 minutes. The spin column was 
washed again with Buffer FRN and the flow-through reapplied to the 
membrane. Washing occurred twice with Buffer RPE before being centrifuged 
for 5 minutes to dry the membrane. RNA was eluted in RNase-free water and 
stored at -80oC. 
2.5 Preparation of cDNA for analysis of miRNA expression in 
patient samples 
To perform reverse transcription of miRNAs, the TaqMan™ MicroRNA Reverse 
Transcription Kit (4366597; Applied Biosystems; Foster City, USA) was used 
following the manufacturer’s protocol. In brief, up to 200ng total RNA in a 
volume of 3µl was mixed with the reverse transcription reaction mixture 
containing Megaplex™ RT Primers, Human Pool A v.2.1. (4399966; Applied 
Biosystems; Foster City, USA) in 0.2ml PCR® Tubes (321-02-501; Axygen; 
Corning, USA). The mixture was incubated on ice for 5 minutes before being 
placed in a controlled temperature heat block to undergo reverse transcription 




Table 2.5.1: Conditions for reverse transcription of cDNAs (from miRNAs)  




50 1 second 
1 85 5 
1 4 ∞ 
Since low levels of RNA were extracted from the FFPE samples, pre-
amplification of the cDNA was required. This was performed using Megaplex™ 
PreAmp Pool A Primers (4399830; Applied Biosystems; Foster City, USA) and 
the TaqMan® PreAmp Master Mix (4384266; Applied Biosystems; Foster City, 
USA) following the manufacturer’s protocol. In brief, the cDNA was placed in a 
mixture with the Pool A primers and master mix into 0.2ml PCR Tubes (321-02-
501; Axygen; Corning, USA) before being placed in a controlled temperature 
heat block to undergo pre-amplification (Table 2.5.2). The PCR products were 
then diluted with 0.1X TE buffer pH8.0 and stored at -200C. 
Table 2.5.2: Conditions for pre-amplification of miRNAs  
Number of cycles Temperature (oC) Time (min) 
1 95 10 
1 55 2 
1 72 2 
12 
95 15 seconds 
60 4 
1 99.9 10 
1 4 ∞ 
2.6 Expression profiling of miRNAs in patient samples 
To analyse miRNA content, samples were mixed with TaqMan® Universal PCR 
Master Mix (4324018; Applied Biosystems; Foster City, USA) and loaded onto 
TaqMan® MicroRNA Array A cards (4398977; Applied Biosystems; Foster City, 
USA). These were amplified on the 7900HT Fast Real-Time PCR System 
(Applied Biosystems; Foster City, USA). Each individual sample was 
normalised to the mean of all miRNAs expressed within that sample. Those 
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miRNAs detected in only one of the paired samples for each patient were also 
included in the number of miRNAs either up- or down-regulated on the 
condition that the Ct value of the detected sample was a maximum of 38.5. 
2.7 Analysis of mRNAs in patient samples using NanoString 
Total RNA was either analysed directly or was first reverse transcribed followed 
by pre-amplification. Reverse transcription was performed using 1µl 
SuperScript® VILO™ Master Mix (11755050; Thermo Fisher; Waltham, USA) 
and 50-110ng total RNA, in a total volume of 5µl. Equal amounts of total RNA 
were used for matched pre- and post-NAC samples for each patient. The 
mixture was incubated at 25oC for 10 minutes, then 42oC for 60 minutes 
followed by 85oC for 5 minutes. 
Pre-amplification was performed using TaqMan® PreAmp Master Mix (4384266; 
Applied Biosystems; Foster City, USA) and pooled MTE primers (containing 
primers for all genes in the NanoString codeset chosen). Together with all of 
the reverse transcription product (5µl), this mixture, in a total volume of 11µl, 
was placed in a controlled temperature heatblock (see Table 2.7.1 for 
conditions). 
Table 2.7.1: Conditions under which Multiplexed Target Enrichment of 
cDNA was performed in preparation for analysis by NanoString 
Technologies 
Step Temperature (oC) Time 
Denaturation 94 10 mins 
MTE cycles (10x) 
94 15 s 
60 4 mins 
Hold 4  
Total RNA or cDNA was sent for analysis using the nCounter® PanCancer 
Pathway panel (NanoString Technologies) to the NanoString service, Human 
Dendritic Cell Lab, Newcastle University, UK (contact individual was Ms 
Anastasia Resteu; Newcastle University, UK). Data were analysed using the 




2.8 Drugs used in tissue culture and their storage conditions 
Epirubicin hydrochloride (E9406; Sigma; St Louis, USA) was dissolved in 
autoclaved water at a stock concentration of 100mM. It was stored at -20oC in 
aliquots of 10µl. Docetaxel (01885; Sigma; St Louis, USA) was dissolved in 
dimethyl sulphoxide (DMSO) at a stock concentration of 10mM. It was stored at 
-20oC in aliquots of 200µl. Tamoxifen (T5648; Sigma; St Louis, USA) was 
dissolved in 100% ethanol at a stock concentration of 53.8mM. It was stored at 
-20oC in aliquots of 1ml. 
2.9 Cell culture  
MCF7, T47D and MDA-MB-175 cells were available within the Hughes group, 
having been originally purchased from the European Collection of Animal Cell 
Cultures. Cell line identities were confirmed (STR profiles, Leeds Genomics 
Service) and lines were consistently negative for mycoplasma (MycoAlert 
Mycoplasma detection assay, Lonza, Basel, Switzerland). MCF7 and T47D 
cells were routinely cultured in Dulbecco Modified Eagle’s Medium (DMEM) 
(31966; Gibco® by Life Technologies™; Waltham, USA), and MDA-MB-175 
cells were routinely cultured in Leibovitz’s L-15 Medium (11415049; Gibco® by 
Life Technologies™; Waltham, USA), all supplemented with 10% Foetal Calf 
Serum (FCS) (Sigma-Aldrich; St Louis, USA) and 1% Penicillin/Streptomycin 
(15070-063; Gibco® by Life Technologies™; Waltham, USA). MCF7, T47D and 
MDA-MB-175 cells were routinely grown at 37oC and MCF7 and T47D cells 
were also kept in 5% CO2. Cells were passaged when they had reached over 
70% confluency. The media was removed and the cells washed with 
Dulbecco’s Phosphate Buffered Saline (DPBS) (14190; Gibco® by Life 
Technologies™; Waltham, USA). Trypsin solution (0.05% v/v) (15400054; 
Gibco® by Life Technologies™; Waltham, USA) was added and cells were 
incubated for up to 5 minutes at 37oC. To inactivate the trypsin, fresh media 
was added to the cells and – typically – one-twentieth of this volume for MCF7 
and T47D cells (split ratio of 1:20) and one-third of this volume for MDA-MB-




2.9.1 Development of epirubicin resistant MCF7 and T47D cell lines 
MCF7 and T47D cells were treated initially with low doses of epirubicin 
hydrochloride (E9406; Sigma) or vehicle control (water) and cultured 
continuously as described above. Fresh drug was added once a week, with 
doses gradually increased over many months such as to avoid excessive cell 
killing. MCF7 cells were initially treated with 1nM epirubicin and T47D cells 
were initially treated with 10nM epirubicin. Doses were no longer increased 
once MCF7 cells were treated regularly with 350nM epirubicin and T47D cells 
with 1µM epirubicin. 
2.10 Transfection of cells with microRNA mimics and hairpin 
inhibitors, and siRNAs 
Initial studies were performed using microRNA mimics and hairpin inhibitors 
(Dharmacon; Lafayette, USA) with mature sequences listed in Table 2.10.1. 
Different numbers of cells in different sized wells were used depending on the 
end-point assays to be used, as follows. For subsequent RNA extractions and 
colony forming assays, cells were plated into each well of 24-well plates, or for 
MTT assays, cells were plated into each well of 96-well plates. Cells were 
plated for each assay such that they were 70-80% confluent at the time of 
transfection. The following day, Lipofectamine 2000 Transfection Reagent 
(11668019; Invitrogen; Carlsbad, USA) was used to transfect cells with the 
mimics or inhibitors (final concentrations in each complex for each well are 
shown in Table 2.10.1) together with equimolar amounts of the appropriate 
controls in Opti-MEM Reduced Serum Medium (31985; Gibco® by Life 
Technologies™; Waltham, USA). For MCF7 cells, 0.4 times of the final 
transfection mixture volume was added of Lipofectamine 2000 (2:5 ratio). For 
MDA-MB-175 cells, 0.25 times of the final transfection mixture volume was 
added of Lipofectamine 2000 (5:20 ratio). The mixture containing Lipofectamine 
2000 and miRNA mimic or inhibitor was in a final volume of 70µl for 24-well 
plates and 15µl for 96-well plates. Twice this volume of Opti-MEM Reduced 
Serum Medium and one times of this volume of normal media (DMEM for 
MCF7 cells and Leibovitz’s L15 for MDA-MB-175 cells) was also added to each 
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well. Cells were incubated in transfection media for 24 hours, at which point the 
transfection media was replaced with normal media. 
Biotinylated miRCURY LNA microRNA Mimics or a negative control (47997-
671; Exiqon; Venlo, the Netherlands) were used to transfect MCF7 cells in 
T150 tissue culture flasks (CLS430825; Sigma; St Louis, USA) with 
Lipofectamine 2000 as described above. This was performed using mimics of 
miR-26b-5p and miR-195-5p and were transfected into cells at final 
concentrations of 25nM and 15nM respectively in each complex for each flask. 
The siRNAs were purchased from IDT (San Jose, USA) and transfected into 
cells using the same protocol as was used for the miRNA mimics and inhibitors. 






































































Table 2.10.2: Sequences of the siRNAs used in transfections 
mRNA (reference 
number) 
Sequence of antisense strand 
CCDC6 (161436520) 5’ - UGAAAUUCAGACUAAGCUCAUGCAUUA 
REEP4 (76776114) 5’ - GUAUCUGACCAACACUCAUCCUCGGUG 
SEMA6D (76776117) 5’ – UUCUAAGGUACUCAACCUGUAGUAUCU 
PRKCD (76776108) 5’ - GAUGUUGAAGCGUUCUUUCUGGAAUAU 
ARL2 (76776111) 5’ - UUUAUUUCACAACUGAGUGAAGGAUGA 
2.11 Harvesting cells transfected with non-biotinylated miRNA 
mimics or inhibitors or siRNAs for RNA extraction 
At the appropriate time points, media was removed and the cells washed with 
PBS. The cells were then covered with 100µl of BL buffer (Promega; Madison, 
USA) supplemented with 1-Thioglycerol (TG) according to the manufacturer’s 
instructions (Promega; Madison, USA). Cells were incubated in the buffer for 
20 minutes at room temperature with occasional shaking to allow cell lysis to 
occur, followed by collection of the buffer mixture that was stored at -80oC until 
RNA extraction occurred. 
2.12 Extracting total RNA from cells  
RNA was extracted using the ReliaPrep™ RNA Cell Miniprep System (Z6012; 
Promega; Madison, USA) according to the manufacturer’s instructions. In brief, 
isopropanol was added to the BL+TG buffer cell lysate at a final concentration 
of 34%. Samples were placed into a ReliaPrep™ Minicolumn. All centrifugation 
steps occurred at 12000g unless stated otherwise. Minicolumns were then 
washed with RNA Wash Solution. A DNaseI mix was freshly prepared 
containing Yellow Core Buffer, MnCl2 and DNaseI enzyme that was added to 
the membrane and left to incubate for 15 minutes followed by addition of 
Column Wash Solution and centrifugation for 15 seconds. This was followed by 
two washes with RNA Wash Solution. The final centrifugation step lasted 2 
minutes. Nuclease-free (NF) water was then added to the membrane and left 
for 1 minute before centrifugation for 1 minute at 5500g. Extracted RNA was 
stored at -80oC. 
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2.13 Analysing miRNA expression using real-time quantitative 
PCR (individual miRNAs) 
RNA samples first underwent reverse transcription, resulting in stable cDNA 
samples. This was achieved using the TaqMan Reverse Transcription Kit 
(4366597; Applied Biosystems; Foster City, USA) according to the 
manufacturer’s instructions. In brief, 1-10ng of total RNA was mixed with a 
master mix containing dNTPs, reverse transcriptase, RNase inhibitor and 
reverse transcription buffer in a total volume of 15µl. Reactions were placed in 
a controlled temperature heat block to allow reverse transcription to occur (see 
Table 2.13.1 for conditions). 
Table 2.13.1: Conditions for miRNA reverse transcription  




MiRNA qPCR was performed by combining TaqMan 2x Universal PCR Master 
Mix, No AmpErase UNG (4324018; Applied Biosystems; Foster City, USA), NF 
water, the primers for the miRNA of interest, and the reverse transcription 
product in 10µl total volumes, in technical triplicate reactions. The reference 
miRNA used was RNU48.  
Reactions occurred in MicroAmp® Optical 96-Well Reaction Plates (N8010560; 
Applied Biosystems; Foster City, USA) using a QuantStudio 5 Real-Time PCR 
System (Applied Biosystems; Foster City, USA). The conditions for the 
reactions are shown in Table 2.13.2. 
Table 2.13.2: Conditions for miRNA real-time quantitative PCR  
 
 
Step Temperature (oC) Time (mins) 
HOLD 95 10 
40 cycles 




2.14 Analysing mRNA expression using real-time quantitative 
PCR 
RNA samples first underwent reverse transcription, resulting in stable cDNA 
samples. This was achieved using the GoScript™ Reverse Transcription 
System (A5001; Promega; Madison, USA) according to the manufacturer’s 
instructions. In brief, 0.5-1μg of total RNA was diluted in NF water before 
addition of Random Primers in a total volume of 5µl. Samples were then 
incubated at 70oC for 5 minutes and placed in ice water immediately after. 
Reactions were combined in a total volume of 20μl containing NF water, 
GoScript™ 5X Reaction Buffer, MgCl2, PCR Nucleotide Mix and GoScript™ 
Reverse Transcriptase. Two control reactions were performed: one lacking 
Reverse Transcriptase, and one lacking RNA template. Reactions were placed 
in a controlled temperature heat block to allow reverse transcription to occur 
(see Table 2.14.1 for conditions). 
Table 2.14.1: Conditions for mRNA reverse transcription  
Temperature (oC) Time (mins) Function 
25 5 Annealing 
42 60 Extension 
70 15 
Thermal inactivation of 
reverse transcriptase 
Quantification of mRNA levels of genes of interest was performed using the 
GoTaq® qPCR Master Mix kit (6001; Promega; Madison, USA) according to the 
manufacturer’s instructions. In brief, separate mixtures were prepared 
containing GoTaq® qPCR Master Mix (2X), CXR Reference Dye and forward 
and reverse primers for each gene of interest (Table 2.14.2Error! Reference 
source not found.). The reference gene used was beta-actin. Reactions 
occurred in MicroAmp® Optical 96-Well Reaction Plates (N8010560; Applied 
Biosystems; Foster City, USA) in a total volume of 10μl in technical triplicates. 
96-well plates were centrifuged for 1 minute at 1000g. Analyses were 
performed in the 7500 Real Time PCR System machine (Applied Biosystems; 
Foster City, USA) or QuantStudio 5 Real-Time PCR System (Applied 
Biosystems; Foster City, USA), using the 7500 System SDS Software (v1.2) or 
the QuantStudio 5 Real-Time PCR Software. The conditions under which the 
reactions took place are shown in Table 2.14.3.  
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Table 2.14.2: qPCR primer sequences for mRNAs 
 
Table 2.14.3: Conditions for real-time quantitative PCR for mRNAs 
 
2.15 Chemo-survival assays using MTT assays 
Cells were seeded at the appropriate density into 96-well plates. For 
transfections, target confluency for the next day was 70-80%. For drug 
treatments, target confluency for the next day was 90%. The following day, 
cells were either transfected with miRNA mimics/inhibitors/controls or target 
siRNAs or controls, treated with epirubicin or docetaxel, or transfected and then 
treated with epirubicin forty-eight hours later. Survival was assessed using MTT 
assays up to 48 hours after chemotherapy treatment. Medium was removed 
Primer name (Supplier) Primer sequence 
Beta-actin Forward (Sigma) 5’ – TTCTACAATGAGCTGCGTGTG 
Beta-actin Reverse (Sigma) 5’ – GGGGTGTTGAAGGTCTCAAA  
ABCG2 Forward (Sigma) 5’ – CAGGTGGAGGCAAATCTTCGT  
ABCG2 Reverse (Sigma) 5’ – ACACACCACGGATAAACTGA  
CCDC6 Forward (IDT) 5’ - CTCCAGAAAATATGATGCGTCAC 
CCDC6 Reverse (IDT) 5’ – CCTCCAGATACTGTGCCATT 
PRKAR2B Forward (IDT) 5’ – TCTCTTTTTGGCATTGTTTTTCAC 
PRKAR2B Reverse (IDT) 5’ - CTACAATCACTGCTACCTCTCC 
GNAI3 Forward (IDT) 5’ - CATCCTCTGAATAGCCATCCTC 
GNAI3 Reverse (IDT) 5’ - AAAAAGCGGCCAAAGAAGTG 
E2F7 Forward (IDT) 5’ - CAATGTCATAGATGCGTCTCCT 
E2F7 Reverse (IDT) 5’ - GCTCGCTATCCAAGTTATCCC 
PRKCD Forward (IDT) 5’ - GGATACATGGTCGGCTTCTTC 
PRKCD Reverse (IDT) 5’ - CATCGCCTTCAACTCCTATGAG 
SEMA6D Forward (IDT) 5’ - ACTGGACTTCCCATCGTACA 
SEMA6D Reverse (IDT) 5’ - TGCTGTTAACCGAAGACTTCT 
ARL2 Forward (IDT) 5’ - TTAGCAAAGATGAGGAGGGTTG 
ARL2 Reverse (IDT) 5’ - GAACTACTTTGAGAGCACCGAT 
REEP4 Forward (IDT) 5’ - GTACATCATCCACCGCACAT 
REEP4 Reverse (IDT) 5’ - ATGATCTGTCGCCTGGTG 
Number of cycles Temperature (oC) Time (mins) 
1 50 2 
1 95 10 
40 




and 25µl of 5mg/ml MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazdium 
Bromide) reagent (M6494; Invitrogen; Carlsbad, USA) was added. Cells were 
then incubated at 37oC in 5% CO2 in the dark for four hours followed by 
removal of the MTT reagent and addition of 50µl 100% isopropanol. Plates 
were then placed on a shaker for 15-30 minutes and absorbance was read at 
570nm using a Mithras LB 940 Multimode Microplate Reader (Berthold 
Technologies; Bad Wildbad, Germany). 
2.16 Colony forming survival assays 
Cells were transfected with miRNA mimics/inhibitors/controls or targeting 
siRNAs or controls as described in section 2.10. Forty-eight hours post-
transfection, MCF7 cells were treated with 30nM epirubicin for twenty-four 
hours, or MDA-MB-175 cells were treated with 300nM or 600nM epirubicin for 
twenty-four hours. After treatment, cells were removed from the wells using 
trypsin as described in section 2.9, and re-seeded at low density in 6-well 
plates (technical duplicates for each condition).  For MCF7 cells, 100 cells were 
plated per well, while for MDA-MB-175 cells 200 cells per well were plated. 
Importantly, MDA-MB-175 cells were re-plated in medium that had been pre-
conditioned by MDA-MB-175 cells; this medium was prepared by being placed 
on confluent MDA-MB-175 cells for twenty-four hours and then being removed 
and centrifuged to ensure no carry-over of cells. This conditioned medium was 
prepared fresh where possible. When not possible, conditioned medium was 
prepared and stored at -20oC. Following plating, cells were incubated under 
standard culture conditions for fourteen days to allow colonies to grow. These 
plates were incubated in an incubator dedicated to colony forming assays, 
which was opened minimally during experiments; this was important to ensure 
that growing colonies were not disturbed and thereby avoid single colonies 
being split into multiple smaller colonies. 
After fourteen days, growth media was removed and cells washed with DPBS. 
Cells were then fixed and stained simultaneously using the following solution 
containing 5mg/ml crystal violet (V5265-500ML; Sigma; St Louis, USA): 30% 
water, 50% methanol, and 20% ethanol. After four minutes, the solution was 
removed and colonies were washed twice with de-ionised water. The plates 
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were then air-dried before the number of colonies for each condition was 
manually counted. Tight groups of at least 30 cells were considered to be 
colonies. To validate the reproducibility of colony counts, a second count of ten 
plates was performed by Lisa Allinson (LA; a PhD student colleague at the 
University of Leeds) who had also performed colony forming survival assays in 
MCF7 cells. Results are shown in Figure 2.16.1, with a R2 value of 0.999, 
demonstrating that counting of colonies was highly reproducible. 
 
Figure 2.16.1: Raw colony counts are highly reproducible 
Ten plates of colony forming assays were counted by both Lisa Allinson 
(LA) and the author (DB). Raw counts were plotted and a line of best fit 
drawn, with the correlation coefficient calculated. 
2.17 Pulldowns of biotinylated-miRNA mimic transfected cells 
and RNA preparation 
Initially, it was necessary to block the streptavidin-coated agarose beads to be 
used in the pulldowns with non-specific RNA and protein, in order to reduce 
background recovery. Pierce High Capacity Streptavidin Agarose beads 
(20357; Thermo Fisher Scientific; Waltham, USA) were blocked in aliquots of 
50l of slurry. 500l of ice-cold lysis buffer was added to each aliquot in a 1.5ml 
microcentrifuge tube. These were centrifuged at 12000g for 30 seconds before 
being washed in lysis buffer and centrifuged again. The beads were then 
resuspended in 50l lysis buffer and final concentrations of 1mg/ml tRNA 
(AM7119; Ambion; Foster City, USA) and 1mg/ml albumin (acetylated from 
bovine serum) (B2518-10MG; Merck; St Louis, USA) were added. This mixture 

























Number of colonies (LA)
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twice with 300l ice-cold lysis buffer before being resuspended in 100l ice-
cold lysis buffer. 
MCF7 cells were transfected with biotinylated miRNA mimics as described in 
section 2.10. Twenty-four hours post-transfection, cells were harvested with 
trypsin and washed twice with ice-cold PBS and centrifuged at 400g for 5 
minutes to form a pellet that was resuspended in ice-cold 1.5ml lysis buffer 
(see Appendix A.1). This resuspension was vortexed, placed on ice for 20 
minutes and vortexed again. The mixture was then centrifuged at 12000g for 15 
minutes at 4oC. The majority of the supernatant (except 50l that was kept 
aside as an input control) was added to 100l blocked Streptavidin Agarose 
beads and incubated whilst rotating for 4 hours at 4oC. The mixture was then 
centrifuged at 12000g for 1 minute at 4oC and the supernatant removed. The 
beads were washed five times with 1ml ice-cold lysis buffer. After the final 
wash, beads (and the input control samples) were resuspended in 100l ice-
cold lysis buffer.  
To extract total RNA, 500l TRI-Reagent (T9424; Sigma; St Louis, USA) was 
added to each sample and incubated at room temperature for 5 minutes whilst 
mixing occasionally. Then, 100l chloroform (10332702; ACROS Organics; 
Hampton, USA) was added and the mixture was shaken vigorously for 30 
seconds before centrifuging at 4oC for 15 minutes at 16000g. The aqueous 
phase was transferred to a fresh tube and 5l GlycoBlue Coprecipitant 
(AM9515; Ambion; Foster City, USA) was added. RNA was precipitated in 2.5 
volumes of 100% ethanol and 0.1 volume of sodium acetate (S7899; Sigma; St 
Louis, USA) at -80oC overnight. 
The next day, the mixtures were centrifuged at 4oC for 30 minutes at 16000g. 
The supernatant was removed and the pellet washed in 1ml 75% ethanol 
followed by vortexing and centrifugation at 4oC for 15 minutes at 16000g. This 
wash step was repeated once. After the second, the ethanol was removed and 




2.18 Library preparation for RNA-Seq 
Samples of total RNA were first depleted of rRNA using the Ribo-Zero Gold 
rRNA Removal Kit (MRZG12324; Illumina; San Diego, USA) according to 
manufacturer’s instructions. In brief, rRNA binding buffer and removal mix were 
added to total RNA before denaturation at 68oC for 5 minutes, in a total volume 
of 15µl. For the input RNA samples, 438-511ng total RNA was used, and for 
the pulldown RNA samples, 102-122ng total RNA was used. rRNA removal 
beads were then added and binding allowed to occur for 1 minute at room 
temperature before the supernatant was cleaned using RNAClean XP beads 
and washing with 70% ethanol followed by elution in 11µl Elution Buffer. This 
elution was further processed by the addition of an equal volume of Elute, 
Prime, Fragment High Mix and the mixture incubated at 94oC for 8 minutes 
followed by a brief centrifugation to mix any condensation with the rest of the 
mixture. 
The whole volume of rRNA-depleted RNA samples then underwent first strand 
cDNA synthesis using SuperScript II Reverse Transcriptase and First Strand 
Synthesis Act D Mix in a total volume of 25µl followed by incubation at 25oC for 
10 minutes, 42oC for 15 minutes and 70oC for 15 minutes. 
Second strand cDNA synthesis was then performed by adding 20µl Second 
Strand Marking Master Mix to the first strand cDNA synthesis product and 
incubation at 16oC for 1 hour. The sample was then cleaned using 90µl 
AMPure XP beads and 80% ethanol followed by resuspension in 17.5µl 
Resuspension Buffer.  
Following cDNA synthesis, adenylation of the 3’ ends was performed in order to 
facilitate ligation to the unique sequence adapters using 12.5µl A-Tailing Mix in 
a total volume of 30µl followed by incubation at 37oC for 30 minutes and 70oC 
for 5 minutes. This was followed by ligation of the indexing adapters unique to 
each sample using 2.5µl RNA Adapter Indexes and 2.5µl Ligation Mix, followed 
by incubation at 30oC for 10 minutes. 5µl Stop Ligation Buffer was added to 
inactivate the ligation, followed by two washes using 80% ethanol and AMPure 
XP Beads. Samples were eluted in 20µl Resuspension Buffer. 
Samples then underwent PCR amplification specific for those DNA fragments 
with adapter molecules on both ends using the PCR Primer Cocktail and PCR 
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Master Mix in a total volume of 50µl and incubation at 98oC for 30s and 15 
cycles of 98oC for 10 seconds, 60oC for 30 seconds and 72oC for 30 seconds 
followed by incubation at 72oC for 5 minutes. Samples were cleaned using 50µl 
AMPure XP Beads and 80% ethanol and eluted in 30µl Resuspension Buffer. 
Samples were quantified using the Quanti-iT™ High Sensitivity dsDNA Assay 
Kit (Q33120; Life Technologies; Carlsbad, USA) and Qubit® 2.0 Fluorometer 
(Q32866; Life Technologies; Carlsbad, USA). To assess the presence of only 
library prepared fragments and no primer dimers in the final samples, the 
quality of the samples was assessed using the Agilent 2200 TapeStation using 
the High Sensitivity D1000 ScreenTape (Agilent; Santa Clara, USA). Samples 
were sequenced combined in a single lane of paired end sequencing using the 
Illumina HiSeq 3000 sequencing platform (San Diego, USA). 
2.19 Analysis of RNA-Seq data 
All analyses described here were performed by Dr James Poulter (a colleague 
at the University of Leeds). FASTQ files were aligned to the human genome 
using a FASTA reference file using the Spliced Transcripts Alignment to a 
Reference (STAR) software (Dobin et al., 2013). This was performed using the 
two pass alignment method that has been shown to permit higher sensitivity of 
novel splice junction detection than the single pass alignment method 
(Veeneman et al., 2016). Header and Read Groups were then manually added 
to the SAM files using Picard Tools (Broad Institute; Cambridge, USA) to label 
individual samples. Quality control of data was performed using FastQC 
(Babraham Institute; Cambridge, UK) before and after removal of adapter 
sequences, primers and poly-A tails using Cutadapt software (Martin, 2011). All 
samples passed quality control. 
Differential expression of genes in samples containing targeting miRNA bait 
compared with samples with a non-targeting miRNA bait was performed using 
two different methods. The first method involved using the Model-based 
Analysis of ChIP-Seq (MACS2) algorithm (Zhang et al., 2008), which identifies 
enriched regions of sequence, detecting these regions as peaks. A p value for 
each peak is calculated using a dynamic Poisson distribution that takes into 
consideration read background levels. This software was designed to analyse 
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ChIP-Seq data. My RNA-Seq data was analysed using this software on the 
basis that the experiment was performed using a pulldown method and 
included samples from both input and pulldown samples. As this software 
identifies peaks of read counts above the background level, another factor 
taken into consideration was the fact that there would be many more reads of 
genes bound to the miRNA bait than any other reads and should therefore be 
easily identified by the MACS2 algorithm as peaks.  
The second method used DESeq (EMBL; Heidelberg, Germany), an R package 
that can be used to test for differential expression of genes by use of the 
negative binomial distribution (see Appendix B for commands used). This also 
involved the use of featureCounts to annotate the reads with the corresponding 
gene identification using hg38 as a reference, to ensure only read pairs were 
counted as paired end sequencing was performed, and to ensure chimeric 
fragments (fragments with two reads mapped to different chromosomes) were 
not counted. Differential expression of genes was calculated after read counts 
were normalised to the total number of reads in each sample i.e. pseudocounts 
for each test (miR-26b targets compared with non-targeting miRNA targets, and 
miR-195 targets compared with non-targeting miRNA targets). Differential 
expression of genes was calculated between input samples and between 
pulldown samples. 
2.20 Staining for REEP4 and SEMA6D in breast cancer tissue 
samples by immunohistochemistry (IHC) 
Immunohistochemistry was performed on tissue microarrays (TMAs) containing 
breast cancer tissue samples. TMAs were constructed by Ms Stacey Jones 
(colleague at University of Leeds). 
Immunohistochemistry was performed by the author and by Dr Filomena 
Esteves (colleague at University of Leeds). Sections were dewaxed and 
hydrated by being placed in xylene three times for 3 minutes each followed by 
100% ethanol for 1 minute each and finally running tap water for 5 minutes. 
Antigen retrieval was performed using a 10mM citrate buffer pH6.0 and heating 
in a 900W microwave for 10 minutes followed by rinsing in tap water. 
Endogenous peroxidase was then blocked using 0.3% hydrogen peroxide 
59 
 
solution for 10 minutes before being rinsed in running tap water for 5 minutes. 
Sections were then blocked using 100µl antibody diluent (003218; Invitrogen; 
Carlsbad, USA) before addition of the primary antibody and incubation in a 
humidified chamber. See Table 2.20.1 for concentrations of primary antibody 
used. 
Table 2.20.1: Primary antibodies used for IHC and the dilutions at which 
they were used 
Antigen Antibody Dilution (Time) 
REEP4 
Anti-REEP4 (rabbit) (ab237689; 
Abcam; Cambridge, UK) 
1:1000 (1 hour) 
SEMA6D 
Anti-SEMA6D (N-terminal) (rabbit) 
(ab198745; Abcam; Cambridge, UK) 
1:25 (overnight at 4oC) 
The following day, sections were washed twice for 5 minutes each with 1x Tris-
Buffered Saline with 0.1% Tween 20 (TBST) (see Appendix A.5) followed by 
washing for 5 minutes with 1x Tris-Buffered Saline (TBS) before addition of the 
secondary antibody: SignalStain® Boost IHC Detection Reagent (HRP, Rabbit) 
(8114P; Cell Signaling Technology; Danvers, USA) was added so as to cover 
the section and allowed to incubate in a humidified chamber for 30 minutes at 
room temperature. Sections were then washed as before with TBST and TBS 
followed by addition of 3,3’-diaminobenzidine (DAB) working solution using the 
SignalStain® DAB Substrate Kit (8049P; Cell Signaling Technology) and 
incubation at room temperature for 1-5 minutes until brown staining developed. 
Sections were then rinsed in running tap water for 5 minutes before 
counterstaining with Mayer’s Haematoxylin (HST011; Solmedia; Shrewsbury, 
UK), washing in running tap water for 1 minute and blueing in Scott’s tap water 
(see Appendix A.4) for 1 minute and another 1 minute wash in running tap 
water. Finally, sections were dehydrated once again using 3x 100% ethanol for 
a total of 4 minutes and 3x xylene for 1 minute each before coverslips were 
mounted using DPX. Slides were scanned using an Aperio Digital Pathology 





2.21 Analysis of REEP4 and SEMA6D expression in patient 
samples 
Of the 305 cases, 42 were scored for each antigen separately by myself and Dr 
Eldo Verghese (consultant breast histopathologist at Leeds Teaching Hospitals 
NHS Trust and co-supervisor for this work) from the same digital images. 
Staining for both antigens was largely cytoplasmic, with scoring an assessment 
of staining intensity. Scoring of REEP4 was divided into three groups: weak, 
moderate and strong, with scores of 1, 2 and 3 given respectively. Scoring of 
SEMA6D was divided into two groups: weak and strong, with scores of 1 and 2 
given respectively. 
Linear weighted kappa statistics were calculated to determine the concordance 
between the two scorers using VassarStats (Lowry, 1998). Correlations 
between replicate antigen expression scores and between antigen expression 
scores and clinical factors were calculated using Spearman rho correlation 
coefficients using the statistical software SPSS version 25 (IBM SPSS 
Statistics; Armonk, USA). Associations between antigen expression and 
disease free survival and overall survival were analysed by Kaplan-Meier 
survival curves and log rank tests also using SPSS. All tests were 2-tailed. The 
limit of significance was 0.05 for all tests. 
2.22 Extraction of matched protein and RNA from cells  
Cells were removed from culture plastic using trypsin as described previously 
(see section 2.9). Following this procedure, 4ml fresh media was added to the 
cell suspension. This was then divided into two 15ml falcon tubes: 1ml (for RNA 
extraction) and 3ml (for protein extraction) and centrifuged at 400g for 5 
minutes. The pellet to be used for protein extraction was washed twice with 
PBS before adding 200μl RIPA buffer (see Appendix A.3) supplemented with 
the chelating agents 1mM EDTA (E6758; Sigma; St Louis, USA) and 0.5mM 
EGTA (E3889; Sigma; St Louis, USA) and 1mM of the protease inhibitor PMSF 
(36978; Thermo Fisher Scientific; Waltham, USA). This mixture was left on ice 
for 15 minutes to allow cell lysis to occur, followed by centrifugation at 14 000g 
for 10 minutes at 4oC. The supernatant containing the extracted protein was 
stored at -20oC. 
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The smaller pellet was washed once with PBS before being re-suspended in 
BL buffer (Promega; Madison, USA) supplemented with 1-Thioglycerol (TG) 
according to the manufacturer’s instructions (Promega; Madison, USA) and 
stored at -80oC until RNA extraction occurred (see section 2.12). 
2.23 SDS-PAGE and Western blotting 
A final concentration of 1x Laemmli sample buffer (see Appendix A.2) 
supplemented with 0.2M dithiothetriol (DTT) (Y00122; Invitrogen; Carlsbad, 
USA) was added to the protein sample for a final volume of 50μl. This mixture 
was denatured at 105oC for 5 minutes before being transferred to ice for a 
further 5 minutes. The samples were then centrifuged at 8000g for 30 seconds 
followed by re-suspension and storing on ice until ready to load on the gel. 
Samples were loaded onto 4-12% Bis-Tris Gels (NP0321BOX; Novex by Life 
Technologies; Carlsbad, USA). A PageRuler Plus Prestained Protein Ladder 
(26619; Thermo Fisher Scientific; Waltham, USA) was used to confirm the 
correct molecular weights of identified proteins at a later stage. Samples were 
separated using the XCell SureLock Mini-cell electrophoresis system 
(Invitrogen; Carlsbad, USA) in 1x NuPage MOPS SDS Running Buffer 
(NP0001; Invitrogen; Carlsbad, USA). Gels were run at 180V for 60 minutes. 
Proteins were transferred onto 0.45μm Polyvinylidene fluoride (PVDF) 
membranes (88518; Thermo Fisher Scientific; Waltham, USA) using a wet 
method. PVDF membranes were activated by soaking in methanol for 30 
seconds followed by rinsing with running water for 5 minutes. A sandwich was 
formed using sponges and filter paper (88600; Thermo Fisher Scientific; 
Waltham, USA) to flank the gel and the membrane; all soaked in 1x NuPage 
Transfer Buffer (NP0006-1; Invitrogen; Carlsbad, USA). The sandwich was 
placed in an XCell II Blot Module (359577-063; Invitrogen; Carlsbad, USA), 
which was locked into the XCell SureLock Mini-cell electrophoresis system. 
The blot module was filled with 1x Transfer Buffer and the outer chamber was 
filled with de-ionised water. Transfer occurred at 30V for 90 minutes. 
Once transfer was complete, the membrane was blocked with the appropriate 
blocking buffer (Table 2.23.1) for 1 hour at room temperature to inhibit non-
specific antibody binding. The blot was washed for 5 minutes with TBST to 
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remove excess milk proteins. All antibodies were diluted in 1% milk powder 
dissolved in TBST. Primary antibodies were added and incubated for the 
appropriate times (Table 2.23.1). The blots were then washed 3 times for 10 
minutes each with TBST, followed by incubation with appropriate secondary 
antibody (Table 2.23.1) diluted in 1% milk powder for 1 hour at room 
temperature. The secondary antibody used was a polyclonal rabbit anti-mouse 
immunoglobulin conjugated with a horseradish peroxidase (HRP) molecule 
(P0260; Dako; Santa Clara, USA) and used at a 1:2000 dilution. A further 3 
washes with TBST for 10 minutes each ensured removal of unbound 
secondary antibody. Blots were developed using the SuperSignal West Pico 
Trial kit (34079; Thermo Fisher Scientific; Waltham, USA) and imaged using 
the Bio-Rad Gel Doc Imaging system together with the Image Lab software 
(version 5.2.1).  
If blots were to be re-probed with a different antibody, blots were re-blocked in 
either 5% or 1% milk powder (Table 2.23.1). 
Table 2.23.1: Primary antibodies and the conditions in which they were 
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2.24 Cell cycle profiles analysis 
Cells were harvested using trypsin (see section 2.9) so as to detach cells from 
the flask followed by addition of media to inactivate trypsin. Cells were then 
counted using a haemocytometer and 500000 cells were washed in PBS 
before being resuspended in 1ml ice-cold 70% ethanol in PBS. Cells were fixed 
on ice for 1-2 hours before being transferred to polystyrene round-bottom tubes 
(352052; Corning life sciences; Corning, USA). Pellets were formed by 
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centrifugation at 500g for 3 minutes at 4oC followed by washing with 500µl ice-
cold PBS and finally resuspension in 470µl ice-cold PBS. Propidium iodide (PI) 
was added at a final concentration of 0.02mg/ml (P4864; Sigma; St Louis, 
USA) and RNase A (EN0531; Thermo Fisher Scientific; Waltham, USA) at a 
final concentration of 0.4mg/ml. Samples were incubated at room temperature 
in the dark for 20 minutes before being placed on ice. Samples were analysed, 
with 10000 events counted for each sample using the Attune® Acoustic 
Focusing Cytometer (Applied Biosystems; Foster City, USA) and 
accompanying Attune Cytometric Software Version 2.1. The gating of cells 
using forward, side and PI stain scatter parameters is shown in Figure 2.24.1A. 
Data was analysed using the ModFit LT software (Verity Software House; 
Topsham, USA) with a representative histogram shown in Figure 2.24.1B. 
 
Figure 2.24.1: Representative density plots with gatings used to identify 
cell populations of interest 
(A) The left panel shows the forward and side scatter plots with the black 
square showing the gate used to identify live cells. The middle panel 
shows the propidium iodide (PI) (BL3-A) and forward scatter plots with the 
black square showing the gate used to identify nuclei successfully stained 
with PI. The right panel shows the PI area (BL3-A) and height (BL3-H) 
scatter plots with the black outline showing the gate used to identify single 





Chapter 3: Consistent changes in microRNA and mRNA 
expression are apparent post-neoadjuvant chemotherapy in 
breast cancer 
3.1 Abstract 
Resistance to chemotherapy in tumours is a common problem encountered in 
cancer patients. The aim in this chapter was to identify potential mediators of 
chemoresponse using tumour samples from patients with primary breast 
cancer taken before and after neoadjuvant chemotherapy (NAC) treatment. My 
hypothesis was that in patients showing only a partial response to the 
treatment, expression changes between these matched samples may be 
associated with chemoresistance.  
Formalin-fixed paraffin embedded (FFPE) tissues comprising matched core 
biopsy (pre-NAC) and resection (post-NAC) tumour samples were selected 
from five primary breast cancer patients. These patients all had tumours that 
expressed the oestrogen receptor and displayed only a partial response to the 
administered chemotherapy regimen consisting of epirubicin and 
cyclophosphamide (EC). Tumour epithelial cells were isolated from these 
samples using laser capture microdissection (LCM) and RNA was extracted. 
Expression of miRNAs and mRNAs was profiled using low-density qPCR 
arrays and NanoString mRNA quantification respectively; fold changes post-
NAC were determined. All miRNAs and mRNAs that were consistently 
deregulated post-NAC across all five patients were identified. For miRNAs, 
thresholds were set for fold changes of interest, allowing identification of miR-
26b (mean fold change post-NAC of 4.9), miR-195 (2.6) and miR-10a (-4.15) 
for further analyses. For mRNAs, pathway analysis using the whole dataset 
demonstrated up-regulation of the MAPK and PI3K-AKT pathways, partial up-
regulation of the JAK-STAT pathway and partial down-regulation of the TGF-
Beta pathway post-NAC. I concluded that these miRNA and mRNA expression 
analyses identified several potential mediators of chemoresistance for further 




Whether patients with primary breast cancer are administered chemotherapy, 
endocrine therapy or both depends in part on the molecular characteristics of 
their tumours (see section 1.2.2). Patients with hormone receptor positive 
breast cancers are only sometimes administered chemotherapy, since 
endocrine therapies are often sufficient in combatting the tumour and are 
generally less toxic (Semiglazov et al., 2007). However, luminal B-type tumours 
are generally treated with chemotherapy and chemotherapy is also usually 
recommended for those patients with larger or node-positive tumours (Gnant et 
al., 2015, Ignatiadis and Sotiriou, 2013). In some cases, tumour cells are 
intrinsically resistant (de novo resistance), or alternatively cells can develop 
resistance during the course of the treatment (Li et al., 2008). It is estimated 
that of all patients diagnosed with primary breast cancer, 20-50% of these will 
eventually suffer a recurrence and develop metastatic disease (Brufsky, 2017). 
In the context of metastatic disease, chemoresistance is thought to contribute 
to over 90% of cases of treatment failure (Coley, 2009).  
Chemoresistance in breast cancer has been associated with various changes 
in gene expression (see section 1.4), such as increased expression of 
xenobiotic export pumps (Wilson et al., 2006). More recently, changes in 
microRNA (miRNA) expression have also been associated with 
chemoresistance (Kutanzi et al., 2011, Wang et al., 2015). It has been 
observed that overall, miRNAs are down-regulated in cancers as compared to 
normal cells (Lu et al., 2005). However, individual miRNA levels have now been 
shown to increase in breast cancer, leading to resistance. The gene PTEN is 
known to have a tumour suppressive function. Evidence has shown that 
inhibition of this gene’s function leads to resistance to chemotherapy in breast 
cancer (Steelman et al., 2008). Several miRNAs have now been shown to 
contribute to this inhibition; with increased miR-21 expression in doxorubicin-
resistant MCF7 cells compared with parental cells concurrent with reduced 
expression of PTEN (Wang et al., 2011). Similar cases of increased miR-19 
(Liang et al., 2011) and miR-130b (Miao et al., 2017) expression in 
chemoresistant cells and/or patient samples, together with a decrease in PTEN 
expression have also been published. 
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Treatment with chemotherapy leads to numerous responses in breast cancer 
cells such as changes in gene expression (Klintman et al., 2016) that can lead 
either directly to cell death or to the activation or inhibition of specific molecular 
pathways that function to increase the probability of cell survival.  
The administration of neoadjuvant chemotherapy provides matched tumour 
samples before and after chemotherapy. Analysing gene expression of such 
samples taken from patients who responded poorly to the treatment (indicative 
of relative chemoresistance) could lead to the identification of changes in gene 
expression that are relevant to the resistance phenotype, and therefore the 
identification of novel drug targets to use to attempt to overcome the 
resistance. This approach has been used previously. One example of such an 
approach is a study in which biopsy samples were taken from gastric cancer 
patients prior to treatment with cisplatin and fluorouracil. Of these, 22 patients 
developed resistance to the treatment and a second biopsy was taken. Both 
pre- and post-treatment samples were analysed using a microarray and 
compared. The acquired resistance signature identified consisted of 633 genes 
that function in multiple pathways known to contribute to chemoresistance 
when deregulated, including DNA repair pathways, drug metabolism and 
embryonic stem cell signatures (Kim et al., 2011). A similar approach was 
taken in this chapter where the transcriptomes of cancer cells were analysed 
from five breast cancer patients both before and after chemotherapy. As these 
patients had all displayed only a partial response to the chemotherapy, the aim 
was to identify molecular pathways that were altered post-chemotherapy that 
could contribute to chemoresistance. 
3.2.1 Specific objectives 
There were three key objectives in the work described in this chapter: 
1. To determine whether FFPE samples of cancer tissue pre-
chemotherapy (core biopsy samples) and post-chemotherapy (resection 
samples) could be used successfully to extract RNA of sufficient quality 
to perform miRNA and mRNA analyses. 
2. To determine miRNA and mRNA expression profiles of a group of breast 
tumours that were partially resistant to the administered neoadjuvant 
chemotherapy before and after therapy. 
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3. To determine a prioritised list of miRNA and mRNA expression changes 
of interest associated with chemotherapy treatment to direct future 
studies on these molecules as potential mediators of chemoresponse. 
3.3 Results 
3.3.1 RNA of sufficient quantity and quality for downstream 
analyses can be extracted from small clinical (FFPE) cancer 
samples 
Fixing tissue in formalin results in multiple modifications of several key 
components of cells that are also of interest in research studies. This includes 
RNA, which is susceptible to degradation even in the absence of formalin (Auer 
et al., 2003, Schroeder et al., 2006) and suffers further damage when fixed (Li 
et al., 2007, Masuda et al., 1999). As the purpose of this study was to identify 
changes in miRNA and mRNA expression that occur during chemotherapy, a 
preliminary optimisation study was performed to investigate whether the 
quantity and quality of RNA extracted from FFPE tissue samples would be 
potentially sufficient for the planned down-stream analysis methods. 
Small, representative, clinical FFPE samples were used for this preliminary 
study – namely two biopsy samples and two resection samples from colon 
cancers (at this optimisation stage, the specific cancer type was not felt to be 
important. However, the aim was to use samples of similar overall size, cell 
type (carcinoma) and clinical fixation procedures). These were sectioned, 
stained with haematoxylin and eosin (H&E) and total RNA was extracted from 
the whole tissue sections. Biopsy samples were of a comparable size to those 
of the breast cancer core biopsies to be used for later analyses whereas, these 
resection samples were on average slightly smaller than the breast cancer 
resection samples, thereby representing a more stringent test. In order to 
assess the impact of using different numbers of sections for extraction on total 
RNA recovery, different numbers of sections were used: three (Biopsy 1 and 
Resection 1) or four (Biopsy 2 and Resection 2) whole sections for each 
sample were used for the final RNA extraction. The RNA quantity and quality 
were analysed using the Agilent TapeStation automated analysis machine 
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(Figure 3.3.1 and Appendix C). The total RNA yields obtained are shown in 
Table 3.3.1. Total RNA yield was consistently greater when four sections of 
tissues were used as opposed to three tissue sections. By contrast, the larger 
tissue areas of the resections did not consistently yield more RNA than the 
smaller biopsies (compare Resection 2 and Biopsy 2). The two platforms 
chosen to be used for subsequent miRNA and mRNA expression analyses on 
breast tissues require an absolute minimum of 60ng total RNA combined, 
although a minimum of 150ng is preferred. Of the four optimisation samples 
tested, one biopsy sample and one resection sample had RNA yields that were 
too low (38.96ng and 59.92ng respectively) but the other two samples had RNA 
yields large enough for further analyses.  
Another metric of interest was the RINe value, quantified on a scale of 1 for 
complete degradation to 10 for no degradation (Table 3.3.1) (Padmanaban et 
al., 2012). The RINe values obtained from these samples are low compared 
with values obtained from RNA extracted from fresh samples, but were similar 
to those in the literature for other FFPE tissues (Ribeiro-Silva et al., 2007).  
It has been debated that no minimum RIN value is required for miRNA 
expression analysis using RT-qPCR as the assays are inherently robust due to 
the short lengths of miRNAs themselves (Dijkstra et al., 2012). Expression 
analysis of mRNAs extracted from FFPE tissues with low RIN values 
comparable with those obtained here has previously been successful using 
NanoString technologies (Chen et al., 2016a). It was therefore concluded that 
RNA of sufficient quality as well as quantity could be extracted from FFPE 
tissues with the chosen extraction method. 
Table 3.3.1: Concentration and quality of RNA extracted from four FFPE 
tumour samples 
Tissue sample RNA yield (ng) RINe 
Biopsy 1 39.0 1.7 
Biopsy 2 196.0 2.1 
Resection 1 59.9 2.1 
Resection 2 113.6 2.3 
Total RNA was extracted from either three (Biopsy 1 and Resection 1) or 
four (Biopsy 2 and Resection 2) whole FFPE tissue sections stained with 
H&E. The RNA was then analysed using the Agilent TapeStation 
automated analysis machine to determine yield and RNA quality (RINe). 
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The sizes of the RNA fragments was also a metric of interest as this measure 
of quality might determine which downstream analysis technologies would be 
likely to succeed. RNA fragments obtained from these optimisation samples 
were largely over 200 nucleotides long in all samples. A representative graph 
showing the range of fragment lengths is shown in Figure 3.3.1. These 
fragment sizes are much larger than is required for analysis of miRNA 
expression (miRNAs are themselves only 18-22 nucleotides long) and were 
potentially suitable for analysis of mRNA expression using NanoString 
technology, for which RNA fragments of only 100 nucleotides long are required 
and have previously been shown to give data from FFPE tissue representative 
of those from matched fresh frozen samples (Chen et al., 2016a, Reis et al., 
2011). 
 
Figure 3.3.1: Representative graph showing range of nucleotide fragment 
lengths of RNA extracted from test FFPE samples 
RNA was extracted from four FFPE tumour samples; two from biopsy 
samples and two from resection samples. The RNA was run on the 
Agilent 2200 TapeStation using the High Sensitivity RNA ScreenTape to 
determine average lengths of RNA fragments extracted from tissues 
stored as FFPE samples. This graph shows results from the Biopsy 2 
sample, with the size of the fragments shown on the x-axis and the 
quantity of fragments shown on the y-axis. The large peak at 25nt is a 
marker used for reference. 
3.3.2 Total RNA was successfully extracted from isolated cancer 
epithelial cells of five pairs of matched pre-NAC and post-NAC 
primary breast tumour samples 
Breast cancer patients who could potentially be included in the study were 
identified. Patients were included if they were diagnosed with primary breast 
cancer, invasive ductal carcinoma of no special type, of the clinically-defined 
luminal A subtype (tumours expressing ER but not HER2). These criteria were 
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chosen in order to reduce inherent heterogeneity within the cohort associated 
with different tumour subtypes. A second reason for these criteria was that 
tumours of this subtype typically respond relatively poorly to NAC compared 
with other subtypes such as luminal B (Ignatiadis and Sotiriou, 2013), and very 
rarely achieve pCR (Colleoni and Montagna, 2012). This maximised the 
chances of having sufficient cancer cells post-treatment to allow analysis. 
Within the above subgroup of patients, the search was further limited to those 
patients who displayed only a partial response to the administered NAC. An 
incomplete response to the chemotherapy would suggest that the tumour is 
partially resistant to the therapy. As one of the main objectives of this study was 
to determine the molecular changes that are associated with chemoresistance, 
this limitation was necessary. 
Finally, the search was also limited to patients treated only with the epirubicin 
and cyclophosphamide (EC) regimen. This additional filter was performed in 
order to reduce further the heterogeneity within the results obtained as different 
drugs would potentially activate different pathways of resistance and may 
therefore make identifying potential therapeutic targets more difficult if certain 
pathways were affected in some patients treated with one therapy but were not 
affected in other patients treated with a different therapy. The EC regimen was 
chosen as that was the most common initial regimen used in this patient group 
at St James’s University Hospital, Leeds at the time of sample retrieval.  
Limiting the search to only patients who displayed a partial response and were 
treated with EC significantly reduced the number of eligible patients. This was 
because patients who display no response or poor response to the therapy are 
usually switched to a different chemotherapy regimen (typically taxanes). The 
final limitation was the availability of sufficient tissue for both pre-NAC and post-
NAC samples. 
Once patients had been identified, tumour histology was examined, using either 
diagnostic archival H&E slides or new H&E slides produced for the purpose, in 
order to assess whether the tissue itself was suitable for the planned analysis. 
This was important in terms of the presence of sufficient tumour epithelial cells 
(the cells of interest) for downstream analyses as opposed to large amounts of 
unwanted elements such as lymphocytes and other stromal cells. Combining all 
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of the above criteria, five patients and their tumours were determined to be 
appropriate. Table 3.3.2 shows the clinico-pathological features of the patients 
whose tumours were used in this study. One of the patients showed a very 
good response to NAC during treatment, however the tumour resumed growing 
once treatment had ended. 
Table 3.3.2: Clinico-pathology features of patients/tumours that were 
used in this study 
Characteristic Categories Number 
Mean Age (Range)  51 (41-64) 








Response to NAC (as 
assessed at surgery) 
Very good 1 
Very limited 4 
As the purpose of this study was to determine molecular changes that occur in 
the cancer cells specifically, isolation of these tumour epithelial cells was 
required. This was achieved by sectioning the tissue, staining with 
haematoxylin and eosin (H&E) in order to distinguish between tumour cells and 
the surrounding stroma, and then isolating the epithelial cells using laser 
capture microdissection (LCM). It was felt that this step was particularly 
necessary since NAC treatment is known to reduce cancer cellularity within the 
tumour mass (Sahoo and Lester, 2009, Masood, 2016), therefore analyses 
comparing pre-NAC and post-NAC samples without purifying the tumour cells 
risk identifying expression changes simply associated with differences in the 
tumour-stroma ratio, rather than true expression differences in the tumour cells 
present. LCM protocols, with representative images, are described in detail in 
section 2.3. These protocols were optimised in order to yield the maximum 
amount of RNA possible, largely by isolating tumour epithelial cells available 
from up to twenty tissue sections. The settings on the LCM equipment were 




Total RNA was extracted from the isolated tumour epithelial cells from pre-NAC 
and post-NAC samples from the five cases, and was quantified (using 
Nanodrop analysis; assessment of RNA amount/quality using the TapeStation 
automated analysis machine was not performed in order to preserve the 
maximum amount of RNA for downstream analyses). Total RNA amounts 
obtained for each pre-NAC and post-NAC sample per patient are shown in 
Table 3.3.3. These met the minimum required amounts for the downstream 
analyses: a minimum of 100ng total RNA is preferred for the low density 
miRNA RT-qPCR arrays and at least 50ng total RNA is required for NanoString 
analysis of mRNA expression; although in one sample (patient 4, pre-NAC) this 
was only just the case. 
Table 3.3.3: Total RNA extracted from LCM-isolated tumour epithelial cells 
from each patient sample 
Patient Pre-NAC (ng) Post-NAC (ng) 
1 1999.4 16814.2 
2 
469.3 575.63 
3 785.2 942.95 
4 153.4 401.8 
5 305.4 1944.6 
A summary of the details of the patient cohort used in this study and the 




Figure 3.3.2: CONSORT diagram of samples used in this study 
Five patients were identified who met all the required criteria (top box), 
whose samples were prepared for total RNA extraction (middle box) for 
miRNA and mRNA differential expression analysis between pre- and 
post-NAC samples (bottom box). 
3.3.3 MiRNAs miR-26b, miR-195 and miR-10a were consistently 
deregulated post-NAC in five breast cancer samples 
Expression levels of 384 RNAs, including a very large panel of commonly 
expressed miRNAs and several RNAs traditionally used as housekeeping 
RNAs when investigating miRNA expression such as U6 and RNU48, were 
analysed using low density RT-qPCR arrays. Data were normalised to the 
mean expression of all RNA species detected.  
In my first analysis, I used unsupervised hierarchical clustering to investigate 
which miRNA expression profiles were most similar across the samples. It was 
possible that the predominant similarities between samples would be between 
matched pre-NAC and post-NAC samples, suggesting that tumour specific 
differences were relatively more important compared with changes induced by 
chemotherapy, or would be within the post-NAC group, suggesting that 
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chemotherapy-induced expression changes were predominant. This analysis is 
presented as a heat map in Figure 3.3.3. Results from this analysis showed 
that there is not a predominant post-NAC miRNA expression profile associated 
with NAC. This is demonstrated in the fact that post-NAC samples were not 
clustered together. This analysis also shows that there is no clear relationship 
within individual tumour samples as pre-NAC and post-NAC samples from the 
same patient do not cluster together. Indeed, the results of this analysis show a 
combination of these two possible clusters occurs. For example, the two 
samples from Patient 4 cluster together but the pre-NAC samples from Patients 
1 and 5 also cluster together. This shows that differences between both 





Figure 3.3.3: Unsupervised hierarchical clustering of patient samples pre-
NAC and post-NAC using miRNA expression data does not show 
definite relationships between sample types 
RNA was extracted from tumour epithelial cells from pre-NAC and post-
NAC samples from five patients and expression of an array of miRNAs 
was determined using low-density miRNA microarrays. Results were 
normalised to the average Ct value of each sample and unsupervised 
hierarchical clustering was performed. The resultant heat map is shown, 
with the dendrogram showing the relationships between the ten samples 
at the top. 
Following this initial analysis, miRNAs with altered expression between the 
matched pre-NAC and post-NAC samples from each individual patient were 







































































































































regulated across all five patient samples post-chemotherapy were then 
selected as possible candidates for further study. Eleven miRNAs were 
consistently up-regulated post-NAC whereas two miRNAs were consistently 
down-regulated post-NAC. In order to prioritise those miRNAs for further study, 
a minimum fold change in each patient was used as a threshold to define the 
miRNAs of interest. However, previous studies have suggested that even small 
changes in miRNA expression can have large impacts downstream (St. Laurent 
et al., 2013, Calin and Croce, 2006). Therefore, conservative thresholds were 
set, requiring fold changes of more than 1.3 for up-regulation or less than -1.25 
for down-regulation. Using these criteria, three miRNAs were selected for 
further analysis: miR-26b, miR-195 and miR-10a with mean fold changes of 
4.9, 2.6 and -4.15 respectively. Fold changes for each individual patient are 
shown in Table 3.3.4. A further nine miRNAs were identified that were up-
regulated in all five patients but the fold-change in one patient sample did not 
reach the minimum threshold or was not detected in one patient (Appendix D). 
One other miRNA was consistently down-regulated but did not meet the 
chosen criteria (Appendix D). Tests for statistical significance of deregulated 
miRNA expression were considered. However, the cohort was too small for 
these tests to be meaningful, adjustments for multiple testing were severe 
because of the large panel of RNAs assessed and the suitability of 
parametric/non-parametric tests was uncertain. Therefore, I decided to proceed 
with candidates based on consistency of deregulation and my (arbitrary) 
thresholds for size of fold changes. 




1 2 3 4 5 Mean 
miR-26b 3.389 1.537 1.922 1.793 15.707 4.870 
miR-195 3.464 1.837 1.7 1.333 4.497 2.566 
miR-10a -2.33 -1.42 -14.39 -1.27 -1.36 -4.154 
MicroRNAs that were consistently deregulated post-NAC across all five 
patients were identified. For up-regulated miRNAs, a minimum threshold 
for the fold change for each individual patient was 1.3 and for down-
regulated miRNAs, a maximum threshold for the fold change for each 
individual patient was -1.25. The mean fold change across all patients for 
each miRNA is also shown. 
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3.3.4 Identifying a mRNA expression signature associated with 
chemotherapy treatment 
3.3.4.1 Multiple assays failed and conclusions may not be reliable 
For mRNA analyses, RNA samples were sent to the Institute of Cellular 
Medicine, Newcastle University where they were analysed using the nCounter 
PanCancer Pathways Panel (NanoString Technologies) to asses expression of 
730 cancer-related genes and 40 internal reference controls. This technology is 
based on fluorescent counting of individual target molecules based on their 
attachment to barcoded probes. Raw data were normalised relative to a panel 
of housekeeping genes; followed by calculation of fold changes for genes post-
NAC compared with pre-NAC. It was, however, noted that two samples failed 
quality control. These displayed either low counts for the internal positive 
controls within the analysis (patient 3; post-NAC), potentially indicating the 
presence of chaotropic contaminants, or low counts for the genes themselves 
(patient 3; post-NAC and patient 5; pre-NAC), potentially suggesting excessive 
RNA fragmentation or low sample input. 
However, for both samples, expression of a few genes was successfully 
quantified and levels of these were taken into account in downstream analyses, 
although the fold changes in these two patients (3 and 5) should be treated with 
some caution. 
In an attempt to overcome these issues, I decided to pre-amplify the pairs of 
samples from these two patients (Patients 3 and 5) and to repeat the 
NanoString analysis with this amplified input. As a positive control, the pair of 
samples from Patient 1 were also pre-amplified, which had previously worked 
well, in order to allow analysis of how non-amplified (initial - Run 1) and pre-
amplified (repeat - Run 2) analyses compare. Samples underwent pre-
amplification using a pool of primers specific for the genes on the nCounter 
PanCancer Panel, before being re-analysed by the Institute of Cellular 
Medicine, Newcastle University, on the same nCounter PanCancer Pathways 
Panel. 
Initial observations of the new data from the two samples that had failed in the 
first run showed that even after pre-amplification, these samples failed again. 
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Analysis of the new data for Patient 1, which was repeated with pre-
amplification as a control, also presented concerns. Only eighteen more genes 
were detected in the pre-amplified second analysis compared with the first 
analysis. This represents only 0.02% of all genes on the panel and one-
hundred and eighty four genes were still undetected in both the pre-NAC and 
post-NAC samples after pre-amplification, representing 24% of all genes on the 
panel. This suggested that pre-amplification had not substantially increased 
sensitivity. To determine whether pre-amplification introduced any bias and 
whether results between the two runs were comparable, the correlation 
between the fold changes determined in the two runs of Patient 1’s samples 
were first determined (Figure 3.3.4). 
 
Figure 3.3.4: Fold changes obtained from pre-amplified samples (Run 2) 
correlate poorly with those obtained from non-amplified samples 
(Run 1) 
Tumour epithelial cells were isolated from pre-NAC and post-NAC 
samples from a single patient (Patient 1) and RNA was extracted. Gene 
expression profiles were determined using this extracted RNA either 
without pre-amplification (Run 1) or with pre-amplification (Run 2) using 
NanoString PanCancer Pathway analyses. Fold changes in gene 
expression comparing post-NAC to pre-NAC in samples that underwent 
pre-amp (Run 2) were plotted against fold changes in the same genes as 
determined with RNA that did not undergo pre-amplification (Run 1). This 
includes the expression of all genes that were detected in all samples 
(398 genes). A correlation line is shown along with the R-squared value.  
The correlation between the gene expression fold changes obtained in the two 
separate runs for samples from Patient 1 was low: the correlation coefficient 














was only 0.1185. This suggests that results obtained from samples that 
underwent pre-amplification were not similar to those obtained from samples 
that did not undergo pre-amplification. However, it should be noted that any 
genes that were not detected in one or more samples were not included as 
values for fold changes could not be calculated; therefore this correlation may 
under-represent the actual concordance.  
3.3.4.2 Changes in gene expression post-NAC lead to alterations in 
signalling cascades 
Since results obtained after pre-amplification were not similar to those obtained 
before pre-amplification and the pre-amplified samples were considered to be 
most prone to be unrepresentative due to amplification biases, further analyses 
were limited to the results obtained from samples that did not undergo pre-
amplification. Of the samples that successfully passed quality control (eight 
samples in total; three matched pairs and individual samples from Patients 3 
and 5), a mean of 547 genes (of the 730 targets) were detected. Of the 
samples that did not pass quality control, 62 genes were successfully detected 
in the Patient 3 post-NAC sample, and 261 genes were successfully detected 
in the Patient 5 pre-NAC sample. Once data were normalised and fold changes 
calculated, genes consistently changed across all five patients (Table 3.3.5) or 
across only the patients for whom the assays worked more reliably (Patients 1, 




Table 3.3.5: Genes consistently changed post-NAC across all five patient 
samples 
Gene Expression change 
post-NAC 
Mean fold change 
KITLG Up 1.654 
NR4A1 Up 11.380 
WEE1 Up 1.802 
COL5A1 Down -1.471 
EFNA3 Down -3.816 
MYB Down -2.066 
NOTCH3 Down -2.028 
PPP3R1 Down -1.771 
PRKDC Down -1.836 
RHOA Down -2.095 
Tumour epithelial cells were isolated from pre-NAC and post-NAC 
samples from five patients and RNA extracted. Gene expression analyses 
were performed using the NanoString PanCancer Pathway Panel. 
Expression of genes that were successfully quantified in all five patients 
both pre-NAC and post-NAC were identified and those consistently 
changed were noted. Mean fold changes for each of these genes were 
calculated. 
Analysis was then performed to determine whether consistently deregulated 
genes were clustered in specific molecular pathways. This analysis was limited 
to the 209 genes found to be consistently deregulated in the three patients for 
whom the NanoString analyses were most reliable. Genes were grouped into 
their functional pathways, as defined by the classifications associated with the 
NanoString PanCancer Pathways Panel, and the directions of fold changes 
were assessed for each individual gene to determine whether it represented 
up-regulation or down-regulation of the pathway overall. Pathways where most 
consistently deregulated genes identified were representative of the same 
overall change in pathway activity were noted. 
3.3.4.2.1 MAPK pathways are activated post-NAC 
Of the genes on the NanoString PanCancer Pathways Panel that are part of 
the MAPK signalling pathway (157 genes in total), forty-six genes were 
consistently deregulated post-NAC. Taking into consideration the function of 
these genes (see Figure 3.3.5) and whether they were up-regulated or down-
regulated post-NAC, the global changes in gene expression suggested that this 
pathway was activated post-NAC. Of the forty-six consistently deregulated 
genes, thirty-four were changed in such a way as to contribute to this 
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activation. In order to make an assessment of whether this expression pattern 
showed characteristics of statistically significant activation, a binomial 
probability test was performed. The result was a p value of 0.00055, suggesting 
that this distribution is not likely to have occurred by chance. Genes of note 
included several of the MAPK genes themselves as well as several 
downstream targets such as FOS and JUN. 
 
Figure 3.3.5: The MAPK pathway is activated post-NAC 
Diagram showing the major elements that function in the MAPK 
pathway. Genes consistently up-regulated post-NAC are shown in green 
whereas genes consistently down-regulated post-NAC are shown in red. 
Genes shown in white are either not consistently changed or are not 
present on the NanoString PanCancer Pathways Panel. Overall, 
changes in gene expression suggest increased activation of this 
pathway post-NAC (p=0.00055). 
 
3.3.4.2.2 The PI3K-AKT pathway is activated post-NAC 
Of the genes on the NanoString PanCancer Pathways Panel that are part of 
the PI3K-AKT pathway (201 genes in total), fifty-three genes were consistently 
deregulated post-NAC. As this pathway affects many processes downstream of 
AKT including several other pathways, for the purposes of determining whether 
this pathway was significantly altered post-NAC, only genes upstream of and 
including AKT were included in this analysis. Of these genes (201 in total), 
forty-two were consistently de-regulated post-NAC. Taking into consideration 
the function of these genes (see Figure 3.3.6) and whether they were up-
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regulated or down-regulated post-NAC, the global changes in gene expression 
suggested that this pathway was activated post-NAC. Twenty-nine consistently 
deregulated genes were changed in such a way as to contribute to this 
activation. As with the analysis of the MAPK pathway, a binomial probability 
test was performed to determine whether this expression pattern showed 
characteristics of statistically significant activation. The result was a p value of 
0.0058, suggesting that this distribution is not likely to have occurred by 
chance. Genes of note included several extracellular matrix components such 
as COL1A2, integrin receptor components such as ITGA2 and ITGB4 as well 
as PIK3CG.  
Of the downstream effectors, several proteins involved in regulating processes 
such as the cell cycle and apoptosis were either up-regulated or down-
regulated, resulting in certain arms of the PI3K-AKT pathway being activated 
and others being suppressed.  
 
Figure 3.3.6: The PI3K-AKT pathway is activated post-NAC 
Diagram showing the major elements that function in the PI3K-AKT 
pathway. Genes consistently up-regulated post-NAC are shown in green 
whereas genes consistently down-regulated post-NAC are shown in red. 
Genes shown in white are either not consistently changed or are not 
present on the NanoString PanCancer Pathways Panel. Overall, changes 
in gene expression of genes upstream of and including AKT suggest an 




3.3.4.2.3 Genes involved in regulating proliferation and metastasis are up-
regulated post-NAC 
Fifty-one genes that influence cell proliferation and/or metastasis processes 
were consistently deregulated post-NAC, from a total of 137 genes defined as 
contributing to this pathway overall on the analysis panel. Of these, thirty-two 
(62.7%) were either up-regulated or down-regulated in such a way as to 
contribute to increased cell proliferation and/or metastasis post-NAC. A 
binomial probability test was performed to determine whether this expression 
pattern showed characteristics of statistically significant activation of these 
processes. The result was a p value of 0.022, suggesting that this distribution is 
potentially not likely to have occurred by chance, although this significance is 
marginal in the context of testing multiple potentially significant pathways. 
Genes of note included JAK3, MEN1, BCL2A1 and CDKN2A. 
3.3.4.2.4 Although individual genes show consistent deregulation, a number of 
other pathways do not demonstrate evidence of overall significant 
activation or repression 
Many other genes included in the NanoString PanCancer Pathway Panel can 
be defined as components of a number of further molecular pathways and were 
found to be consistently deregulated post-NAC. These include components of 
the RAS, JAK-STAT, WNT and TGF-Beta pathways. Assessments were made 
as to whether these pathways were overall potentially activated or repressed 
post-NAC, using the methodology as above for the MAPK, PI3K-AKT and 
proliferation/metastasis pathways. However, when binomial probability tests 
were performed as before, there was no evidence of significant overall pathway 




Table 3.3.6: Pathways that were not significantly altered post-NAC 
Pathway Activation / 
Repression 
post-NAC 









RAS Activation 36 22 0.055 
JAK-STAT Activation 16 11 0.067 
WNT Activation 24 14 0.117 
TGF-Beta Repression 16 9 0.175 
Individual genes on the NanoString PanCancer Pathway Panel that were 
consistently deregulated post-NAC were noted. According to their function 
within pathways and whether they contributed to the overall activation or 
repression of these pathways, binomial probability tests were performed to 
determine whether these overall activations or repressions were 
statistically significant. 
3.4 Discussion 
Resistance to chemotherapy can present in patients as either de novo or 
acquired resistance (Hazlehurst and Dalton, 2006). In the neoadjuvant setting, 
this results in primary tumours failing to reduce in size substantially or even 
growing bigger. For sub-clinical metastatic cells that have already seeded into 
pre-metastatic niches, this chemoresistance can lead to metastatic recurrences 
and poor prognoses (Abdullah and Chow, 2013, Kajiyama et al., 2007). 
Therefore, it is important to identify the mechanisms behind this resistance in 
order to discover alternative molecular targets that can be used in cancer 
treatment.  
3.4.1 Methodologies for investigating chemoresistance 
3.4.1.1 The use of clinical samples versus breast cancer cell lines 
A variety of approaches have been used by researchers in attempts to identify 
molecular mechanisms that contribute to chemoresistance. Part of this 
research includes the attempt to identify gene expression signature patterns 
associated not only with chemoresistance but also with chemoresponse. These 
approaches have been used to identify altered expression patterns of both 
mRNAs and miRNAs. 
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The majority of studies that have been performed to identify mRNAs and 
miRNAs with altered expression associated with chemoresistance in breast 
cancer utilised various breast cancer cell lines, usually with matched parental 
and drug-resistant cells. This approach is popular likely due to the ease of 
obtaining the required samples. It was used to identify miR-298 as a modulator 
of chemoresistance; with reduced expression in doxorubicin resistant breast 
cancer cells compared with the sensitive parental cell line. This reduced 
expression was associated with increased expression of the xenobiotic drug 
transporter P-glycoprotein, thereby conferring resistance (Bao et al., 2012). A 
similar approach of using drug-resistant breast cancer cells was used in the 
identification of miR-19 (Liang et al., 2011) and miR-21 (Wang et al., 2011), 
both of which have increased expression in resistant cell lines compared with 
parental controls and were associated with decreased PTEN expression. As a 
slight variation of this approach, creating drug-resistant cell lines by 
manipulating gene expression has also been performed. For example, Martz et 
al. produced cells expressing pre-identified mutant cDNAs (activating or 
inhibiting) that function in pathways known to enhance survival of cancer cells, 
and investigated the response to several targeted therapies (Martz et al., 
2014). 
There are limitations to this approach, however, as there are many other cell 
types and extracellular components present in tumour that may influence 
response to chemotherapy that are not present under in vitro conditions. A 
second approach that uses tumour samples taken from breast cancer patients 
would provide a more accurate conclusion in this respect. There have been a 
small number of studies that have taken pre-treatment breast cancer samples, 
analysed gene expression and correlated these expression data with 
responses to subsequent chemotherapy. The primary objective of one such 
study was to distinguish separate gene expression patterns for response and 
resistance to the chosen chemotherapy regimen. In this study, pre-NAC core 
biopsy samples were used for analysis (Cleator et al., 2006). It is important to 
note that core biopsy samples are not the only pre-NAC samples available. 
Fine needle aspirations have also been used in similar studies (Ayers et al., 
2004, Gonzalez-Angulo et al., 2012), although the identification of genes 
associated with chemoresistance was not the purpose of these studies. 
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In this study, I have used samples taken from tumours of primary breast 
cancer. These were matched samples taken pre-NAC (core biopsy) and post-
NAC (resection) from tumours that showed only a partial response to the 
administered chemotherapy that consisted of a regimen of epirubicin and 
cyclophosphamide, suggesting a degree of chemoresistance. This allowed the 
identification of changes in mRNA and miRNA expression post-NAC compared 
with pre-NAC of a large panel of genes. It is possible that these changes are 
associated with the observed chemoresistance. Such an approach of using 
matched pre-NAC and post-NAC samples has, although rarely, previously been 
used in an attempt to identify genes associated with chemoresistance. 
In one such study, pre-treatment core biopsy samples and post-treatment 
resection samples (multiple therapy regimens) were used to investigate 
expression of multiple genes known to be involved in conferring resistance in 
order to observe expression patterns of these genes with respect to response 
or non-response to the administered chemotherapies. Interestingly, different 
combinations of genes had altered expression post-NAC depending on type of 
chemotherapy regimen given (Litviakov et al., 2013). This demonstrates the 
fact that different therapies result in different molecular responses.  This means 
that if a particular change in expression is associated with resistance to a 
particular chemotherapeutic drug, it does not translate into the same change in 
expression being associated with resistance to all chemotherapeutic drugs. It is 
for this reason that I have used tumour samples taken from patients who were 
all treated with the same chemotherapy regimen so as to minimise variations 
due to different treatments. This study by Litviakov et al. however, used this 
approach to determine expression of pre-selected genes rather than for 
screening to identify new genes of interest (Litviakov et al., 2013). 
3.4.1.2 Whole tumour, microdissection and laser capture microdissection 
tissue samples for analysis 
Multiple approaches have been used previously when using breast cancer 
tissue samples to analyse gene expression in order to identify genes 
associated with chemoresistance. The simplest of these approaches is to use 
the entire tissue sample available for analysis. In some cases, no mention is 
made of samples being dissected in any way (Bhola et al., 2013), however, in 
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some instances, specific criteria were set as to what samples were eligible for 
analysis. One such criteria was the cellularity of tumour samples, with minimum 
thresholds set (Cleator et al., 2006). 
A more popular method used by researchers when using clinical samples is the 
microdissection of highly cellular regions of available breast tumour samples. In 
these cases, one section was used to demarcate areas of tumour cells ranging 
between minimum thresholds of 20% to 50% cellularity and these demarcations 
were used to guide the manual microdissection of further sections using 
needles or razor blades (Balko et al., 2012, Magbanua et al., 2015, Klintman et 
al., 2016). The advantage of using samples enriched for tumour cells only is 
important when attempting to discover genes specifically associated with 
chemoresistance of tumour cells as the influence of gene expression in other 
cell types may confound results. This differential expression between sample 
types has previously been reported on, where differentially expressed genes 
were compared in ER positive tumour samples that had been manually 
microdissected with tumour epithelial samples and tumour stroma samples (Xu 
et al., 2015). Comparing those genes deregulated in epithelial and stroma 
samples, 86% of them were consistently deregulated, with the remaining 14% 
of genes inconsistently deregulated. Of these genes consistently deregulated in 
epithelial and stroma samples, 91% of genes were found to overlap when 
comparing with deregulated genes in the microdissected samples. However, 
when comparing deregulated genes in the microdissected samples with those 
inconsistently deregulated in the epithelial and stroma samples, the 
consistency score was only 52%. These results reinforce the importance of 
using only the cell populations of interest for analysis. 
The most accurate but much more time consuming method of laser capture 
microdissection to isolate tumour cells has also been used previously. This is 
the method that I used in this study, although few other studies have used this 
technique in a similar context. Other than the time aspect, one possible reason 
for this method not being widely used is the amount of tumour sample required 
for sufficient material for analysis. In this study, I have used up to twenty 
sections of one case for laser capture microdissection in order to collect 
enough material for downstream analyses. In the studies where manual 
microdissection was used, authors have used three to five sections for each 
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case (Balko et al., 2012), four sections for each case (Magbanua et al., 2015) 
or one to six sections for each case (Klintman et al., 2016). In contrast, to gain 
enough RNA to perform microarray analysis, another group required three 
sections and two rounds of RNA amplification (Ma et al., 2003). If avoidance of 
RNA amplification is desired, many more sections are required as only a limited 
amount of RNA can be extracted from microdissected cells (Fuller et al., 2003). 
3.4.2 Specific microRNAs are consistently dysregulated post-NAC 
in partially chemoresistant tumours 
MicroRNAs have previously been shown to be dysregulated in breast cancer 
(Mulrane et al., 2013). Although dozens of dysregulated miRNAs have been 
identified, multiple studies investigating the same miRNA sometimes observe 
differences in expression and/or function, therefore only those where multiple 
studies have shown similar results are concluded to definitely be involved in 
breast cancer. These are largely subdivided into two functional groups: tumour 
suppressors and oncogenic miRNAs, with eighteen and sixteen major miRNAs 
respectively including the miR-200 family in the former group and miR-221/222 
in the latter considered as being involved in breast cancer in 2015 (van 
Schooneveld et al., 2015, Starlard-Davenport et al., 2015), although these 
numbers may have expanded since then. More recently, miRNAs have also 
been linked with resistance to chemotherapy (Wang et al., 2015, Kutanzi et al., 
2011). One such miRNA is miR-21. This miRNA was noted to be involved in 
the resistance of breast cancer cells to chemotherapeutic taxols, as inhibition of 
this miRNA led to increased sensitivity of cells to this treatment (Mei et al., 
2010). Further studies with breast cancer cells have also shown that up-
regulation of miR-21 also leads to resistance to doxorubicin (Wang et al., 
2011). However, it has been noted that the same miRNAs may be dysregulated 
in different ways depending on the context such as type of cancer and 
treatment. An example of this is with miR-195 expression, which when up-
regulated in glioblastoma multiforme cells contributes to resistance to 
temozolomide but increases sensitivity of breast cancer cells to adriamycin 
treatment (Ujifuku et al., 2010, Yang et al., 2013). It is therefore important to 
identify expression signatures for each cancer type and treatment regimen.  
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An array of 384 miRNAs was chosen and miRNAs that were consistently either 
up- or down-regulated post-NAC when compared with pre-NAC were identified. 
MicroRNAs that met the chosen requirements were selected.  
3.4.2.1 MiR-26b, -195 and -10a are potential mediators of 
chemoresistance 
Three miRNAs were selected that had large enough fold changes across all 
five patient samples. These were miR-26b, miR-195 and miR-10a. The first two 
were up-regulated post-NAC, with mean fold change expressions of 4.87 and 
2.57 respectively, whereas miR-10a was down-regulated post-NAC, with a 
mean fold change of -4.15. Considering the fact that these patients all 
displayed partial resistance to the administered chemotherapy, it is possible 
that these consistently changed miRNAs may contribute to the 
chemoresistance. 
Previous studies have shown that all three of these miRNAs do play roles in 
chemoresistance in other cancer types and in some cases in breast cancer 
treated with other chemotherapeutics such as platinum-based therapies (Zhao 
et al., 2014, Yang et al., 2013, Pogribny et al., 2010), although evidence is 
conflicting. Evidence in hepatocellular carcinoma suggests that miR-26b 
expression enhances the chemosensitivity of these cells to docetaxel, TNFα 
and doxorubicin, in part by targeting TAK1 and TAB3 and suppressing NF-ĸB 
signalling (Rui et al., 2010, Zhao et al., 2014). In contrast, evidence obtained 
from work with non-small cell lung carcinoma, both in vitro and in vivo, 
suggests that over-expression of miR-26b leads to increased resistance to the 
chemotherapeutic drug cisplatin (Liang et al., 2015). These apparent conflicting 
data support the theory that, as with other miRNAs, the function of miR-26b is 
dependent on context. Previous studies in breast cancer have shown that miR-
26b expression is decreased compared with normal tissue and up-regulation of 
this miRNA contributes to suppressed cell proliferation and the promotion of 
apoptosis (Liu et al., 2011, Li et al., 2013, Li et al., 2014a). However, there is as 
yet no direct evidence linking aberrant expression of miR-26b in tumour 




As with miR-26b, miR-195 has previously been shown to have decreased 
expression in tumour tissues including breast cancer and non-small cell lung 
carcinoma. As such, miR-195 is generally considered to be a tumour 
suppressor (Li et al., 2011, Luo et al., 2014, Liu et al., 2015b). Also similarly, 
the role of miR-195 in chemoresistance is not fully understood. Up-regulation of 
this miRNA has been shown to result in increased chemosensitivity to 
adriamycin in breast cancer (Yang et al., 2013), doxorubicin in colon cancer 
(Qu et al., 2015) and 5-FU in hepatocellular carcinoma (Yang et al., 2012). 
However, increased expression of miR-195 has also been implicated in 
acquired temozolomide resistance in glioblastoma multiforme cells (Ujifuku et 
al., 2010) and resistance to doxorubicin in small cell lung cancer cells (Guo et 
al., 2010b). This again supports the theory that miRNAs have differing functions 
depending on context. 
Finally, miR-10a has been shown to have numerous functions. An interesting 
function includes the ability of this miRNA to enhance the translation of 
ribosomal protein mRNAs (Ørom et al., 2008). This function is the opposite of 
the classically defined function of miRNAs where the binding of target mRNAs 
results in the reduced expression of these targets (Farh et al., 2005, Guo et al., 
2010a, Huntzinger and Izaurralde, 2011). In cancers, miR-10a has been shown 
to result in increased cell growth in a subset of chronic myeloid leukaemia cells 
(Agirre et al., 2008). It is also down-regulated in colorectal cancer tumour 
tissues and cells (Eyking et al., 2016). However, decreased expression of miR-
10a blocks the metastatic behaviour of pancreatic cancer (Weiss et al., 2009) 
and increased expression has been observed in lymph node metastases of 
gastric cancer (Chen et al., 2012) and in medullary thyroid carcinoma (Hudson 
et al., 2013). As with miR-26b and miR-195, miR-10a also seems to play 
various roles with regards to sensitivity to chemotherapeutic agents. Silencing 
of this miRNA reverses cisplatin resistance in a resistant lung cancer cell line 
(Sun et al., 2015) and increased expression of miR-10a was found in a cisplatin 
resistant ER positive breast cancer cell line (Pogribny et al., 2010). In contrast, 
miR-10a was down-regulated in gemcitabine resistant non-small cell lung 
cancer cell lines (Zhang et al., 2013b). In breast cancer, increased expression 
of miR-10a was associated with a longer relapse-free time in ER positive 
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tumours following treatment with the anti-oestrogen tamoxifen (Hoppe et al., 
2013). 
In view of all this conflicting evidence, miR-26b, miR-195 and miR-10a are all 
possible candidates for contributing to resistance to anthracycline-based 
therapies in primary ER positive breast cancers. 
3.4.3 Multiple pathways are dysregulated post-NAC in partially 
resistant tumours 
Several genes have previously been shown to contribute to chemoresistance in 
a variety of cancers. These include the MAPK and PI3K pathways as well as 
drug efflux pumps (Haagenson and Wu, 2010, Martz et al., 2014, Sun et al., 
2012). In order to identify the pathways that contribute to chemoresistance of 
primary ER positive breast cancers to anthracycline-based therapies, total RNA 
extracted from five patients who displayed only a partial response to NAC that 
was used to perform a miRNA microarray was also used to determine changes 
in mRNA expression using NanoString technology.  
3.4.3.1 Identifying candidate mRNA genes that contribute to 
chemoresistance using pre-NAC and post-NAC samples 
As mentioned briefly in 3.4.1.1, the use of pre-NAC and post-NAC samples to 
identify genes associated with chemoresistance in breast cancer is not as 
widely used as the use of matched parental and chemoresistant cell lines, or 
the use of pre-NAC samples and associated correlations with subsequent 
clinical data. However, there are some studies that have used pre-NAC and 
post-NAC samples, although the primary purpose of these studies was not 
always to investigate genes associated with chemoresistance. 
Creighton et al. examined breast cancer biopsy samples and matched post-
treatment samples to determine the molecular features of surviving tumour 
cells (Creighton et al., 2009). Patients were treated with either endocrine 
therapy (letrozole) or chemotherapy (docetaxel). It had previously been noted 
that post-chemotherapy, breast cancer samples had an increased proportion of 
cells with a CD44+/CD24-/low phenotype compared with pre-chemotherapy 
samples and that these cells also have an increased ability to form 
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mammospheres. These cells were classed as tumour-initiating cells and 
deemed more chemoresistant (Li et al., 2008). Subsequently, this was tested 
with samples post-NAET and post-NAC compared with their matched pre-
treatment samples and the increased presence of such cells was confirmed 
post-treatment. Several mesenchymal associated genes that had previously 
been found to be expressed in this cell population using microarray analysis 
were also found to be more highly expressed; a feature usually associated with 
the claudin-low subset of breast cancers (Creighton et al., 2009). Claudin-low 
breast cancers are largely hormone-receptor negative, have a poor prognosis 
and of all the breast cancer subtypes most closely resemble epithelial stem 
cells (Prat et al., 2010). 
Other studies have also used microarray profiling using pre-NAC and post-NAC 
samples. One such study used this method and these samples as well as 
samples taken during chemotherapy to analyse gene expression changes that 
occur during the course of chemotherapy and then related these changes with 
either a response to the chemotherapy (anthracycline followed by a taxane) or 
subsequent recurrences. Both a decreased expression of cell cycle inhibitors 
together with increased expression of cell proliferation genes and an increase 
in interferon signalling were associated with poor response and reduced 
recurrence free survival (Magbanua et al., 2015).  
3.4.3.2 NanoString Technologies: limitations to sensitivity and 
reproducibility 
It has been well established that changes in gene expression are associated 
with chemoresistance. However, investigations into these changes in patients 
using FFPE tissue samples are limited due to this storage method resulting in 
cross-linking and fragmentation of RNA as well as modifications (Masuda et al., 
1999, Gnanapragasam, 2010, Kokkat et al., 2013). Unlike with microarrays 
where a total signal is measured for each gene, NanoString Technologies uses 
probes attached to a barcode unique for each gene and these are then counted 
individually. Sample fragment lengths must be at least 100 nucleotides for the 
probes (Geiss et al., 2008). As shown in Figure 3.3.1, total RNA extracted from 
my FFPE tissues largely met this requirement. 
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The technology offered by NanoString is relatively new compared with more 
standard technologies used in gene expression analysis, such as microarrays. 
The use of NanoString technology is attractive when using RNA sourced from 
FFPE samples as very little input of total RNA is required and it can be the 
case that no reverse transcription and subsequent amplification of the RNA is 
required, thus removing any potential biases associated with these processes 
(Reis et al., 2011). NanoString technologies have also been shown to be more 
sensitive than other comparable technologies, such as microarrays (Geiss et 
al., 2008). 
NanoString assays have been used for a number of purposes in the last 
decade, although literature searches have revealed that input RNA is usually 
derived from tumour samples rather than cells used in vitro. This perhaps 
reflects the idea that this technology may provide more accurate results 
compared with microarray technology when using limited samples. A 
customised NanoString Panel was used to characterise a previously defined 
side population of cells in pancreatic tumour samples. Both tumour samples 
and adjacent normal tissue fresh frozen samples were used, with some 
samples excluded as the RNA extracted had to have a RIN value of greater 
than 7. This side population of cells was found to express cancer stem cell 
associated and prognostic genes (Van den Broeck et al., 2013). This minimum 
RIN value is markedly higher than the RIN values of RNA that I have used in 
this study. However, in the above study, RNA was extracted from fresh frozen 
tissue whereas I have extracted RNA from FFPE tissue. 
In a study of locally advanced head and neck squamous cell carcinoma 
(HNSCC), FFPE samples of pre-treatment tissues were collected. Patients 
were treated with a combination of chemotherapy (cisplatin or mitomycin C) 
and radiotherapy. Of the 158 FFPE samples that matched the specific criteria, 
twenty samples had to be omitted due either to insufficient material or low yield 
of RNA. Gene expression profiles were identified using a customised 
NanoString Panel and together with HPV status, tumour volume and stem cell 
marker expression, subgroups of patients with a good prognosis were identified 
(Linge et al., 2016). 
NanoString Technologies have also been used to analyse gene expression 
using breast cancer samples. Klintman et al. used pre-NAC core biopsy and 
94 
 
post-NAC resection samples to analyse gene expression using a customised 
NanoString Panel in order to identify genes with altered expression post-
treatment and associate these changes with prognostic implications (Klintman 
et al., 2016). At first, 220 patients were identified, although this number was 
reduced due to a number of factors including low cellularity of the tumour. 
Three samples were excluded due to insufficient RNA yield where 50-100ng 
total RNA was used for NanoString analysis. These are similar amounts of 
RNA to the amounts that I have used in this study. 
Gene expression analysis using NanoString Technologies of post-NAC breast 
cancer samples to identify genes associated with chemoresistance was 
performed on 98 samples. One of these samples failed quality control after 
being analysed using the NanoString Panel. Using data from the remaining 97 
samples, this study concluded that decreased expression of DUSP4 post-NAC 
was associated with chemoresistance (Balko et al., 2012). 
On running the RNA extracted from the patient samples in this study, two 
samples failed quality control following the run, although for different reasons to 
that described previously (Balko et al., 2012). This was determined to be likely 
due to chaotropic contamination, low concentrations of RNA and highly 
fragmented RNA. This demonstrates that although NanoString Technologies 
may be more sensitive than other similar technologies such as microarrays 
(Geiss et al., 2008), low RNA quantity and quality are still important limiting 
factors when analysing gene expression using RNA extracted from FFPE 
tissues. 
Samples from one patient that were successfully analysed using the 
NanoString assays without pre-amplification were pre-amplified together with 
the samples that failed the initial analyses in order to allow comparison of 
reproducibility with and without pre-amplification, and thereby determine if any 
bias was introduced between samples that underwent pre-amplification and 
those that didn’t. Fold changes of genes differentially expressed between pre-
NAC samples and post-NAC samples were plotted comparing between values 
obtained without pre-amplification (Run 1) and those obtained after pre-
amplification (Run 2). The correlation coefficient had a very low value indicating 
that results obtained from samples that underwent pre-amplification were 
largely not comparable with those obtained from samples that were not pre-
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amplified. This suggests that the process of pre-amplification does introduce 
bias, and therefore should be avoided. This has recently been observed in a 
study investigating whether circulating tumour cells could be reliably detected 
using NanoString assays (Porras et al., 2018). 
Combining all the studies mentioned as well as my own, it is clear that whilst 
NanoString assays may indeed be more sensitive and require less input RNA, 
as well as being able to analyse gene expression using RNA extracted from 
FFPE tissue samples (Geiss et al., 2008, Reis et al., 2011), there are still 
limitations of this technology. 
3.4.3.3 Consistent changes in gene expression are observed post-NAC 
and suggest altered activity of several pathways leading to 
chemoresistance 
Using the available complete and incomplete datasets, many genes were 
identified that were consistently either up- or down-regulated post-NAC across 
at least the three patient samples that were successfully analysed. Genes that 
were successfully detected in the two patient samples that largely failed 
analysis were also taken into account. Using the KEGG database (Kanehisa 
and Goto, 2000, Kanehisa et al., 2015, Kanehisa et al., 2016) and the 
annotations provided by NanoString Technologies that indicated which 
pathways each gene functions in, each pathway was manually annotated 
depicting whether individual genes were up-regulated or down-regulated. Each 
pathway was then examined to determine whether overall, the changes in gene 
expression would lead to activation or suppression of the pathway as a whole 
and statistical tests using the binomial test were performed to determine if 
these changes were significant. Investigating the functions of these pathways 
together with literature searches revealed whether the altered activities of these 
pathways may contribute to the partial chemoresistant phenotype observed in 
these patients.  
MAPK and PI3K-AKT pathways were activated post-NAC and many genes 
contributing to alterations in proliferation and metastasis were also involved. 
Increased activity of the MAPK pathway, in particular the JNK and p38 arms, 
has previously been linked with chemoresistance (Igea and Nebreda, 2015, 
Leung et al., 2008, Suzuki et al., 2015). Previous studies have also indicated 
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that activation of the PI3K-AKT pathway has previously been linked with 
chemoresistance (West et al., 2002). The activation and suppression of distinct 
arms of this pathway downstream of AKT in these patient samples post-NAC 
may reflect the fact that these patients do partially respond to chemotherapy 
but also display some resistance. The activation of these two pathways and the 
changes in gene expression of 25% of genes that are altered in such a way as 
to contribute to increased cell proliferation and/or metastasis indicate that these 
pathways contribute to the chemoresistance observed in these patients. 
As with the PI3K-AKT pathway, elements of the RAS pathway such as genes 
involved in cell motility and cell survival are down-regulated, reflecting the fact 
that these tumours showed a partial response to chemotherapy. Other 
elements of this pathway such as genes involved in cytoskeletal remodelling 
and activating components of the MAPK pathway are up-regulated, reflecting 
the partial resistance exhibited by these tumours. Increased activation of the 
RAS pathway has previously been shown to contribute to chemoresistance and 
has also been shown to act via the MAPK and PI3K-AKT pathways (Jin et al., 
2003).  
3.4.4 Conclusions 
In this chapter, I have used breast tumour samples taken from patients before 
and after NAC, who displayed only a partial response to the chemotherapy. 
Consistent changes in mRNA and miRNA expression were observed, with 
results suggesting activation of the MAPK and PI3K-AKT pathways, and up-
regulation of miR-26b and miR-195, and down-regulation of miR-10a. The next 
aim was to determine whether any of these changes in expression were 
associated with changes in chemoresponse in vitro. Further studies were first 
designed to investigate the dysregulated miRNAs as these provided individual 
molecules to study, rather than the whole molecular pathways provided by the 
mRNA expression data.  
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Chapter 4: Deregulation of microRNAs in ER positive breast 
cancer causes altered chemosensitivity 
4.1 Abstract 
I have identified miR-26b, miR-195 and miR-10a as consistently deregulated in 
luminal A breast cancer cells that survived chemotherapy treatment; this 
suggested that these miRNAs may contribute to defining chemoresponse. In 
this chapter, I investigated firstly whether these miRNAs alter chemosensitivity 
of ER positive breast cancer cells in vitro using miRNA mimics and inhibitors 
with two separate chemoresponse assays, and secondly, whether it was 
possible to identify the targets of these miRNAs that may be responsible for 
their influences. 
Increased expression of miR-26b or miR-195 using miRNA mimics resulted in 
significantly increased resistance to the anthracycline epirubicin in two cell lines 
representative of luminal A breast cancers (MCF7 and MDA-MB-175); this was 
in accordance with the observed increase in expression of these miRNAs in 
cancer cells surviving NAC in patients. Surprisingly, increased expression of 
miR-10a also resulted in increased chemoresistance in vitro, an observation 
apparently in conflict with the down-regulation of miR-10a that was observed 
post-NAC in patients. Decreasing expression of miR-26b, miR-195 and miR-
10a using inhibitors generally had less effect, although when significant findings 
were made, the results were the opposite of over-expression, as would be 
expected. Also, investigation of expression of miR-26b and miR-195 in two ER 
positive breast cancer cell lines that had been selected to become resistant to 
epirubicin revealed that the expression of these two miRNAs was increased in 
the resistant cell lines compared with parental controls. 
Next, attempts were made to identify the mRNA targets through which miR-26b 
and miR-195 contribute to chemoresistance using predictive algorithms, 
literature searches and mining of public datasets. Six putative targets of miR-
26b and five putative targets of miR-195 were identified, including CCDC6 as a 
potential target of both. Expression analysis of CCDC6 after transfection with 
miR-26b or miR-195 mimics and inhibitors confirmed that CCDC6 is indeed 
downstream of the miRNAs but chemosensitivity assays after transfection with 
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CCDC6 siRNA demonstrated that this gene did not alone influence 
chemoresistance. 
I concluded that miR-26b and miR-195 can contribute to chemoresistance in 
breast cancer, but that other assays will be required to identify the pathways 
downstream. 
4.2 Introduction 
4.2.1 The role of miRNAs in chemoresistance 
MiRNAs are short, non-coding sequences of RNA typically between twenty and 
twenty-four nucleotides long. They were first discovered twenty-five years ago 
(Wightman et al., 1993, Lee et al., 1993) and have since been found to regulate 
gene expression at post-transcriptional levels (Obernosterer et al., 2006). 
There are two principal mechanisms used by miRNAs in this function. These 
are the ability to sequester mRNAs such that the transcripts are no longer 
accessible to translational machinery (Pillai, 2005) and the ability to mark the 
transcripts for destruction (Orang et al., 2014). Ultimately, both of these 
mechanisms lead to decreased protein production (see section 1.3.2).  
Since their discovery, evidence has shown that individual miRNAs have the 
potential to bind to multiple mRNA targets. An example of this is miR-21, which 
has been shown to regulate the expression of PTEN (Wang et al., 2011), 
PDCD4 (Asangani et al., 2008) and BCL2 (Dong et al., 2011). Increasing the 
complexity of miRNA function, evidence has also shown that a single mRNA 
transcript can be targeted by multiple miRNAs. This is evidenced by the fact 
that PTEN has been shown to be regulated by both miR-19 (Liang et al., 2011) 
and miR-21 (Wang et al., 2011). 
The observation that miRNAs generally have decreased expression in cancer 
tissue compared to normal tissue (Lu et al., 2005) has led to increased interest 
in their regulation and function in multiple contexts, including their ability to 
contribute to the classification of tumour subtypes (Blenkiron et al., 2007) or to 
determine whether tumours are likely to respond to specific systemic therapies 
(van Schooneveld et al., 2015, Muluhngwi and Klinge, 2015). 
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Several miRNAs have been identified as regulators of chemoresponse, for 
example miR-298 expression has been implicated in response to doxorubicin in 
breast cancer (Bao et al., 2012). It is important to note, however, that the same 
miRNA may have differing functions depending on context. This has been 
shown with miR-195, which when up-regulated results in resistance to 
temozolomide in glioblastoma multiforme cells but is also associated with 
increased sensitivity to adriamycin in breast cancer (Ujifuku et al., 2010, Yang 
et al., 2013). This highlights the importance of identifying molecular profiles 
associated with sensitivity and resistance to specific treatment regimens rather 
than expecting findings to be generic. It is also important that these molecular 
profiles are identified for each tumour subtype. 
The validation of miRNAs that contribute to chemoresistance has previously 
involved the use of miRNA mimics and inhibitors. Such a method was used 
after it had been established that miR-130b was up-regulated in primary breast 
tumours compared with adjacent normal tissue and the discovery that this 
miRNA was also up-regulated in MCF7 cells that had been selected to become 
resistant to adriamycin as compared to parental cells. With the use of a miR-
130b mimic, it was discovered that the up-regulation of this miRNA in normal 
MCF7 cells was sufficient to increase chemoresistance and proliferation, and to 
decrease apoptosis. The down-regulation of this miRNA using an inhibitor in 
MCF7 cells that were resistant to adriamycin increased chemosensitivity and 
apoptosis, and reduced proliferation (Miao et al., 2017). A similar approach was 
taken in this chapter. MiR-26b, miR-195 and miR-10a were identified as 
consistently deregulated in terms of expression in the cancer cells surviving 
NAC in ER positive tumours that displayed a partial response to the 
chemotherapy (see section 0). In this chapter, I have used mimics and 
inhibitors of these miRNAs to assess whether changes in their expression 
levels are sufficient to cause altered chemosensitivity of ER positive breast 







4.2.2 Specific objectives 
There were two specific objectives in this chapter: 
1. To identify whether miR-26b, miR-195 or miR-10a influence 
chemoresponse of ER positive breast cancer cells in vitro. 
2. To use predictive algorithms together with literature searches and public 
datasets in an attempt to identify putative mRNA targets of the miRNAs 
that contribute to chemoresponse and determine if these genes 
contribute to the altered chemosensitivity. 
4.3 Results 
4.3.1 Deregulated miRNAs affect chemo-sensitivity in vitro 
Three miRNAs, miR-26b, miR-195 and miR-10a, were identified in Chapter 3 
(section 0) as potentially involved in defining chemoresponses of breast 
cancers, based on their consistent deregulation of expression in breast cancer 
cells that had survived chemotherapy treatment. My next aim was to investigate 
in vitro whether these miRNAs individually play roles in contributing to 
chemoresponse of breast cancer cells. To do this, I used two different cell lines 
representative of the luminal A subtype of breast cancer, since this was the 
subtype of breast cancer examined in Chapter 3: these were MCF7 and MDA-
MB-175 cells. The MCF7 cell line is a well-established luminal A representative 
(Holliday and Speirs, 2011), whereas MDA-MB-175 cells were classified as 
luminal B cells according to the PAM50 classification although there appear to 
be results that suggest that this cell line is also luminal A (Jiang et al., 2016). In 
addition, two separate methods of determining chemosensitivity were 
employed: MTT assays to observe short-term survival of cells after treatment 
with an appropriate chemotherapy agent, and colony forming assays to 
determine long-term effects on cell viability as assessed by ability to proliferate 
sufficiently after treatment to generate a colony of progeny cells. The 
anthracycline epirubicin was used, as this was the key component of the 
clinical regimen in the treatment of the patients studied in Chapter 3. 
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4.3.1.1 The two luminal A representative cell lines MCF7 and MDA-MB-
175 have very different sensitivities to epirubicin 
First, it was necessary to determine the sensitivities of the two cell lines to be 
used to epirubicin, so that cells could be treated with doses in the appropriate 
range after manipulation of miRNA expression. In this context, an appropriate 
range meant doses resulting in approximately 20-80% survival, and thereby 
suitable for assessment of any induced changes in survival, as opposed to 
doses causing very dramatic death or having little effect, which may be 
relatively impervious to protection or sensitisation from single gene influences. 
MCF7 or MDA-MB-175 cells were treated with a wide range of doses of 
epirubicin for 24 hours and MTT assays were performed (Figure 4.3.1). As 
expected, epirubicin induced dose-dependent reductions in survival. MCF7 
cells were considerably more sensitive than MDA-MB-175 cells, with respective 
IC50 doses of 1.1µM and 178µM. 
   
Figure 4.3.1: Different epirubicin doses are appropriate in the two 
different representative breast cancer cell lines 
MCF7 or MDA-MB-175 cells were seeded and treated with a range of 
epirubicin concentrations for 24 hours. Cell viability was then measured 
using MTT assays. Cell survival at each dose was calculated relative to 
viability of vehicle control (water) treated cells for each cell line. (A) The 
dose-response curve for MCF7 cells. Data represent means of two 
biological repeats with error bars showing SEM. (B) The dose-response 
curve for MDA-MB-175 cells. Data represent means of three biological 
repeats with error bars showing SEM. 
 
 








































4.3.1.2 MiRNA mimics and inhibitors successfully modify miRNA 
expression levels 
Next, I aimed to modify the cellular expression levels of the miRNAs of interest 
by transfecting with miRNA mimics or inhibitors, therefore transfections were 
performed and RT-qPCR used to assess expression levels. MCF7 or MDA-MB-
175 cells were transfected with targeted miRNA mimics or inhibitors for miR-
26b, miR-195, or miR-10a or appropriate non-targeting mimic or inhibitor 
controls. RNA was extracted seventy-two hours later and expression of these 
miRNAs was then quantified by RT-qPCR (Figure 4.3.2). Transfection with 
miRNA mimics or inhibitors resulted in successful over-expression (by 145 to 
4500 fold) or down-regulation (to 0.4 or lower relative to control levels) of the 






Figure 4.3.2: MiR-26b, miR-195 and miR-10a were successfully up- or 
down-regulated in MCF7 and MDA-MB-175 cells 
MCF7 (top panels) or MDA-MB-175 (bottom panels) cells were 
transfected as shown with individual miRNA mimics (left panels) or 
inhibitors (right panels) or controls, and total RNA extracted seventy-two 
hours post-transfection. Expression of the targeted miRNAs was 
quantified by RT-qPCR relative to RNU48 and is presented relative to 
levels in cells transfected with control mimics or inhibitors. These graphs 
represent means of three technical replicates from one biological repeat, 
with error bars showing SD.  
4.3.1.3 Over-expression of miR-26b or miR-195 increases resistance of 
MCF7 and MDA-MB-175 cells to chemotherapy 
Having successfully confirmed the altered expressions of the miRNAs of 
interest with the miRNA mimics and inhibitors, I then wanted to assess the 
influence of over-expression and knockdown of these miRNAs individually on 
chemoresponse. Initially, I focussed on miR-26b and miR-195, both of which 
were up-regulated in the cancer cells that survived NAC in patients. MCF7 or 
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appropriate controls. Forty-eight hours post-transfection, cells were treated with 
two different doses of epirubicin for twenty-four hours and then MTT assays 
were performed to determine effects of the miRNA mimics or inhibitors on cell 
viability. Note this forty-eight plus twenty-four hours protocol means that MTT 
assays were performed at the same time point as I used previously to test the 
degrees of over-expression or knockdown (Figure 4.3.2). Epirubicin doses were 
chosen so as to result in approximately 75% or 25% cell viability in the control 
transfected samples.  
Data obtained from MTT assays in MCF7 cells (Figure 4.3.3) and in MDA-
MB175 cells (Figure 4.3.4) showed that when cells over-expressed miR-26b or 
miR-195, cells were significantly more viable after treatment with epirubicin 
(p<0.05), suggesting that they were more resistant to the epirubicin treatment 
compared with their control counterparts. By contrast, the inhibitors of miR-26b 
or miR-195 did not cause compelling changes in chemoresponse, with no 
significant differences seen in MCF7 cells, while in MDA-MB-175 cells a slight 
(but significant, p<0.05) chemo-protection was seen from the miR-195 inhibitor 
at one epirubicin dose only.  
The data from these MTT assays in both cell lines suggested that an increase 
in either miR-26b or miR-195 expression in ER positive breast cancer cells 
caused increased resistance to chemotherapy. Despite these increases in cell 
survival being relatively small, the suggestion that the up-regulation of these 
miRNAs did contribute to chemoresistance appeared convincing based on the 
facts that: 1) the increases in cell survival were significant at various doses and 
in both cell lines; 2) doses that did not show significant differences appeared to 
show similar trends; and 3) these data were consistent with expectations from 
patient data where increased expression of these miRNAs was observed in 
cells that had survived chemotherapy treatment (see section 0). 
Conversely, data obtained using inhibitors of these miRNAs were unexpected 
considering the effects of the mimics as it might be expected that the inhibitors 
would have the opposite effects on cell survival after epirubicin treatment. 
However, data obtained from these MTT assays suggested that decreased 
expression of these miRNAs had little effect. In MDA-MB-175 cells, the inhibitor 
for miR-195 (Figure 4.3.4D) led to a significant increase in cell survival at the 
higher dose of epirubicin (p<0.00005). However, this was the only significant 
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result obtained with the miRNA inhibitors and was only observed in one cell line 
at one dose of epirubicin, and could therefore be considered an anomaly. In 
particular, it may be worth noting that transfection of MDA-MB-175 cells with 
the miR-195 inhibitor resulted in the least effective change in expression seen 
across the whole panel of miRNA mimics and inhibitors (a decrease in 
expression of approximately 60%; Figure 4.3.2), therefore, the result of 
increased survival following inhibition of miR-195 and treatment with epirubicin 





     
    
 
    
    
Figure 4.3.3: Increased miR-26b and miR-195 expression in MCF7 cells 
confers chemoresistance 
MCF7 cells were transfected with either mimics (left panels) or inhibitors 
(right panels) of miR-26b (A and B) or miR-195 (C and D). Forty-eight 
hours post-transfection, cells were treated with two concentrations of 
epirubicin (0.5µM or 1µM) or vehicle control (water). Twenty-four hours 
post-treatment, MTT assays were performed. Raw absorbance values 
were normalised to the control transfected and control untreated samples. 
The top panels show the effects of epirubicin on overall survival whereas 
the bottom panels are normalised to allow focus on the effects of the 
targeted miRNA mimic or inhibitor on survival in epirubicin-treated 
samples. Three biological repeats were performed for each experiment, 










































































































































































































































     
      
Figure 4.3.4: Increased miR-26b and miR-195 expression in MDA-MB-175 
cells confers chemoresistance 
MDA-MB-175 cells were transfected with either mimics (left panels) or 
inhibitors (right panels) of miR-26b (A and B) or miR-195 (C and D). Forty-
eight hours post-transfection, cells were treated with two concentrations of 
epirubicin (174µM or 300µM) or vehicle control (water). Twenty-four hours 
post-treatment, MTT assays were performed. Raw absorbance values 
were normalised to the control transfected and control untreated samples. 
The top panels show the effects of epirubicin on overall survival whereas 
the bottom panels are normalised to allow focus on the effects of the 
targeted miRNA mimic or inhibitor on survival in epirubicin-treated 
samples. Two biological repeats were performed for each experiment, 





































































































































































































































































4.3.1.4 Over-expression of miR-10a increases resistance of MCF7 and 
MDA-MB-175 cells to chemotherapy 
Next, I took the same approach to investigate the role of miR-10a in 
chemoresponse; miR-10a had been identified as down-regulated in cancer 
cells that survived NAC in patients. MCF7 and MDA-MB-175 cells were 
transfected with mimics and inhibitors, treated with epirubicin, and survival was 
assessed as before (Figure 4.3.5). MiR-10a mimics induced increased survival 
after epirubicin treatment, which was significant in one cell line at one dose 
(p<0.05), while – as previously – the inhibitors had little effect. 
The data from these MTT assays in both cell lines suggested that, as with miR-
26b and miR-195, increased expression of miR-10a contributed to increased 
chemoresistance compared with control transfected cells. Despite the fact that 
there was only one significant result in one cell line at one dose, all of the other 
results consistently showed an apparent increase in cell viability in both cell 
lines, supporting the conclusion that increased miR-10a expression led to 
increased cell survival. However, these results were surprising since they were 
not concordant with expectations based on patient data, as miR-10a was down-
regulated in cells that survived chemotherapy treatment (see section 0), leading 




Figure 4.3.5: Increased miR-10a expression in MCF7 and MDA-MB-175 
cells confers chemoresistance not chemosensitivity 
MCF7 (A and B) or MDA-MB-175 (C and D) cells were transfected with 
either miR-10a mimic (left panels) or miR-10a inhibitor (right panels) or 
appropriate control mimic/inhibitor. Forty-eight hours post-transfection, 
cells were treated with two concentrations of epirubicin or vehicle control 
(water). Twenty-four hours post-treatment, MTT assays were performed. 
Raw absorbance values were normalised to the control transfected and 
control untreated samples. The top panels show the effects of epirubicin 
on overall survival whereas the bottom panels are normalised to allow 
focus on the effects of the targeted miRNA mimic or inhibitor on survival in 
epirubicin-treated samples. Three biological repeats were performed using 
MCF7 cells and two biological repeats were performed using MDA-MB-
175 cells, with error bars showing SEM (*p<0.05).  
   
  
   



























































































































































































































































4.3.1.5 Expression levels of miR-26b, miR-195 and miR-10a influence 
clonogenic survival following chemotherapy in MCF7 and MDA-
MB-175 cells 
The data obtained from these short-term MTT assays suggested that over-
expression of miR-26b, miR-195 or miR-10a individually contribute to 
chemoresistance. However, it is important to consider that this assay simply 
observes cell viability directly after twenty-four hours treatment with the 
chemotherapy drug and does not take into account longer-term influences on 
proliferative ability. For this reason, colony forming assays were performed as 
these assess whether cells retain proliferative capacity, as opposed to merely 
staying alive, and therefore these assays may be more sensitive to influences 
of some regulators of response. 
These experiments were performed using the same initial procedure as that 
used in the previous MTT protocol (sections 4.3.1.3 and 4.3.1.4), where cells 
(MCF7 or MDA-MB-175) were transfected with individual miRNA mimics or 
inhibitors or controls. Forty-eight hours post-transfection, cells were treated with 
doses of epirubicin for twenty-four hours. Instead of performing an MTT assay, 
however, cells were seeded at low densities in fresh media without epirubicin 
and left in culture for two weeks to observe what proportion of cells retained the 
ability to form colonies following the epirubicin treatment (Figure 4.3.6 and 
Figure 4.3.7). 
Epirubicin doses were again selected to allow approximately 50% of cells to 
survive epirubicin treatment (ie grow into a colony); note these doses are 
considerably lower than the previous short-term assay, since long-term 
proliferative ability is sensitive to much lower doses. Initially, experiments were 
performed targeting miR-26b or miR-195 (Figure 4.3.6), since for these 
miRNAs MTT data were concordant with patient data therefore these 
represented the most promising candidate mediators of clinically relevant 
chemoresistance. 
Over-expression of miR-195 caused a significant increase in cell survival in 
MCF7 cells after epirubicin treatment (p<0.005) and increased miR-26b also 
caused an increase in cell survival, although this was not significant (Figure 
4.3.6A). In marked contrast to the MTT assays, the miRNA inhibitors also had 
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functional effects in this assay. When MCF7 cells were transfected with miR-
26b or miR-195 inhibitors, clonogenic survival was decreased, which was 
significant with the miR-195 inhibitor (Figure 4.3.6B, p<0.0005).  
Similar results were observed when miRNA mimics or inhibitors were 
transfected into MDA-MB-175 cells, with significant increases in relative 
survival when cells were transfected with miRNA mimics (Figure 4.3.6C, 
p<0.0005) and significant decreases in survival when cells were transfected 
with miRNA inhibitors (Figure 4.3.6D, p<0.005).  
The data obtained from colony forming assays suggested that increased 
expression of miR-26b and miR-195 led to an increased ability of both MCF7 
and MDA-MB-175 cells to survive and form colonies after chemotherapy 
treatment. Conversely, decreased expression of these miRNAs led to both cell 
lines becoming more sensitive to chemotherapy treatment resulting in fewer 
colonies being formed. These results are concordant with those obtained from 
MTT assays and also from patient data, providing strong evidence that miR-
26b and miR-195 modulate chemoresistance. 
Clonogenic survival assays were also performed after transfection with mimics 
or inhibitors for miR-10a in exactly the same way (Figure 4.3.7 [page 110]). 
MiR-10a over-expression caused a significant increase in cell survival after 
epirubicin treatment in both MCF7 and MDA-MB-175 cells (p<0.05), while miR-
10a down-regulation caused a significant decrease in cell survival after 
epirubicin treatment in both cell lines (p<0.05). These data were concordant 
with those obtained from MTT assays, but again did not meet expectations 
based on patient data where miR-10a expression was decreased in cells that 




       
   
Figure 4.3.6: Increased miR-26b and miR-195 expression in MCF7 and 
MDA-MB-175 cells confers clonogenic survival 
MCF7 (A and B) or MDA-MB-175 (C and D) cells were transfected with 
either miRNA mimics (A and C) or inhibitors (B and D) or a miRNA control 
mimic or inhibitor. Forty-eight hours post-transfection, MCF7 cells were 
treated with 30nM epirubicin and MDA-MB-175 cells were treated with 
600nM epirubicin for twenty-four hours before being seeded at low 
densities and left to grow for fourteen days. Colonies were fixed and 
stained with a mixture of methanol, ethanol and crystal violet solution 
before being counted. The top panels show for each condition, epirubicin-
treated samples were normalised to their untreated counterparts. The 
bottom panels show the miRNA transfected and treated samples 
normalised to the control transfected and epirubicin-treated sample. Three 
biological repeats were performed with MCF7 cells and two biological 
repeats were performed with MDA-MB-175 cells, with error bars showing 






























































































































































































































































        
   
Figure 4.3.7: Increased miR-10a expression in MCF7 and MDA-MB-175 
cells confers clonogenic survival 
MCF7 (A and B) or MDA-MB-175 (C and D) cells were transfected with 
either a miR-10a mimic (A and C) or inhibitor (B and D) or a miRNA 
control mimic or inhibitor. Forty-eight hours post-transfection, MCF7 cells 
were treated with 30nM epirubicin and MDA-MB-175 cells were treated 
with 600nM epirubicin for twenty-four hours before being seeded at low 
densities and left to grow for fourteen days. Colonies were fixed and 
stained with a mixture of methanol, ethanol and crystal violet solution 
before being counted. The top panels show for each condition, epirubicin-
treated samples were normalised to their untreated counterparts. The 
bottom panels show the miRNA transfected and treated samples 
normalised to the control transfected and epirubicin-treated sample. Three 
biological repeats were performed with MCF7 cells and two biological 
repeats were performed with MDA-MB-175 cells, with error bars showing 




























































































































































































































































































Combining data from both short-term and long-term survival analyses, I 
concluded that over-expression of all three miRNAs can individually contribute 
to increased chemoresistance and that down-regulation of these miRNAs 
individually can contribute to increased chemosensitivity. As miR-26b and miR-
195 were observed to be up-regulated in breast cancer cells post-
chemotherapy in patients, the in vitro data I have obtained are concordant with 
these observations. However, miR-10a was observed to be down-regulated 
post-chemotherapy in patients, thus the data I have obtained do not conform 
with expectations. As such, further work was performed on miR-26b and miR-
195 only, and not miR-10a. 
4.3.1.6 Combined manipulation of expression of miR-26b and miR-195 
does not strikingly enhance their effects on chemoresponse 
Since miR-26b and miR-195 both showed promising results in multiple assays 
individually, I decided to observe whether manipulating the expression of both 
miRNAs simultaneously would have any additive or synergistic effects on 
chemoresponse in the assays previously used. Therefore, I initially transfected 
MCF7 cells with either both miRNA mimics or both inhibitors or relevant 
controls using the same method described previously (section 4.3.1.2) and 
quantified expression levels of both miRNAs post-transfection relative to control 
transfected samples (Figure 4.3.8). Simultaneous transfection with both miRNA 
mimics or inhibitors resulted in successful over-expression (by 8 and 1200 fold) 






Figure 4.3.8: MiR-26b and miR-195 were successfully up- and down-
regulated in MCF7 cells 
MCF7 cells were simultaneously transfected with miR-26b and miR-195 
mimics (A) or inhibitors (B) or relevant controls and total RNA extracted 
seventy-two hours post-transfection. Expression of the targeted miRNAs 
was quantified by RT-qPCR relative to RNU48, and are presented relative 
to levels in cells transfected with control mimics or inhibitors. These 
graphs represent mean of three technical replicates from one biological 
repeat, with error bars showing SD. 
Having successfully confirmed the altered expressions of the miRNAs of 
interest, I then wanted to assess the influence of over-expression and 
knockdown of these miRNAs together on chemoresponse. MCF7 cells were 
transfected with either both miRNA mimics or inhibitors, or appropriate controls. 
Forty-eight hours post-transfection, cells were treated with epirubicin for twenty-
four hours and then either MTT or colony forming assays performed as 
previously described (sections 4.3.1.3 and 4.3.1.5) (Figure 4.3.9). 
Data from these MTT assays and colony forming assays suggested that when 
cells over-expressed miR-26b and miR-195 together, significantly more cells 
survived after epirubicin treatment (p<0.05) (Figure 4.3.9A and C). Decreased 
expression of both of these miRNAs in MCF7 cells did not have any effect on 
cell survival in either of the assays (Figure 4.3.9B and D). 
The data obtained from these two assays suggested that increased expression 
of both miR-26b and miR-195 led to an increased ability of MCF7 cells to 
survive chemotherapy treatment over both a short term and long term. These 
results are concordant with those obtained from MTT assays and colony 




























































































































concordant with patient data. However, over-expression of both miRNAs 
simultaneously did not appear to have any additive or synergistic effects on 
chemoresistance compared with over-expression of individual miRNAs. 
Conversely, decreased expression of both miRNAs together did not affect the 
chemoresponse of MCF7 cells, even in colony forming assays. This was in 
contrast with data obtained from colony forming assays following decreased 
expression of individual miRNAs where significant increases in 
chemosensitivity were observed (Figure 4.3.6). I therefore concluded that 
manipulation of both miRNAs simultaneously did not provide any additional 
information regarding their roles in chemoresponse. As such, further work was 










Figure 4.3.9: Increased expression of miR-26b and miR-195 together in 
MCF7 cells confers chemoresistance 
MCF7 cells were transfected with either both mimics (left panels) or both 
inhibitors (right panels) of miR-26b and miR-195 or controls. Forty-eight 
hours post-transfection, cells were treated with epirubicin or vehicle 
control (water). Twenty-four hours post-treatment, either MTT assays (A 
and B) or colony forming assays (C and D) were performed. For MTT 
assays, raw absorbance values were normalised to the control transfected 
and control untreated samples. The top panels show the effects of 
epirubicin on overall survival whereas the bottom panels are normalised to 
allow focus on the effects of the targeted miRNA mimic or inhibitor on 
survival in epirubicin-treated samples. For colony forming assays, cells 
were seeded at appropriate densities and left to grow for fourteen days. 
Colonies were fixed and stained with a mixture of methanol, ethanol and 
crystal violet solution before being counted. The top panels show for each 
condition, epirubicin-treated samples were normalised to their untreated 
counterparts. The bottom panels show the miRNA transfected and treated 
samples normalised to the control transfected and epirubicin-treated 
sample. Three biological repeats were performed for MTT assays and two 
biological repeats were performed for colony forming assays, with error 


























































































































































































































































4.3.1.7 MiR-26b and miR-195 are up-regulated in two ER positive 
epirubicin resistant breast cancer cell lines 
As a further tool for the study of resistance to epirubicin in ER positive breast 
cancer, I developed two cell lines with stable constitutive epirubicin resistance. 
To achieve this, I treated the breast cancer cell lines MCF7 and T47D with 
initial low doses of epirubicin and gradually increased the drug concentration 
over many months of continuous culture, while avoiding increasing excessively 
and thereby killing all the cells. I also continuously grew parental cell lines 
without epirubicin in parallel, to provide appropriate control cells. I assessed the 
degree of resistance of each selected cell line by performing epirubicin dose 
responses for the resistant cells as compared to their untreated parental 
controls using MTT assays (Figure 4.3.10), exactly as previously described in 
section 4.3.1.1. The resistant MCF7 cells had an estimated IC50 12.9 times 
greater than that of their parental control cells (Figure 4.3.10A) and the 
resistant T47D cells had an estimated IC50 16.7 times greater than that of their 
parental control cells (Figure 4.3.10B). 
Having concluded that transient over-expression of miR-26b or miR-195 can 
lead to increased resistance to epirubicin (sections 4.3.1.3 and 4.3.1.5), and 
that these miRNAs were up-regulated in relatively chemotherapy resistant 
breast cancer cells in patients, I was next interested in testing whether up-





    
Figure 4.3.10: MCF7 and T47D cells are more chemoresistant than their 
parental lines after long-term exposure to epirubicin 
Epirubicin resistant cell lines were developed by continuous exposure to 
increasing concentrations of epirubicin in both MCF7 and T47D cells. 
Resistant (R) and parental (wild type, WT) MCF7 (A) or T47D (B) cells 
were then exposed to a wide range of doses of epirubicin for 24 hours 
before cell viability was measured using MTT assays. Each drug dose 
was measured in triplicate. Cell survival at each dose was calculated 
relative to cell viability of vehicle control (water) treated cells for each cell 
line. The dose-response curves show one biological repeat with error bars 
showing +/- SD of technical replicates. 
I performed RT-qPCR to determine whether there was differential expression of 
miR-26b or miR-195 in the resistant cell lines compared to their parental 
controls (Figure 4.3.11). Expression of both miR-26b and miR-195 was 
increased in the epirubicin resistant cells compared with their parental controls. 
These data further support the hypothesis that both of these miRNAs contribute 
to chemoresistance in breast cancer cells. 
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Figure 4.3.11: MiR-26b and miR-195 were up-regulated in epirubicin 
resistant MCF7 and T47D cells 
Total RNA was extracted from MCF7 (A) and T47D (B) epirubicin resistant 
(R) or parental control cell lines (wild type, WT). Relative expressions of 
miR-26b and miR-195 were quantified by RT-qPCR, using RNU48 as the 
control. Data are expressed relative to wild type, and represent one 
biological repeat with error bars showing +/- SD of technical replicates. 
4.3.1.8 Epirubicin resistance does not confer resistance to a taxane 
Breast cancer patients who are found to have tumours that are substantially 
resistant to an initial chemotherapy regimen are often switched to a different 
regimen to assess whether responses can be improved by different agents that 
may act in different ways (Porkka et al., 1994, Thomas et al., 2004, Polyzos et 
al., 2009). In the context of breast cancer neoadjuvant chemotherapy, initial 
therapies are often anthracycline-based (such as epirubicin), whereas the 
alternative may be taxane-based (such as docetaxel) (Esteva and Hortobagyi, 
2008, Rivera and Gomez, 2010). I was therefore interested to investigate 
whether the epirubicin resistant cell lines that I had developed were also more 
resistant to an alternative chemotherapeutic drug with a different mode of 
action. Therefore, epirubicin (an anthracycline) resistant and parental MCF7 
and T47D cells were treated with a range of doses of the taxane docetaxel and 
relative survival was determined using MTT assays (Figure 4.3.12). 
Interestingly, neither epirubicin resistant line was also resistant to docetaxel; in 
T47D cells there was no difference in sensitivity to docetaxel between the 
epirubicin resistant and parental control cells, while – surprisingly – in MCF7 
cells, the epirubicin resistant cells were actually more sensitive to docetaxel 








































different agents can be unrelated and do not necessarily give multi-drug 
resistance. 
   
Figure 4.3.12: Epirubicin resistant MCF7 and T47D cells are not resistant 
to docetaxel 
MCF7 (A) and T47D (B) epirubicin resistant (R) and wild type (WT) cells 
were exposed to increasing doses of docetaxel. MTT assays were 
performed twenty-four hours post-treatment to measure cell viability. Each 
drug dose was measured in triplicate. Cell survival at each dose was 
calculated relative to cell viability of vehicle control (DMSO) treated cells 
for each cell line. Graphs show means of two biological repeats (+/- 
standard error).  
4.3.2 Identification of miRNA targets that potentially contribute to 
the chemoresistance phenotype 
Having established that over-expression of miR-26b and miR-195 contributes 
to chemoresistance, and that increased expression of these miRNAs is 
observed in epirubicin resistant cell lines, I then attempted to identify the 
possible mechanisms of action of these miRNAs by investigating their potential 
mRNA targets. 
4.3.2.1 Identifying putative mRNA targets of miR-26b-5p and miR-195-5p 
using predictive algorithms and literature searching 
Initially, the on-line resource starBase v2.0 (Yang et al., 2011, Li et al., 2014b) 
was used to identify mRNAs that are potentially targeted by either miR-26b or 
miR-195. This program gathers data from five prediction algorithms (miRanda, 
PicTar, TargetScan, RNA22 and PITA) that use multiple factors to predict 
targets including sequences in the mRNAs that match the seed region of 















































miRNAs and the accessibility of these sequences to the miRNAs using free 
energy assessments of secondary structures, and also incorporates 
experimental evidence, if any. This led to the identification of several thousand 
possible targets for both miRNAs. 
To narrow down the number of possible targets, those mRNAs predicted by all 
five prediction algorithms were given priority. Twenty-four mRNAs were 
predicted by all five algorithms for miR-26b and fifty-five mRNAs were predicted 
for miR-195. A search of the literature for all seventy-eight potential targets was 
performed, to identify genes within the list that had previously been linked or 
suggested to be linked to chemoresistance when down-regulated. This criterion 
was used since an up-regulation of miRNA expression would most likely lead to 
a down-regulation of target mRNA and/or protein. In addition, transcripts 
consistently down-regulated in all the original patients used for initial miRNA 
discovery according to NanoString mRNA expression data (see section 3.3.4) 
were also investigated if predicted to be targets of miR-26b or miR-195 by any 
of the predictive algorithms. Transcripts were also considered if consistently 
down-regulated in the three patients with complete datasets but not in one of 
the other patients with incomplete datasets if they were predicted by all five 
predictive algorithms. The final list of candidate targets of interest is shown in 
Table 4.3.1 (miR-26b) and Table 4.3.2 (miR-195), along with a summary of the 
evidence that led to the inclusion of each entry. It was particularly interesting to 




Table 4.3.1: Top predicted mRNA targets of miR-26b 








PPP3R1 4 Down (5/5 patients) Activates mitochondrial 
apoptosis pathway in 
human hepatoma HepG-2 
cells (Yang et al., 2017) 
PRKAR2B 1 Down (3/3 patients) Down-regulated in 
etoposide and cisplatin 
resistant small cell lung 
cancer H446 cell line 
compared with parental 
cell line (Chen et al., 
2017) 
GSK3B 5 Down (3/4 patients) Inactivation leads to 
increased resistance to 
doxorubicin and tamoxifen 
in MCF7 breast cancer 
cells (Sokolosky et al., 
2014) 
CCDC6 5 Not on panel Reduced expression 
confers resistance to 
cisplatin in non-small cell 
lung cancer but confers 
sensitivity to olaparib 
(Morra et al., 2015) 
ULK1 5 Not on panel Down-regulated in most 
breast cancers, addition 
of synthetic agonist 
induced cell death 
associated with 
autophagy (Zhang et al., 
2017) 
WNT5A 5 Down (3/3 patients) Decreased expression in 
poor responders to 
chemotherapy in 
osteosarcoma patients 
and in chemoresistant cell 
line compared with 
responders (Walters et 
al., 2008) 
Potential targets for miR-26b were selected for further study using a 
combination of bioinformatics predictions (five different algorithms used), 
mRNA expression data concerning down-regulation in breast cancers in 
patients post-NAC (Chapter 3), and literature searching for published roles 




Table 4.3.2: Top predicted mRNA targets of miR-195 








APH1B 1 Down (3/3 patients) Down-regulated in MCF7 
breast cancer cells 
resistant to adriamycin 
and paclitaxel (Zhang et 
al., 2016) 
MYB 5 Down (5/5 patients) Knockdown in MCF7 
breast cancer cells 
increased tumourigenesis 
and resistance to 
tamoxifen (Thorner et al., 
2010) 
E2F7 5 Not on panel Reduced expression in 




sensitive tumours (Reimer 
et al., 2007) 
CCDC6 5 Not on panel Reduced expression 
confers resistance to 
cisplatin in non-small cell 
lung cancer but confers 
sensitivity to olaparib 
(Morra et al., 2015) 
GNAI3 5 Not on panel Identified in gene 
expression signature - 
decreased expression in 
taxane-based resistant 
breast cancer patients 
(He et al., 2014b) 
Potential targets for miR-195 were selected for further study using a 
combination of bioinformatics predictions (five different algorithms used), 
mRNA expression data concerning down-regulation in breast cancers in 
patients post-NAC (Chapter 3), and literature searching for published roles 
contributing to chemoresistance. 
At this point, public datasets were mined in order to determine whether there 
were significant negative correlations between miR-26b or miR-195 expression 
and their predicted mRNA targets in breast cancers, as might be expected if 
the miRNA really does target the mRNA in actual breast cancer tissues. These 
data are shown in Figure 4.3.13, in the form of scatter plots with correlation 
best-fit lines.  
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Of the six predicted targets for miR-26b, only one (PRKAR2B) showed a 
significant negative correlation between its expression and miR-26b 
expression. There were also negative correlations between miR-26b 
expression and both CCDC6 and ULK1 expression although these were not 
significant (p values 0.1824 and 0.1089 respectively). These analyses support 
the proposal that in breast cancer, miR-26b targets PRKAR2B and may target 
CCDC6 and ULK1. 
Of the five predicted targets for miR-195, there were significant negative 
correlations between miR-195 expression and expression of CCDC6, E2F7 and 







Figure 4.3.13: Correlations between miR-26b and miR-195 expression and 
expression of their predicted mRNA targets 
Expression data for miRNAs and mRNAs of interest in breast cancers 
were accessed from a public dataset (TCGA, 2012) by Dr J Thorne 
(University of Leeds). Data were obtained from matched miRNA 
sequencing and Agilent mRNA expression arrays respectively from 489 
breast cancer tumours. The x axes show expression levels of the miRNA 
of interest (relative read depth) whereas the y axes show expression 
levels (gene-median centered and log2 transformed) of the mRNAs of 
interest. (A) Pearson correlations between miR-26b expression and the 
six selected predicted mRNA targets (***p<0.0005). (B) Pearson 
correlations between miR-195 expression and the five selected predicted 






4.3.2.2 CCDC6 is the only potential target gene that can be validated in 
MCF7 and MDA-MB-175 cells 
In vitro assays were next used to assess whether the miRNA-mRNA pairs 
supported by significant negative correlations above were reproduced in cell 
lines. In addition, since CCDC6 was to be tested as a target for miR-195, I also 
tested whether it was a target for miR-26b even though this latter relationship 
was not significant in Figure 4.3.13. MCF7 and MDA-MB-175 cells were 
transfected with either miRNA mimics or inhibitors or their controls as 
previously, and RNA was extracted seventy-two hours later. Expression levels 
of mRNAs were determined using RT-qPCR (Figure 4.3.14 and Figure 4.3.15). 
A confirmed canonical miRNA target would be down-regulated by the presence 
of the miRNA mimic, and up-regulated by the miRNA inhibitor. 
In MCF7 cells, PRKAR2B expression was not significantly altered by over-
expression or inhibition of miR-26b. Similarly, expression of neither E2F7 or 
GNAI3 was significantly altered by over-expression or inhibition of miR-195. 
However, data concerning CCDC6 looked more promising: CCDC6 expression 
was reduced by mimics of both miRNAs (significantly for miR-26b) and was 
increased by inhibitors of both miRNAs (significantly for miR-195).  
The same experiments were also performed in MDA-MB-175 cells. Results 
(Figure 4.3.15) were more variable but did suggest that CCDC6 is a potential 
target of miR-26b in these cells. However, results also appeared to 
demonstrate that CCDC6 is not targeted by miR-195 in MDA-MB-175 cells, 






Figure 4.3.14: CCDC6 is a target of miR-26b and miR-195 in MCF7 cells 
but PRKAR2B, E2F7 and GNAI3 are not 
MCF7 cells were transfected with either the miRNA mimic or inhibitor of 
interest or appropriate controls. Cells were harvested seventy-two hours 
post-transfection and RNA extracted followed by RT-qPCR to quantify 
expression of the potential miRNA targets of interest. These graphs show 
three biological repeats and error bars show SEM (*p<0.05). (A) 
PRKAR2B expression following transfection with either miR-26b mimic or 
inhibitor. (B) E2F7 expression following transfection with either miR-195 
mimic or inhibitor. (C) GNAI3 expression following transfection with either 
miR-195 mimic or inhibitor. (D) CCDC6 expression following transfection 
with either miR-26b or miR-195 mimic or inhibitor.  
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CCDC6 expression following miRNA mimic/inhibitor 




























Figure 4.3.15: CCDC6 appears to be targeted by miR-26b but not miR-195 
in MDA-MB-175 cells, while PRKAR2B, E2F7 and GNAI3 are not 
targeted 
MDA-MB-175 cells were transfected with either the miRNA mimic or 
inhibitor of interest or appropriate controls. Cells were harvested seventy-
two hours post-transfection and RNA extracted followed by RT-qPCR to 
quantify expression of the potential miRNA targets of interest. These 
graphs show two biological repeats and error bars show SEM (*p<0.05). 
(A) PRKAR2B expression following transfection with either miR-26b mimic 
or inhibitor. (B) E2F7 expression following transfection with either miR-195 
mimic or inhibitor. (C) GNAI3 expression following transfection with either 
miR-195 mimic or inhibitor. (D) CCDC6 expression following transfection 
with either miR-26b or miR-195 mimic or inhibitor. 
4.3.2.3 CCDC6 expression does not negatively correlate with miR-26b 
and/or miR-195 expression in MCF7 and T47D epirubicin resistant 
cell lines 
As CCDC6 appeared to be a potential target of miR-26b and miR-195, CCDC6 
expression was quantified in the MCF7 and T47D epirubicin resistant cells in 
which I had already shown that both of these miRNAs were overexpressed 
(Figure 4.3.11). RNA was extracted from the epirubicin resistant and parental 
control cell lines and CCDC6 expression in resistant cells relative to parental 
control cells was determined by RT-qPCR (Figure 4.3.16). Expression of this 
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its matched control, but was significantly increased in the T47D resistant cell 
line. These results suggest that although CCDC6 may be targeted by either or 
both of miR-26b and miR-195, this influence is not the main determinant of 
relative CCDC6 expression and decreased expression of this gene does not 
contribute to chemoresistance in these two epirubicin resistant lines. 
 
Figure 4.3.16: CCDC6 is not differentially expressed in epirubicin 
resistant cell lines in accordance with a role downstream of miR-26b 
or miR-195 in chemoresistance 
CCDC6 expression was quantified by RT-qPCR in two ER positive 
epirubicin resistant (R) breast cancer cells relative to expression in 
sensitive parental cells (WT). This graph shows two biological repeats and 
error bars show SEM (*p<0.05). 
4.3.2.4 CCDC6 does not modify chemoresponse in MCF7 cells 
Although CCDC6 was not significantly down-regulated in the stable epirubicin 
resistant cell lines and therefore its down-regulation was seemingly not 
contributing to this stable resistance, it remained possible that down-regulation 
of CCDC6 was contributing to the miR-26b or miR-195 induced transient 
resistance seen in Figure 4.3.3, Figure 4.3.4 and Figure 4.3.6. In addition, 
CCDC6 has previously been linked with chemoresponse (Morra et al., 2015). 
Therefore, siRNA against CCDC6 was used to knock-down expression and 
chemosensitivity assays were performed to determine whether this decreased 
expression would result in increased resistance of breast cancer cells to 
epirubicin, thereby supporting miR-26b and miR-195 acting via CCDC6.  
To confirm down-regulation of CCDC6 by a targeted siRNA, MCF7 cells were 
first transfected with the siRNA or a non-targeting control. RNA was extracted 















































RT-qPCR (Figure 4.3.17). Results show that expression of CCDC6 was 
successfully reduced by the siRNA by approximately 90%. 
 
Figure 4.3.17: CCDC6 was successfully inhibited by a targeted siRNA 
MCF7 cells were transfected with a siRNA targeting CCDC6 or a control 
non-targeting siRNA. RNA was extracted seventy-two hours post-
transfection and CCDC6 expression was quantified by RT-qPCR relative 
to expression in non-targeted siRNA transfected MCF7 cells. This graph 
represents one biological repeat with error bars showing +/- SD of three 
technical replicates. 
To assess chemosensitivity, MCF7 cells were transfected with the siRNA 
targeting CCDC6 or a non-targeting control, and forty-eight hours post-
transfection were treated with epirubicin for twenty-four hours. Response to 
epirubicin was then assessed by performing either MTT assays or colony 
forming assays as previously (Figure 4.3.18). 
Results from both MTT assays and colony forming assays indicated that MCF7 
breast cancer cells with decreased expression of CCDC6 had almost exactly 
the same sensitivity to epirubicin treatment as their control transfected 
































Figure 4.3.18: Reduced CCDC6 expression is not sufficient to induce 
chemoresistance in MCF7 cells 
MCF7 cells were transfected with siRNAs targeting CCDC6 or control 
non-targeting siRNAs. Forty-eight hours post-transfection, cells were 
treated with either 1μM or 3μM epirubicin for MTT assays or 30nM 
epirubicin for clonogenic survival assays for twenty-four hours. MTT 
assays (A) or clonogenic survival assays (B) were then performed. These 
graphs show the results of two biological repeats and error bars show the 
standard error of the mean. (A) Each sample was first normalised to its 
untreated counterpart (left panel), then the CCDC6 siRNA transfected 
samples were normalised to the control transfected samples for each 
concentration of epirubicin in order to determine the effects of CCDC6 
knockdown on chemosensitivity (right panel). (B) Colonies were counted 
and numbers were normalised to each untreated sample (left panel), or 
relative survival after epirubicin treatment in CCDC6 siRNA transfected 
samples was normalised to relative survival in control siRNA transfected 
samples after treatment with epirubicin (right panel). 
4.4 Discussion 
4.4.1 Mimics and/or inhibitors of specific miRNAs have 
successfully been used to investigate chemosensitivity  
In this chapter I have used mimics and inhibitors of my three miRNAs of 
interest, as identified in the screens performed in section 0, to investigate their 
roles in chemoresponse. This was performed by transfecting ER positive breast 























































































epirubicin. This was the same chemotherapeutic drug that was used to treat the 
patients in the cohort used for the initial screens (see Chapter 3). Then, by 
assessing the cell viability and clonogenic ability of the cells, I successfully 
identified miR-26b and miR-195 as contributors to chemoresistance when up-
regulated. This was in accordance with data obtained from the initial screens 
performed in section 0 where expression of these two miRNAs was increased 
post-NAC compared with pre-NAC in partially chemoresistant breast cancers.  
My use of miRNA mimics and/or inhibitors to investigate roles for miRNAs in 
chemosensitivity of cancer cells has a few highly-related published precedents. 
A mimic for the miRNA let-7a was used to investigate in vitro what effect 
increased expression of this miRNA would have on the sensitivity of epirubicin 
resistant HER2 positive breast cancer cells to epirubicin (Wu et al., 2015). It 
was noted that following transfection of this mimic into these drug resistant 
cells, the IC50, determined by MTT cell viability assays, was significantly less 
than their control transfected counterparts (1.53µg/ml compared with 
2.25µg/ml). Although this shift in IC50 is comparatively small, compared to the 
difference between parental and stably resistant cell lines in my work, it should 
be noted that I have not formally assessed IC50s after transient transfections 
with mimics and inhibitors; the differences I have seen in this context by MTT or 
colony forming survival assays have generally been small and could be of 
similar magnitude. Let-7a was previously identified as a miRNA of interest in 
breast cancer as it was noted to be rarely expressed in breast tumour initiating 
cells but was more highly expressed in differentiated breast tumour cells (Yu et 
al., 2007). As this population of tumour initiating cells is generally known to be 
more chemoresistant than their differentiated counterparts, the authors 
hypothesised that let-7a expression may be reduced in patients with 
chemoresistant tumours when compared to those with chemosensitive tumours 
and that modulation of let-7a levels may influence chemoresponse (Wu et al., 
2015). In my dataset, let-7a was not consistently changed across all patients 
and was therefore not investigated further. 
A second example is the use of both mimics and inhibitors of miR-195, the 
exact same miRNA I have tested, to investigate the role of miR-195 in the 
chemosensitivity of ER positive breast cancer cells to adriamycin (Yang et al., 
2013). This study showed that miR-195 mimic reduced cell viability following 
134 
 
adriamycin treatment in both MCF7 wild-type and adriamycin resistant cells, as 
measured by MTT assays. Increased miR-195 expression had a greater effect 
on cell viability in MCF7 wild-type cells compared with resistant cells. However, 
when expression of this miRNA was reduced by the inhibitor, no corresponding 
increase in cell viability was observed. This is in marked contrast to my study, 
where I found miR-195 mimic to protect MCF7 cells from epirubicin, although 
my data concur that inhibitors appear to be less successful in inducing changes 
in response at least in short-term survival assays. This difference between the 
efficacy of mimics and inhibitors may relate to their differing abilities to induce 
fold changes in expression of the miRNA – with mimics commonly leading 
directly to much greater over-expression than the fold-inhibition of inhibitors 
(Figure 4.3.2). Having defined the role of miR-195 in chemoresponse, the 
authors then identified Raf-1 as a potential target of this miRNA, and observed 
increased protein expression in chemoresistant cell lines compared to parental 
cell lines. However, unlike my work, no attempts were made to test functionally 
whether the mRNA is a target of miR-195. 
These two studies combined emphasise the fact that miRNAs can have 
different functions depending on context – in this case the chemotherapy agent 
being the difference. Adriamycin, also known as doxorubicin, is a member of 
the same chemical family as epirubicin, the anthracyclines. The only difference 
between these two drugs is a slight structural modification in epirubicin 
resulting in the reorientation of a hydroxyl group. However, multiple clinical 
trials have revealed that therapeutically, epirubicin is as effective as 
doxorubicin but that off-target toxicities are less harsh (Khasraw et al., 2012). It 
is evident that despite the fact that these two drugs are both anthracyclines and 
are therefore thought to have similar mechanisms of action, the seemingly 
minor structural alteration in epirubicin does appear to have far reaching 
effects. It is possible that miR-195 is one of the factors that responds differently 
to these slight differences in structure that ultimately leads to the differences in 
toxicity observed in patients. 
Interestingly, in a previous study in which MCF7 cells were selected for 
resistance to individual chemotherapy drugs including doxorubicin and 
epirubicin, gene expression microarray analyses revealed more genes were 
differentially expressed in doxorubicin resistant cells relative to parental cells 
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than in epirubicin resistant cells (Hembruff et al., 2008). Analyses of 
expressions of various ABC drug transporters revealed that epirubicin resistant 
MCF7 cells, but not doxorubicin resistant cells, had increased expression of 
ABCB1 whereas the latter had increased expression of ABCC1. This provides 
further evidence that doxorubicin and epirubicin affect different molecular 
pathways. 
A final, highly-related example is an investigation into the role of miR-452 in 
adriamycin resistant MCF7 cells, in which a mimic and inhibitor were used to 
demonstrate that decreased expression of this miRNA was associated with 
resistance to adriamycin (Hu et al., 2014). The authors also identified IGF-1R 
as a target of miR-452 by using multiple prediction algorithms and observing 
transcript and protein expression in response to manipulation of miRNA levels. 
This is a similar method to my work to identify and confirm targets of miR-26b 
and miR-195, although I only considered transcript expression and not protein 
expression. As with let-7a, in my dataset, miR-452 was not consistently 
changed post-NAC across all patients and therefore I did not study it further.  
4.4.1.1 Using colony forming assays to determine chemosensitivity 
I also used miRNA mimics and inhibitors in the context of colony forming 
survival assays. Other studies have also previously used this method to 
determine the effect of particular miRNAs on chemoresistance, usually in 
parallel with MTT assays. In a study investigating the role of miR-27b in the 
chemoresponse of ER negative and HER2 positive breast cancer cells, both 
MTT and colony forming survival assays were used (Chen et al., 2018). In this 
study, the inhibition of miR-27b resulted in cells being more resistant to 
paclitaxel. Inhibition of this miRNA also resulted in increased resistance to 
cisplatin, doxorubicin, gemcitabine and fluorouracil, although this was only 
performed with MTT assays. The authors also identified CBLB and GRB2 as 
targets of miR-27b using multiple prediction algorithms, as I have used, 
although they were confirmed as direct targets using luciferase assays instead 
of quantifying transcript expression in response to altered miRNA expression. 
In my dataset, miR-27b was not consistently changed across all patients post-
NAC, therefore this miRNA was not studied in my work. 
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Similarly, a study investigating the role of miR-4443 in chemoresponse also 
used both MTT and colony forming survival assays (Chen et al., 2016b). In this 
study, transfection of the triple negative breast cancer cell line MDA-MB-231 
with a miR-4443 mimic and treatment with epirubicin resulted in increased 
chemoresistance compared with their control transfected counterparts. This 
was shown with both MTT and colony forming survival assays, although the 
reciprocal experiment with a miR-4443 inhibitor was only performed with MTT 
assays. TIMP2 was successfully identified as a target of miR-4443 using only a 
single predictive algorithm and quantification of transcript levels following 
manipulation of miRNA levels. MiR-4443 was not included on the panel used to 
quantify miRNA expression in the patient samples in my study. 
In these two studies, where both MTT and colony forming survival assays were 
performed, results from the two assays showed the same changes in 
chemoresponse. In my dataset however, the measurement of cell viability using 
MTT assays following transfection with miRNA inhibitors did not show changes 
in chemoresponse whereas colony forming survival assays frequently did. 
However, when viewed together, the results from my MTT assays and colony 
forming assays indicated that miR-26b and miR-195 contribute to 
chemoresistance. This was further supported by the observation that 
expression of these miRNAs was also up-regulated in two epirubicin resistant 
cell lines. The fact that the MTT assays and the colony forming assays were 
also performed in two different cell lines using both mimics and inhibitors and 
that all results were consistent, suggests that these results are true indicators 
of the role these miRNAs contribute to chemoresponse in ER positive breast 
cancer. The other studies discussed here did not perform both assays using 
both mimics and inhibitors in multiple cell lines – and in this regard my study 
could be viewed as unusually thorough. 
4.4.2 Predictive algorithms can successfully identify target mRNAs 
of specific miRNAs 
Multiple algorithms exist that use various factors such as nucleotide 
sequences, the number of predicted binding sites and free energies of 
complexes to predict mRNA targets of miRNAs (Witkos et al., 2011). Combined 
with experimental CLIP-Seq (where mRNA fragments bound to argonaute 
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proteins that form part of the RISC and the associated miRNA are sequenced) 
data obtained from multiple studies to validate these predictions, these 
algorithms have demonstrated that of the hundreds of conserved miRNAs and 
protein coding genes, there are several thousand potential interactions 
between miRNAs and their target mRNAs (Li et al., 2014b). 
Some studies use only a single predictive algorithm coupled with data such as 
associations between miRNA expression and observed pathway activity 
obtained previously to identify putative target genes of specific miRNAs. In one 
such study, miR-26b was found to suppress TNFα-induced NF-ĸB signalling in 
hepatocellular carcinoma cells. In order to identify target mRNAs that may 
mediate this phenomenon, the predictive algorithm TargetScan was used. Two 
genes, TAK1 and TAB3, which are upstream positive regulators of the NF-ĸB 
pathway, were predicted to have putative miR-26b binding sites in their 
3’UTRs. Validation of these genes as targets of this miRNA was performed 
using luciferase reporter assays. Sequences containing the wild-type 3’-UTRs 
or mutated 3’-UTRs (where potential binding sites were removed) were co-
expressed with the miRNA, and levels of endogenous proteins and transcripts 
after up- or down-regulation of the miRNA were assessed. Very interestingly, in 
this case target protein levels were significantly reduced when miR-26b 
expression was increased, whereas transcript levels were not affected (Zhao et 
al., 2014). This is in contrast with results I have obtained as I have shown that 
increased expression of miR-26b leads to a significant reduction in the level of 
CCDC6 transcript. This observation suggests that not only do miRNAs have 
different functions depending on context but that their mechanism of action may 
also differ. As such, previous studies have also observed a down-regulation of 
target mRNA expression when miR-26b expression was increased (Gennarino 
et al., 2009).  
The contrast between miR-26b affecting transcript levels versus protein levels 
does highlight the risk presented by the strategy that I have used – observing 
the effects of miRNA expression on potential target mRNA levels only and not 
protein levels as well. I thus risked identifying false negative targets that are not 
affected at the transcript level but are functionally targeted at the protein level. 
This has previously been observed not just with miR-26b but also miR-519 
(Abdelmohsen et al., 2008) and miR-19b (Thorne et al., 2018), which were 
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shown to affect HuR and P-glycoprotein protein levels respectively but not 
transcript levels. 
However, it is more common to investigate putative target mRNAs that are 
predicted by multiple predictive algorithms. Four databases were used in a 
study to identify mRNA targets of miR-27b (Chen et al., 2018). These were 
miRanda, PicTar, TargetScan and miRDB. Even focusing only on those genes 
predicted by all four algorithms, 277 mRNAs were putative targets. Therefore, 
the authors performed functional analyses using KEGG and Gene Oncolcogy 
(GO) databases to narrow down the list of genes of interest. Most target genes 
functioned in cancer-related pathways and drug-response pathways. Of the 
thirteen top candidates, the transcript levels of five genes were found to be 
down-regulated by miR-27b in further validations. Further analyses were 
performed in which mRNA levels in tumour tissues and matched normal tissues 
were compared, which led to the identification of CBLB and GRB2 as high 
priority candidate targets. Expression of these two genes was significantly 
higher in tumour tissues than in normal tissues and there was a significant 
negative correlation between miR-27b expression and CBLB and GRB2 
expression in tumour tissues of breast cancer patients. Similarly, I focused on 
genes predicted by five different algorithms: TargetScan, miRanda, PicTar2, 
PITA and RNA22 together with miRNA and mRNA expression data, all 
presented in the starBase v2.0 database (Yang et al., 2011, Li et al., 2014b). I 
then performed literature searches to identify those genes that may play a role 
in contributing to chemoresponse, and then investigating further only genes of 
interest with significant negative correlations between transcript expression and 
miRNA expression in clinical breast cancers using public datasets. The final 
stage was in vitro validation by assessing whether potential target transcript 
levels were modified by over-expression or inhibition of miRNA expression, as 
was performed in the previous study (Chen et al., 2018). As such, I identified 
CCDC6 as a target of both miR-26b and miR-195. 
4.4.3 CCDC6: a function in chemoresponse? 
I have shown that CCDC6 is targeted by both miR-26b and miR-195 and 
therefore was potentially a mediator of their roles in chemoresponse, however 
reduction of CCDC6 expression alone did not appear to reproduce the altered 
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chemosensitivity seen with over-expression of miR-26b or miR-195. CCDC6 
was first identified as part of a fusion gene with the protooncogene RET in 
papillary thyroid carcinoma (Fusco et al., 1987, Grieco et al., 1990). CCDC6 
has since been shown to be involved in the DNA damage response, specifically 
in the ATM pathway. In the event of ATM activation, CCDC6 is phosphorylated, 
which ultimately promotes apoptosis (Cerrato et al., 2018). It has previously 
been noted that attenuation of CCDC6 confers sensitivity to PARP inhibitors in 
prostate cancer cells (Morra et al., 2017) as well as in non-small cell lung 
cancer and confers resistance to cisplatin (Morra et al., 2015). I therefore 
considered CCDC6 to be a strong candidate regulator of epirubicin resistance 
in my experiments. However, in the context of my study, this does not appear 
to be the case, although I cannot rule out that changes in its expression may 
contribute to the resistance seen with over-expression of these miRNAs only in 
the context of the other expression changes they also cause. 
4.4.4 Resistance to one class of chemotherapeutic drug does not 
always result in resistance to a different class of drug 
My results suggest that epirubicin resistance does not alter the 
chemosensitivity of T47D cells to docetaxel. However, in MCF7 cells, results 
suggest that instead of epirubicin resistant cells being more resistant to 
docetaxel, they are actually more sensitive to the second chemotherapeutic 
drug (Figure 4.3.12). These data indicate that resistance to one class of 
chemotherapeutic drug does not necessarily indicate resistance to other 
classes of chemotherapeutic drugs with other mechanisms of action.  
Such a phenomenon has previously been observed in MCF7 cells (Wang et al., 
2014). In this study, the response of MCF7 cells resistant to docetaxel 
(MCF7TXT) or doxorubicin (MCF7DOX) were compared to parental MCF7 cells in 
the presence of docetaxel, paclitaxel or doxorubicin. As expected, MCF7TXT 
cells were more resistant to docetaxel and paclitaxel and MCF7DOX cells were 
more resistant to doxorubicin. However, MCF7DOX cells were not resistant to 
either taxane, indeed these cells were actually slightly more sensitive to these 
drugs than parental MCF7 cells. Similarly, MCF7TXT cells were not resistant to 
doxorubicin. The fact that such resistance mechanisms do not necessarily 
overlap, strongly support the typical clinical practice of combining 
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chemotherapy agents, either concurrently or in sequence (Masui et al., 2013). 
This has the benefit of targeting multiple cell processes, thus decreasing the 
possibility of cells being able to develop resistance to multiple agents instead of 
one. An important clinical consideration however is that the wrong 
combinations and/or doses of agents may prove too toxic for patients. 
An example where multiple therapies has proved to be the most successful is 
in the treatment of HER2 positive breast cancer. Before the development of 
HER2-targeted therapies, HER2 expression was considered a marker of poor 
prognosis and was treated with chemotherapy (Muss et al., 1994). With the 
development of the monoclonal antibody trastuzumab that targets HER2, it 
became common clinical practice to combine HER2-targeted therapies with 
chemotherapy when treating HER2 positive breast cancer after it had been 
shown that addition of this targeting drug was associated with numerous 
benefits including increased disease-free survival and longer survival when 
compared with chemotherapy alone (Slamon et al., 2001). This highlights the 
benefits of targeting multiple cell processes at the same time instead of only a 
single process. 
4.4.5 Conclusions 
I have determined that up-regulation of miR-26b and miR-195 contribute to 
resistance to the chemotherapeutic drug epirubicin in ER positive breast cancer 
but that down-regulation of miR-10a does not. I have attempted to identify 
mRNA targets of miR-26b and miR-195 that function to contribute to this 
chemoresistance. I identified CCDC6 as a target of both miR-26b and miR-195, 
however down-regulation of this gene was not sufficient to reproduce the 
altered chemosensitivity, and its expression profile in constitutively resistant cell 
lines did not implicate it as a key mediator of resistance in this context. In the 
next chapter, I undertake alternative experimental approaches to identify the 
targets downstream of miR-26b and miR-195, with a view to thereby gaining 





Chapter 5: REEP4 and SEMA6D are targets of miR-26b and 
miR-195 and may contribute to chemoresponses in breast 
cancer 
5.1 Abstract 
MiR-26b and miR-195 were identified as potential mediators of chemoresponse 
in breast cancer cells in Chapters 3 and 4. Attempts were also made to identify 
mRNA targets of miR-26b and miR-195 that contribute to this function, by using 
predictive algorithms and public miRNA and mRNA expression datasets. This 
approach, however, did not allow successful identification of any candidate 
genes with relevant functions in chemoresponse. Therefore, in this chapter I 
have taken an unbiased approach to identifying the targets of these miRNAs, 
by performing a pulldown assay using biotinylated miRNA mimics of miR-26b 
and miR-195 as bait, and RNA-Seq to identify RNAs bound to the target 
miRNAs. Putative mRNA targets of these miRNAs were identified by assessing 
pulldown of transcripts relative to control pulldowns, and by taking into account 
relative expression in the input samples based on the hypothesis that true 
targets may show reduced overall expression in miRNA mimic-transfected 
samples. Potential target genes were also prioritised if they were predicted by a 
minimum of two different prediction algorithms to be targets of these miRNAs. 
Finally, a literature search was performed on candidate genes to identify those 
that potentially contribute to chemoresistance when down-regulated. 
Four genes were identified as candidates suitable for further experimental 
follow up: REEP4 and PRKCD as targets of miR-26b and SEMA6D and ARL2 
as targets of miR-195. Cell viability assays were performed following 
knockdown of these genes and treatment with chemotherapy. REEP4 and 
SEMA6D knockdown contributed to increased chemoresistance in accordance 
with roles in chemoresponse down-stream of the miRNAs, but PRKCD and 
ARL2 knockdown did not. However, analysis of REEP4 and SEMA6D protein 
expression in a cohort of breast cancer patients that had received adjuvant 
chemotherapy revealed a significant, but unclear relationship between REEP4 
expression and patient survival, and no significant relationships between 
SEMA6D expression and patient survival. 
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I concluded that further experimentation is required to define the targets of miR-
26b and miR-195 that are relevant to their roles in defining chemoresponse in 
breast cancer. 
5.2 Introduction 
Aberrant expression of miRNAs has been observed in cancer (Lu et al., 2005), 
with more recent evidence showing that aberrant expression of specific 
miRNAs such as miR-298 in breast cancer influence chemoresponse (Bao et 
al., 2012). However, when searching for novel drug targets to overcome 
chemoresistance, it could be potentially dangerous to target miRNAs directly 
due to the fact that individual miRNAs have the potential to bind multiple mRNA 
targets (Asangani et al., 2008, Dong et al., 2011, Wang et al., 2011). It is 
possible that in targeting the expression of a specific miRNA, not only could the 
expression of mRNAs that contribute to chemoresistance be affected, but the 
expression of other mRNAs with different functions could also be affected, 
potentially leading to unforeseen negative consequences.  
Evidence has also shown that the same mRNA can be targeted by multiple 
miRNAs, such as miR-19 and miR-21, which target PTEN (Liang et al., 2011, 
Wang et al., 2011). This poses a second challenge to targeting miRNAs directly 
as altering expression of one miRNA may not significantly alter target mRNA 
expression if a second miRNA can also regulate its expression. These two 
potential challenges demonstrate the importance of identifying the target 
mRNAs of aberrantly expressed miRNAs that contribute appropriately to 
chemoresponse when identifying novel drug targets to overcome 
chemoresistance. 
Algorithms that predict mRNA targets of miRNAs are constantly being 
developed to reflect new discoveries involving the relationships between these 
two RNA species, in order to be more accurate. However, predicted mRNA 
targets still require experimental validation. Multiple methods have been 
proposed to either prove or discover new miRNA:mRNA binding partners 
(Thomson et al., 2011). These include immunoprecipitation of RISC 
components, with target mRNAs being co-immunoprecipitated, with or without 
prior cross-linking of RNA to RNA-binding proteins by ultra-violet radiation 
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(Hendrickson et al., 2008, Hafner et al., 2010). Another method proposed to 
show direct miRNA:mRNA binding involves the use of synthetic biotinylated 
miRNAs transfected into cells and performing a pulldown, followed by 
identification of any mRNAs that were pulled down with the miRNA (Ørom et 
al., 2008). There are of course advantages and disadvantages associated with 
all of these methods (Thomson et al., 2011). 
Identification of mRNA targets of a specific miRNA by using a synthetic 
biotinylated miRNA as bait, performing a pulldown, and identifying RNA 
transcripts by RNA-Seq, has previously been used for miR-522 (Tan et al., 
2014). Over-expression of this miRNA had been observed in triple-negative 
breast cancer, with increased expression associated with poor prognosis. To 
identify how miR-522 contributed to this phenomenon, a synthetic biotinylated 
mimic of miR-522 was transfected into the triple negative breast cancer cell line 
MDA-MB-468, a pulldown performed, and RNA-Seq performed to identify the 
transcripts bound to the miRNA bait. To confirm results obtained from the 
pulldown experiment, microarrays were also performed using samples where 
miR-522 was either over-expressed or not. There was a large overlap between 
mRNAs identified by the pulldown method and those down-regulated when 
miR-522 expression was increased. To discover the functions of miR-522, 
pathway analysis tools were used to identify biological interactions and 
functions of the genes. This led to the conclusions that miR-522 regulates 
cellular processes such as proliferation, migration and epithelial-mesenchymal 
transition, which explain why over-expression of this miRNA was associated 
with a poor prognosis. In this chapter, a similar approach was taken to identify 
mRNA targets of miR-26b and miR-195 that contribute to chemoresponse. I 
have used synthetic biotinylated mimics of these miRNAs, performed a 
pulldown, and identified bound transcripts using RNA-Seq. I then attempted to 
validate functional roles for potential targets using chemosensitivity assays in 







5.2.1 Specific objectives 
There were three key objectives in the work described in this chapter: 
1. To identify mRNA targets of miR-26b and miR-195 by performing 
pulldown assays using biotinylated-miRNA mimics as bait and 
performing RNA-Seq on the bound mRNAs; 
2. To determine the function of these target mRNAs with respect to 
chemoresistance; 
3. To assess the clinical importance of the proteins encoded by these 
target mRNAs in breast cancer patients treated with chemotherapy. 
5.3 Results 
5.3.1 RNA was successfully recovered using miR-26b and miR-195 
mimics as baits, and samples were prepared for RNA-Seq 
In Chapter 4, I demonstrated that miR-26b and miR-195 were regulators of 
chemotherapy response in breast cancer cells, but I failed to identify the mRNA 
targets of the miRNAs that were responsible for these functional effects. My 
aim here was to identify the targets by purifying and sequencing the mRNAs 
bound by the miRNAs. This involves transfecting relevant cells with miRNA 
mimics tagged with biotin at the 3’ end, pulling down the biotinylated miRNAs 
and subsequently performing RNA-Seq to identify RNA molecules bound to the 
miRNAs. Previous studies have successfully identified target mRNAs of 
miRNAs using this method (Krishnan et al., 2013, Tan et al., 2014). Therefore, 
biotinylated miRNA mimics of miR-26b and miR-195 were obtained. 
5.3.1.1 Biotinylated microRNA mimics affect chemosensitivity in a similar 
manner to their non-biotinylated counterparts 
Prior to performing pulldown experiments using biotinylated miRNA mimics, 
chemosensitivity assays were performed using MCF7 cells transfected with 
these new biotinylated mimics and treated with epirubicin to confirm that the 
addition of the biotin tag did not affect the function of these mimics in this 
context (previously shown with unbiotinylated mimics in Figure 4.3.3). MCF7 
breast cancer cells were transfected with either the biotin-tagged miRNA mimic 
or a biotin-tagged mimic control. Cells were treated with epirubicin for twenty-
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four hours and MTT assays performed (Figure 5.3.1). Data supported the 
conclusion that the cells transfected with biotinylated miR-26b or miR-195 
mimics were more resistant to chemotherapy than controls, as was the case for 
the unbiotinylated mimics, and therefore that the biotin tag had no or little effect 
on miRNA function, although it should be noted that the resistance seen in this 
experiment was not statistically significant after the two repeats shown. 
Biotin-miR-26b Biotin-miR-195 
Figure 5.3.1: Biotinylated miRNA mimics cause increased resistance to 
chemotherapy 
Cells were transfected with either biotinylated miR-26b, miR-195 or 
negative control mimics. Forty-eight hours post-transfection, cells were 
treated with epirubicin or vehicle control (water). Twenty-four hours later, 
MTT assays were performed. Data for epirubicin-treated samples were 
first normalised to untreated counterparts, then the biotinylated miRNA 
mimic transfected samples were normalised to the control transfected 
samples for each concentration of epirubicin, in order to determine the 
effects of the biotinylated miRNA mimic on chemosensitivity. This graph 
shows the results of two biological repeats +/- SEM. 
5.3.1.2 RNA was successfully pulled down using biotinylated miRNA 
mimics as bait  
Having shown that the addition of the biotin tag to the miRNA mimics did not 
obviously inhibit the function of these mimics with respect to chemoresistance, 
MCF7 cells were transfected with the biotinylated mimics of either miR-26b or 
miR-195 or biotinylated controls. Twenty-four hours later, the cells were 
harvested, a pulldown assay was performed using streptavidin-coated beads to 
capture the biotinylated miRNA mimics, samples were washed, and total RNA 
was extracted. Also, a small amount of transfected and lysed cells were not 
used in the pulldown, in order to allow extraction of total RNA in the cells, which 
represents the input RNA for the pulldown. RNA was then quantified using the 
















































Table 5.3.1: Total RNA extracted from MCF7 cells transfected with 
biotinylated miRNA mimics before and after a pulldown assay was 
performed 









MCF7 cells were transfected with biotinylated mimics of either miR-26b or 
miR-195 or a control. Twenty-four hours later, cells were harvested. A 
small volume of lysate (50µl from a total of approximately 2ml) from each 
sample was kept separate and total RNA extracted directly as an input 
sample. The remaining lysate was added to streptavidin-coated beads 
and the mixture left to bind. Beads were collected, washed, and the 
pulled-down RNAs were then extracted. RNA was quantified using the 
Qubit High Sensitivity Assay and fluorometer. 
A minimum of 0.1g total RNA was required for RNA-Seq protocols leading to 
analysis by the HiSeq 3000 Sequencing System. The RNA extracted from all 
samples was therefore sufficient to perform the desired analyses. 
5.3.1.3 Libraries of sufficient quantity and quality were successfully 
prepared for RNA-Seq 
Having extracted a sufficient quantity of RNA for the desired analyses, libraries 
of the samples were prepared for RNA-Seq. Since miRNAs have previously 
been shown to interact with not only mRNAs but other non-coding RNA species 
as well (Jalali et al., 2013, Li et al., 2014b), polyA selection, which selects only 
mRNAs with polyA tails, was not performed. Therefore, only rRNA depletion 
was performed prior to library preparation, so as to minimise the influence of an 
overabundance of these rRNAs during subsequent analyses. This was 
performed on the pulldown samples and the input samples. Once the libraries 
had been prepared, samples were analysed to ensure sufficient quantities and 
qualities. A minimum of 3.5ng cDNA was required and single populations with 
fragment lengths of 200-400 base pairs. These parameters were assessed 
using a Qubit fluorometer (Table 5.3.2) and an Agilent TapeStation automated 
analysis machine respectively. Representative graphs showing library-prepared 
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samples from input and pulldown samples are shown in Figure 5.3.2, with 
remaining graphs shown in Appendix E. 
Table 5.3.2: Total cDNA after rRNA removal and library preparation 









Total RNA extracted from MCF7 cells transfected with biotinylated miRNA 
mimics was used to make libraries for RNA-Seq analysis. First, RNA 
samples underwent rRNA removal to remove the overabundance of these 
RNA species, and then cDNA synthesis was performed. 3’ ends were then 
adenylated and adapters ligated onto the ends in order to distinguish 
between samples by adding unique labels, before the cDNA samples 
were amplified. The final products were quantified using the Qubit High 
Sensitivity Assay and fluorometer. 
 









Figure 5.3.2: Representative graphs showing the fragment populations of 
library prepared samples 
Libraries that were quantified in Table 5.3.2 were also analysed using the 
Agilent 2200 TapeStation using the High Sensitivity DNA ScreenTape to 
ensure that only library cDNA fragments were present in the samples and 
no primer dimers were present. The x-axis shows fragment length (base 
pairs) and the y-axis shows abundance. The ‘lower’ and ‘upper’ peaks at 
25nt and 1500nt are markers used as internal references. The left panel 
shows the library prepared from total RNA extracted from cells transfected 
with the miR-195 mimic that did not undergo the pulldown process (input) 
and the right panel shows the library prepared from RNA extracted 
following the pulldown process (pulldown).  
Having confirmed that libraries of sufficient quantity (minimum 3.5ng, see Table 
5.3.2) and quality (populations with fragment lengths of 200-400 base pairs, 
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see Figure 5.3.2) had been prepared, samples underwent paired end RNA 
sequencing using the Illumina HiSeq 3000 sequencing platform. 
5.3.2 Potential targets of miRNAs were successfully identified 
following RNA-Seq analysis  
5.3.2.1 Analysis of RNA-Seq data using the MACS2 algorithm 
successfully identified cancer-related genes 
Analysis of RNA-Seq data was performed using multiple methods. In the first 
method, the Model-based Analysis of ChIP-Seq algorithm version 2 (MACS2) 
(Zhang et al., 2008) was used to identify enriched regions of sequences 
present in the miRNA bait pulldown samples compared with the control 
pulldown sample. Pulldown samples were also compared with input samples, 
to account for biases such as pulldown efficiency and reads sequenced that 
also originate from other areas of the genome. Thus, input samples were used 
as normalisation samples, such that for each transcript, the number of reads in 
the pulldown sample was normalised to the number of reads in the input 
sample. For each miRNA, the top 100 most abundant sequences in the 
pulldown samples compared with the control pulldown sample and compared 
with the input samples were selected. These sequences represented the most 
abundant transcripts, rather than corresponding genes. As a brief validation 
method, the genes encoding these transcripts were analysed by the pathway 
enrichment analysis software Reactome (Fabregat et al., 2017) to observe 
whether they may contribute to chemoresponse. Table 5.3.1 shows that several 
targets of both miR-26b and miR-195 are involved in the cell cycle, DNA repair 
and DNA replication pathways as well as gene expression (transcription) and 
metabolism of proteins, thus suggesting that the methodology has led to 
identification of cancer-relevant genes, which may contain contributors to 
chemoresistance – with DNA repair being of particular potential relevance to 
response to DNA-damaging chemotherapy agents. All 100 sequences, 
representing 80 genes as miR-26b mRNA targets, and 86 genes as miR-195 




Table 5.3.3: Selected pathways and the number of genes identified as 
potential targets of miR-26b and miR-195 that function in them 
Pathway Number of miR-26b 
mRNA targets 
Number of miR-195 
mRNA targets 
Cell Cycle 12 13 
DNA Repair 7 2 




Metabolism of Proteins 27 42 
Genes identified as the top 100 sequences targeted by miR-26b and miR-
195 were analysed by the pathway enrichment analysis software 
Reactome. Pathways where multiple miRNA targets were involved were 
identified, with a focus on those that may contribute to the response of 
cells to chemotherapy. 
5.3.2.2 Analysis of RNA-Seq data using the DESeq package combined 
with comparisons with MACS2 results and predictive algorithms 
showed several genes in common with multiple methods of 
analysis 
In the second method, the input and pulldown samples were initially analysed 
separately. Differential expressions between samples derived from biotinylated 
miRNA transfected cells and the samples derived from biotinylated control 
transfected cells were calculated for both input and pulldown samples, using a 
R package called DESeq (Anders, 2010). To narrow down the number of 
targets for further investigation, thresholds were applied. Both fold differences 
and p value parameters were considered. These p values were calculated 
taking into account several factors including fold differences and number of 
reads in each sample, although it should be noted this statistical assessment is 
still based on only one biological sample. Calculations were performed using 
the parameters suggested by the creators of the DESeq package (Anders, 
2010) when only one repeat was performed. Initially, for the pulldown 
comparisons, the threshold for minimum fold difference was 100, and the 
threshold for significance was p<0.05. For the input samples the threshold for 
fold difference applied was 0.7, thereby selecting as candidate genes those 
that were down-regulated by more than this cut off after transfection with the 
mimics, and the threshold for significance was p<0.1. Interestingly, there were 
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no transcripts that met both thresholds for fold change and significance within 
the pulldown samples or within the input samples, therefore subsequent 
analyses were performed separately for those transcripts that met one of these 
thresholds. The numbers of genes that met each of the above criteria are 
shown in Table 5.3.4. 
Table 5.3.4: Number of genes that complied with chosen criteria 
MiR-26b 
(pulldown) 
No. of genes MiR-26b (input) No. of genes 
Fold difference 
>100 
787 Fold difference 
<0.7 
8523 
p<0.05 86 p<0.1 0 
MiR-195 
(pulldown) 
No. of genes MiR-195 (input) No. of genes 
Fold difference 
>100 
787 Fold difference 
<0.7 
8530 
p<0.05 134 p<0.1 63 
Following differential expression analysis of pulldown and input samples, 
lists of genes were compiled that met the chosen criteria of minimum and 
maximum fold differences and p values. 
Comparisons were then made between transcripts identified by the MACS2 
algorithm, and those downregulated in input samples (whether those with a 
maximum fold difference of 0.7 or p<0.1), and upregulated in pulldown samples 
(whether those with a minimum fold difference of 100 or p<0.05) to identify any 
that were in common. In Chapter 4 (section 4.3.2.1), I used the multiple 
predictive algorithms included in Starbase in attempts to identify putative 
mRNA targets of miR-26b and miR-195 – different numbers of gene targets 
were predicted depending on whether I set requirements that individual genes 
should be predicted by 2, 3, 4 or all 5 specific algorithms available. The 
comparisons between transcripts identified by MACS2 and those identified by 
DESeq were also compared with those identified by these predictive 
algorithms, first to corroborate whether transcripts identified in my experiment 
may be true targets of miR-26b and miR-195, and secondly to narrow down the 
list of potential genes of interest. For this reason, transcripts identified by 
MACS2 and those identified by DESeq were initially compared with those 
genes predicted by 2, 3, 4 and 5 algorithms. Following this, the number of 
predictive algorithms used in these comparisons depended on the number of 
genes common with the other three methods. The aim of these analyses was to 
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initially identify a small number of genes (up to 10 genes of interest) that could 
be searched in the literature for any links with chemoresponse.  
Multiple comparisons were made between genes identified as up-regulated in 
the pulldown samples with those down-regulated in the input samples, those 
predicted by between 2 and 5 predictive algorithms, and the top 100 transcripts 
identified by MACS2. As noted before, there were no genes in common in the 
pulldown samples between those with a minimum fold difference of 100 and 
those with p<0.05, and no genes in common in the input samples between 
those with a maximum fold difference of 0.7 and those with p<0.1. Therefore, 
separate comparisons were made for each of these thresholds. There were no 
genes in common between those representing the top 100 transcripts identified 
by MACS2 and those with a minimum fold difference of 100 for potential targets 
of miR-26b, and only one gene in common for miR-195, which was C12orf60. 
Following these comparisons between two groups, further comparisons were 
made between three separate groups, with focuses largely on those genes 
identified in the pulldown samples and those predicted by a variable number of 
algorithms, with a preference for those predicted by a larger number of 
algorithms. The focus on genes identified in the pulldown samples was due to 
the fact these should only have been present in the sample if they were 
attached to the miRNA bait. The focus on genes predicted by as large a 
number of predictive algorithms as possible was due to the fact that, in 
principle, genes predicted by numerous algorithms would have a larger 
probability of being real targets of the miRNA of interest. Combined with those 
genes identified in the pulldown samples, this method was thought to be an 
effective method of narrowing down the number of potential targets, such that 
the majority of these would be true targets. Since not all mRNAs are down-
regulated by their targeting miRNAs, and since MACS2 used a different method 
for analysing data compared with DESeq, both the genes identified as down-
regulated in the input samples and those representing the transcripts identified 
by MACS2 were used as the third comparison group separately. This was an 
attempt to avoid removing true targets identified by one of these methods from 
the list of genes for final consideration. 
To narrow down the list of potential targets of interest even further, four 
comparisons were made using all four methods. As mentioned previously, 
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there were no genes identified by MACS2 that were also identified in the 
pulldown samples with a minimum fold difference of 100 for miR-26b and only 
one for miR-195, therefore all comparisons with four groups were performed 
using genes identified in the pulldown samples with p<0.05.  
5.3.2.3 Final comparisons between different methods of analysis showed 
seven genes of interest as potential targets of miR-26b and miR-
195 
The final multiple comparisons made were designed to identify genes identified 
commonly by all four methods (Figure 5.3.3, top panels), which represent 
genes highly likely to be true targets of their targeting miRNAs, and those 
identified by three methods (Figure 5.3.3, bottom panels), which represent 
targets with a slightly lower but still high probability of being true targets. The 
comparisons made between three groups were done such as to avoid 
identifying the same targets identified by the comparisons between all four 
groups, therefore either the criteria for the pulldown identification was varied 
between fold change or p value thresholds, and/or the number of Starbase 
algorithms included was altered. For this reason, the comparisons made for 
targets of miR-26b and miR-195 were not the same. The final comparisons 
made between three groups were chosen as these identified a small number of 
genes of interest for further investigation. The combination of comparisons with 
four groups and with three groups finally led to the identification of three genes 
as targets of miR-26b and four genes as targets of miR-195 (within the central 




miR-26b targets miR-195 targets 
 
 
Figure 5.3.3: Final comparisons made between multiple methods of 
identifying miRNA target genes of interest 
These Venn diagrams show the numbers of genes identified by up to four 
different methods. Comparisons were made using genes predicted to be 
targets of miR-26b and miR-195 by the predictive algorithms included in 
Starbase (numbers in brackets indicate how many algorithms predicted 
those targets), differentially expressed genes identified in the input 
samples (with a fold reduction in expression of at least 0.7), differentially 
expressed genes identified in the pulldown samples (either where p<0.05 
or a minimum fold change of 100), and genes identified by the MACS 
algorithm (version 2). Those genes identified by all shown methods were 




Table 5.3.5: List of potential miRNA targets of interest, and brief details of 
published data relating to roles in cancer biology and/or 
chemoresponse 







Potential miR-26b targets 
REEP4 Microtubule binding protein required for cell division 
(Schlaitz et al., 2013). Under-expressed in cancer 
(Hornstein et al., 2008, Doyen et al., 2014). 
4 
PRKCD Tumour suppressor. Functions as pro-apoptotic 
protein during DNA damage-induced apoptosis (Liu 
et al., 2007). 
3 
BLOC1S2 Expression promotes apoptosis, decreased 
expression observed in multiple cancers (not tested 
in breast cancer) (Gdynia et al., 2008). 
3 
Potential miR-195 targets 
CHAC1 Elevated expression associated with a poor 
outcome in breast cancer (Goebel et al., 2012). 
4 
CCNE1 Down-regulated in breast cancer cells resistant to 
doxorubicin (AbuHammad and Zihlif, 2013). 
Amplification observed in residual chemoresistant 
breast tumours post-NAC (Balko et al., 2014). 
4 
ARL2 Reduced expression in breast cancer cells results in 
proliferative advantage (Beghin et al., 2009). 
Expression has been associated with 
chemosensitivity in breast cancer (Beghin et al., 
2008). 
4 
SEMA6D Tumour suppressor function suggested. High 
expression has been associated with a favourable 
outcome in breast cancer (Chen et al., 2015). 
3 
Following identification of likely targets of miR-26b and miR-195, a literature 
search was performed to determine whether these genes may contribute to 
chemoresponse. Published data concerning the functions of these genes are 
summarised in Table 5.3.5. Of these genes, REEP4 and PRKCD seemed to be 
promising targets of miR-26b that may contribute to chemoresponse. REEP4 
was chosen because it is required in cell division, a process that is targeted by 
chemotherapy. PRKCD was chosen because of the evidence of its function as 
a pro-apoptotic protein during DNA damage-induced apoptosis, since one of 
the targets of the chemotherapy agent used in this project is DNA replication. 
BLOC1S2 was not chosen because of the fact that although expression of this 
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gene was decreased in multiple cancers, it had not been observed in breast 
cancer. ARL2 and SEMA6D seemed to be promising targets of miR-195 that 
may contribute to chemoresponse. CHAC1 was not chosen due to the fact that 
elevated expression was associated with a poor outcome in breast cancer, 
whereas as a target of a miR-195, decreased expression would be expected to 
be associated with a poorer outcome. CCNE1 was not chosen due to the 
conflicting evidence between increased and decreased expression in 
chemoresistant breast cancers. ARL2 and SEMA6D were both chosen due to 
the evidence suggesting lower expression would result in poorer outcomes in 
breast cancer. 
5.3.3 Confirming mRNA targets of miR-26b and miR-195 and their 
functions in chemoresponse 
5.3.3.1 Increased miR-26b expression significantly decreased REEP4 
transcript levels, and decreased miR-195 expression significantly 
increased SEMA6D transcript levels  
Having identified two potential mRNA targets of miR-26b and miR-195 each, an 
initial validation step was performed. Although PRKCD was not identified as 
down-regulated post-miR-26b mimic transfection in the input sample, the other 
mRNA targets were identified in the pulldown samples as well as identified as 
down-regulated post-miRNA mimic transfection in the input samples. 
Therefore, it was likely that the up-regulation of these miRNAs in ER positive 
MCF7 cells using miRNA mimics would lead to down-regulation of the target 
transcripts. I tested this by transfecting MCF7 cells with miRNA mimics or 
inhibitors or relevant controls, extracting RNA and performing RT-qPCR to 
investigate target mRNA expression (Figure 5.3.4). The effect of the miR-26b 
mimic or inhibitor on PRKCD expression was also tested as a change in 
expression may have been present in the sample analysed by DESeq that did 
not meet the required criteria. 
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         miR-26b               miR-195 
Figure 5.3.4: REEP4 and SEMA6D are targeted by miR-26b and miR-195 
respectively but not PRKCD and ARL2 
MCF7 cells were transfected with either the miRNA mimic or inhibitor of 
interest or appropriate controls. Cells were harvested seventy-two hours 
post-transfection and RNA extracted followed by RT-qPCR to quantify 
expression of the potential miRNA targets of interest. (A) Gene 
expressions of REEP4 and PRKCD following transfection with either miR-
26b mimic or inhibitor. This graph shows three biological repeats and error 
bars show SEM (*p<0.05). (B) Gene expressions of SEMA6D and ARL2 
following transfection with either miR-195 mimic or inhibitor. This graph 
shows two biological repeats and error bars show SEM (***p<0.0005). 
REEP4 showed a significant decrease in expression when miR-26b was up-
regulated, and no change in expression when this miRNA was down-regulated. 
SEMA6D showed a decrease in expression after transfection with the miR-195 
mimic, and a significant increase in expression when miR-195 was inhibited. 
Whereas, neither PRKCD or ARL2 expression changed significantly in the 
presence of either miR-26b mimic or inhibitor, or miR-195 mimic or inhibitor 
respectively. These data provided support for the hypothesis that REEP4 and 
SEMA6D were regulated by miR-26b and miR-195 respectively, but did not 
support that PRKCD and ARL2 were so regulated, although it should be noted 
that miRNAs do not always impact on the mRNA expression levels of their 
targets. 
5.3.3.2 Expression of miRNA target genes in epirubicin resistant MCF7 
and T47D cells 
In Chapter 4 (section 4.3.1.7), I described the development of two epirubicin 
resistant ER positive breast cancer cell lines. In both resistant cell lines, miR-
26b and miR-195 were both up-regulated (see Figure 4.3.11). Since I was 























































































































this chemoresistance, I investigated expression of my four putative targets in 
these epirubicin resistant cells in comparison to the parental lines with standard 
epirubicin sensitivity, with the expectation that true targets of the miRNAs that 
were contributing to the chemoresistance they cause would be down-regulated 
in the resistant lines. Total RNA was extracted from MCF7 and T47D parental 
and epirubicin resistant cells and expression of the genes of interest were 
determined by RT-qPCR (Figure 5.3.5). Data showed that in MCF7 cells, 
expressions of REEP4 and PRKCD were not changed in resistant cells 
compared with parental cells, whereas SEMA6D and ARL2 both had 
decreased in expression in resistant cells, although these decreases were not 
significant. In T47D cells, however, all transcripts were over-expressed in 
epirubicin resistant cells compared with parental cells, with significant increases 
for REEP4 and PRKCD. 
For the potential miR-26b targets REEP4 and PRKCD, these data provide no 
evidence of potential roles down-stream of miR-26b in chemoresistance, since 
the genes were not down-regulated in the resistant lines. For the potential miR-
195 targets SEMA6D and ARL2, the result is less clear, with down-regulation in 
resistant MCF7 cells supporting a role in resistance down-stream of miR-195, 
but the up-regulation in T47D being compatible with these genes being 
regulated by different unrelated mechanisms in this line. Data from these two 
cell lines highlight the presence of large differences between different cell lines, 









Figure 5.3.5: REEP4, PRKCD, SEMA6D and ARL2 are differentially 
expressed in epirubicin resistant cell lines 
Total RNA was extracted from MCF7 (left panel) and T47D (right panel) 
epirubicin sensitive (WT) and resistant (R) cells and RT-qPCRs were 
performed to determine expression of REEP4 and PRKCD, putative 
targets of miR-26b (top panels) and SEMA6D and ARL2, putative targets 
of miR-195 (bottom panels). These graphs show two biological repeats 
and error bars show SEM (*p<0.05, ***p<0.0005). 
5.3.3.3 Knockdown of SEMA6D caused increased chemoresistance  
As increased expression of miR-26b and miR-195 was observed in cells 
surviving chemotherapy (Chapter 3, section 0) and was also observed to 
contribute to chemoresistance in vitro (Chapter 4, section 4.3.1), decreased 
expression of their target mRNAs that are relevant for this function may also 
lead to increased chemoresistance. To observe whether down-regulation of the 
genes identified by the pulldown assay was sufficient to induce 
chemoresistance, MCF7 cells were transfected with siRNAs targeting these 
genes. Forty-eight hours post-transfection, cells were treated with the 
chemotherapeutic drug epirubicin and chemosensitivity assays were performed 
(Figure 5.3.6).  
Cells transfected with siRNAs targeting SEMA6D were significantly more 





























































































































































































































transfected counterparts. Cells transfected with siRNAs targeting REEP4 were 
also potentially more resistant to chemotherapy although this difference was 
not significant. The knockdown of PRKCD and ARL2 however did not result in 
increased chemoresistance. There was no change in chemosensitivity of cells 
following transfection with a siRNA targeting ARL2 suggesting that this gene 
did not contribute to chemoresponse in this context. However, there was a 
significant increase in chemosensitivity when cells were transfected with 
siRNAs targeting PRKCD followed by treatment with 1M epirubicin, although 
this was not maintained following treatment with 3M epirubicin.  
These results supported the hypothesis that decreased expression of SEMA6D 
contributed to chemoresistance, and were in accordance with data from 
epirubicin resistant MCF7 cells, where expression of this transcript was also 
decreased (Figure 5.3.5). There was also a suggestion that decreased 
expression of REEP4 might contribute to chemoresistance, although this result 
was not significant.  
 
 
Figure 5.3.6: Knockdown of target mRNA genes caused altered 
chemosensitivity of MCF7 cells 
MCF7 cells were transfected with siRNAs targeting the genes of interest 
(or negative control). Forty-eight hours post-transfection, cells were 
treated with two concentrations of epirubicin (1 or 3M) or vehicle control 
(water). Twenty-four hours post-treatment, MTT assays were performed. 
Raw absorbance values were normalised to the control transfected and 
control untreated samples. The left panel shows the effects of epirubicin 
on overall survival whereas the right panel is normalised to allow focus on 
the effects of the targeted miRNA mimic or inhibitor on survival in 
epirubicin-treated samples. Two biological repeats were performed for 





















































5.3.3.4 Knockdown of REEP4 and SEMA6D but not PRKCD or ARL2 
caused increased colony forming ability 
Colony forming assays were also performed to assess the impact of decreased 
expression of my four target mRNAs on chemoresistance, in order to confirm 
the results obtained in 5.3.3.3 in a longer term assay. As before, MCF7 cells 
were transfected with siRNAs targeting each of the four genes of interest or 
with a control siRNA. Forty-eight hours post-transfection, cells were treated 
with 30nM epirubicin or vehicle control for twenty-four hours before being 
seeded at a low density and cultured to allow colonies to grow. Colonies were 
then counted (Figure 5.3.7). As with the short term cell viability assays, 
knockdown of SEMA6D in MCF7 cells resulted in chemoresistance, shown by 
the ability to form significantly more colonies than the control transfected 
counterpart. Again, similarly to the short term assay, knockdown of REEP4 also 
resulted in increased ability to form colonies although again this difference was 
not significant. Knockdown of PRKCD and ARL2 again did not affect colony 
forming ability after epirubicin treatment. 
These data further support the model that REEP4, as a target of miR-26b, and 
SEMA6D, as a target of miR-195, may mediate the increased chemoresistance 
observed on over-expression of these miRNAs. 
  
Figure 5.3.7: Knockdown of target mRNA genes altered colony forming 
ability of MCF7 cells 
MCF7 cells were transfected with siRNAs targeting the genes of interest 
(or negative control). Forty-eight hours post-transfection, cells were 
treated with 30nM epirubicin or vehicle control (water) for twenty-four 
hours before being seeded at low density and left to grow for fourteen 
days. Colonies were counted. The left panel shows epirubicin-treated 
samples normalised to their untreated counterparts. The right panel shows 
the miRNA transfected and treated samples normalised to the control 
transfected and epirubicin-treated sample. Three biological repeats were 




















































5.3.4 Expression of REEP4 and SEMA6D in clinical breast cancer 
samples 
Having identified REEP4 and SEMA6D as target genes of miR-26b and miR-
195 respectively that potentially contribute to the response of breast cancer 
cells in vitro to chemotherapy, further investigations were performed to 
determine whether expression levels of these two proteins provide prognostic 
or therapy predictive insights in patients. Therefore, tissue microarrays (TMAs) 
were constructed using breast cancer samples and immunohistochemistry 
(IHC) performed, followed by correlation tests to determine whether expression 
of the REEP4 and SEMA6D proteins correlated with disease-free survival 
(DFS) and/or overall survival (OS). 
Breast cancer patients who could potentially be included in the study were 
identified by Ms Stacey Jones (Clinical Research Fellow, Leeds Teaching 
Hospitals NHS Trust / University of Leeds). Patients were included if they were 
diagnosed with primary breast cancer between 2005 and 2010, received no 
neoadjuvant systemic therapy, received adjuvant cytotoxic chemotherapy, and 
had complete follow-up data on DFS and OS at the time of sample selection. 
These criteria were chosen in order to allow for a wide variety of breast cancer 
subtypes, such that differences in protein expression between subtypes may be 
noted if present, and also so that the majority of breast cancer subtypes were 
represented. Only patients who received adjuvant chemotherapy were selected 
in order to test the impact of expression of these proteins on outcomes 
specifically after this therapy, although it should be noted that the patients 
received a wide variety of additional therapies including endocrine and HER2-
targeted agents (see Table 5.3.6). 
Once patients had been identified, tumour histology was examined, using 
haematoxylin and eosin (H&E) stained slides in order to assess whether the 
tissue itself was suitable for the planned analysis. This was important in terms 
of the presence of sufficient tumour epithelial cells since chemoresistance was 
attributed to altered expression of the genes of interest in these cells, although 
the presence of stromal cells within cores was not avoided. This procedure was 
also required to ensure three representative cores of tissue were available from 
regions of each tumour. Combining all of the above criteria, 305 patients and 
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their tumours were determined to be appropriate. Table 5.3.6 shows the clinico-
pathological features of these patients and tumours. 
Table 5.3.6: Clinico-pathology features of patients/tumours that were 
used in this study 
Characteristic Categories Number (%) 
Age  
Mean 52, range 25-74 
  
Positive receptor status 
ER 212 (69.5%) 
PR 160 (52.5%) 
HER2 68 (22.3%) 
Grade 
1 16 (5.2%) 
2 113 (37%) 
3 161 (52.8%) 
Number of lymph nodes 
involved 
0 115 (37.7%) 
≥1 190 (62.3%) 
Cytotoxic chemotherapy EC-containing 300 (98.4%) 
HER2-targeting therapy Trastuzumab 68 (22.3%) 
Endocrine therapy 
Tamoxifen 126 (41.3%) 
Anastrozole 104 (34.1%) 
Others 19 (6.2%) 
None 92 (30.2%) 
All patients were treated with adjuvant cytotoxic chemotherapy. 
Once patients had been identified, three cores were taken from FFPE tumour 
blocks by Ms Stacey Jones (Leeds Teaching Hospitals NHS Trust / University 
of Leeds) to construct the TMAs. These TMAs were then stained by IHC using 
antibodies directed against the REEP4 and SEMA6D proteins.  
5.3.4.1 Scoring of immunostained TMAs for REEP4 and SEMA6D 
Once tissues had been immunostained, slides were viewed to determine the 
appropriate scoring methods for each antigen, taking advice from Dr Eldo 
Verghese (project supervisor and consultant breast histopathologist within 
Leeds Teaching Hospitals NHS Trust). Staining of both antigens was largely 
cytoplasmic in the epithelial cells, with approximately equal proportions of 
epithelial cells being stained in all cases. Scoring therefore consisted only of 
staining intensity for both antigens. Representative images of different staining 























Figure 5.3.8: Representative images of staining intensities for REEP4 and 
SEMA6D  
Representative images of tissues stained for REEP4 or SEMA6D (brown) 
and counterstained with haematoxylin (blue) at 40x magnification, with 
corresponding scores assigned on the basis of intensity staining. 
Of the 915 cores representing 305 cancer cases, 765 cores were assessable 
for REEP4 and 773 cores were assessable for SEMA6D. Of the 305 cases, 
these represent 293 cases for REEP4 and 291 cases for SEMA6D. Reasons 
for cores being non-assessable included staining artefacts, absence of tumour 
epithelial cells in the tissue, or core loss.  
5.3.4.2 Scoring concordance between scorers and within cases was 
moderate to high 
To determine whether reproducible scores were assigned for each antigen, 42 
cases were double scored independently by myself and Dr Eldo Verghese. 
Weighted kappa statistics were calculated to determine the degree of 
concordance between the two sets of scores. Weighted kappa values of 0.41-
0.60 indicate moderate agreement, and values of 0.61-0.80 indicate substantial 
agreement (Landis and Koch, 1977), with actual values shown in Table 5.3.7. 
These values demonstrated moderate agreement between scorers for REEP4 
and substantial agreement between scorers for SEMA6D. 
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Table 5.3.7: Weighted kappa values for each antigen with corresponding 
95% confidence intervals (CI) values 
Antigen ĸw 95% CI 
REEP4 0.55 0.41-0.68 
SEMA6D 0.69 0.55-0.83 
Variation between cores from the same cases was also determined by 
calculating Spearman’s rho correlation coefficients. This was to determine the 
probability of selected cores being representative of the whole tumour with 
respect to antigen expression – poor correlations would suggest substantial 
heterogeneity within the tissue and would suggest use of TMAs could be 
problematic. For REEP4, 269 cases were assessed, and for SEMA6D, 264 
cases were assessed, as these had a minimum of two assessable cores. 
Correlations for both antigens were strong and significant, indicating little 
variation within cases (Table 5.3.8). This indicated that scoring was highly likely 
to be representative of the whole tumour. 
Table 5.3.8: Correlation coefficients indicate strong correlations between 
cores of the same cases for REEP4 and SEMA6D 
Antigen No. of cases Correlation coefficient 
REEP4 269 0.92* 
SEMA6D 264 0.91* 
Spearman’s rho correlation coefficients were calculated for replicate cores 
for each antigen, where *p<0.05. 
5.3.4.3 REEP4 and SEMA6D show variable expression in different breast 
cancer cases 
To determine the frequency of expression scores for each antigen, the mean 
expression (rounded to the nearest whole number) was first calculated for each 
case from the cores available. Following this, the frequency of each expression 
score was then calculated (Figure 5.3.9). For both proteins, each available 
score was well represented, demonstrating that expression varied substantially 






Figure 5.3.9: Frequencies of each expression score for REEP4 and 
SEMA6D show variable expression 
Once cases had been scored for the expression of each antigen, the total 
number of cases were calculated for each expression group. The left 
panel shows the number of cases in each expression group for REEP4 
and the right panel shows the number of cases in each expression group 
for SEMA6D. 
5.3.4.4 Expression of REEP4 and SEMA6D does not correlate with 
prognostic factors 
Correlations between expression of REEP4 and SEMA6D and prognostic 
factors were assessed. These prognostic factors included histological grade, 
ER status and presence of lymph node metastasis. Spearman’s rho correlation 
coefficients were calculated for each factor with each antigen. Results are 
shown in Table 5.3.9 and showed no significant correlations between REEP4 
or SEMA6D expression and any of the prognostic factors.  
Table 5.3.9: Correlation coefficients (r) indicate no significant correlations 
between antigen expression and prognostic factors 






r -0.009 0.074 -0.104 
p 0.874 0.204 0.077 
SEMA6D 
r 0.042 -0.046 -0.002 
p 0.472 0.433 0.978 
Spearman’s rho correlation coefficients (r) were calculated for individual 
antigen expression and the prognostic factors. Prognostic factors included 
the presence of metastasis in at least one lymph node, histological grade 
















































5.3.4.5 Expressions of REEP4 and SEMA6D correlate with each other 
Although REEP4 and SEMA6D do not have the same functions, they do have 
one factor in common; in this project, REEP4 and SEMA6D have been shown 
to be targeted by miR-26b and miR-195 respectively and both of these miRNAs 
were up-regulated post-NAC in patients who displayed partial resistance to 
chemotherapy, therefore it can be inferred that both REEP4 and SEMA6D may 
have been down-regulated in these resistant cells. If so, a positive correlation 
between the expressions of these two proteins may exist. Therefore, the 
Spearman’s rho correlation coefficient was calculated for the correlation 
between the two proteins. A moderate but statistically significant correlation 
coefficient of 0.494 was calculated (p=4.97x10-19). This suggests that in this 
context, there may be a relationship, perhaps in terms of co-regulation of gene 
expression, between the two proteins. 
5.3.4.6 No significant differences are seen in disease free or overall 
survival between different expression values of REEP4 and 
SEMA6D 
Although no correlations were observed between REEP4 and SEMA6D 
expression and various prognostic factors, Kaplan-Meier survival analyses 
were performed to determine whether expression of either of these proteins 
had a significant impact on disease free survival (DFS) or overall survival (OS). 
Log rank tests were performed to test the null hypotheses that there were no 
significant differences between the different expression groups of REEP4 and 
SEMA6D with respect to the probability of a recurrence (in the case of DFS) or 
death (in the case of OS). Mean survival times with 95% confidence intervals 
were also calculated. The graphs showing Kaplan-Meier survival curves are 
shown in Figure 5.3.10 and mean survival times are shown in Table 5.3.10.  
Results show there were no significant differences between different 
expression groups of either protein for DFS or OS. There is a trend for patients 
with higher expressions of REEP4 to have a poorer outcome in terms of DFS 
(mean times of 4143 and 3595 days for the low and high groups respectively), 
but this was not significant (p=0.051). These results suggest that neither 




















Figure 5.3.10: Kaplan-Meier survival curves showing DFS and OS for 
different expression groups of REEP4 and SEMA6D 
Kaplan-Meier survival analyses were performed showing DFS (left panel) 
and OS (right panel) for low, moderate and high expression groups of 
REEP4 (top panel), and low and high expression groups of SEMA6D 
(bottom panel). The x-axis shows survival time in days and the y-axis 




Table 5.3.10: Mean DFS and OS times for different expression groups of 
REEP4 and SEMA6D show no significant differences 



































Log rank tests were performed to compare DFS and OS times between 
different expression groups of REEP4 and SEMA6D. Mean survival times 
with 95% confidence intervals are shown for each group with significance 
values shown for each test. 
5.3.4.7 Further analyses reveal significant differences in disease free 
survival between expression values of REEP4 
Since there was almost a significant difference in DFS between the expression 
values for REEP4, and since REEP4 expression was divided into three groups, 
I tried to combine the three groups into two groups in an attempt to improve the 
statistical power of the analysis. To do this, I combined the moderate 
expression group with either the low expression group or with the high 
expression group. Kaplan-Meier survival analyses and log rank tests were then 
performed as before (see section 5.3.4.6). Mean survival times with 95% 
confidence intervals were also calculated. The graphs showing Kaplan-Meier 
survival curves are shown in Figure 5.3.11 and mean survival times are shown 
in Table 5.3.11. 
Results showed significant differences between high and low expression 
groups of REEP4 for both combinations of groups, that is when the low and 
moderate groups were combined, and when the moderate and high groups 
were combined. The analysis with the combination of the low and moderate 
groups showed patients with lower expression of REEP4 to have a significantly 
better outcome in terms of DFS than those with high expression of this protein 
(mean times of 3990 and 3598 days for the low and high groups respectively; 
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p=0.042). The analysis with the combination of the moderate and high groups 
also showed patients with low expression of REEP4 to have a significantly 
better outcome in terms of DFS than those with higher expression of this 
protein (mean times of 4143 and 3765 days for the low and high groups 
respectively; p=0.036). These results suggest that REEP4 does have 
prognostic value in terms of DFS in breast cancer. However, these results were 
the opposite to expectations, when considering the fact that REEP4 is a target 
of miR-26b, which is up-regulated in chemoresistant tumours, therefore low 
expression of REEP4 would be associated with chemoresistance and therefore 
a poorer outcome after chemotherapy in terms of DFS. 
Low + moderate combined (Low) Moderate + high combined (High) 
  
Figure 5.3.11: Kaplan-Meier survival curves showing DFS for the two 
combined expression groups of REEP4 
Kaplan-Meier survival analyses were performed showing DFS for the 
combined expression groups of low + moderate (Low) versus high 
expression (left panel), and the combined expression groups of moderate 
+ high (High) versus low expression (right panel) for REEP4. The x-axis 




Table 5.3.11: Mean DFS times for different combined expression groups 






















Log rank tests were performed to compare DFS between the combined 
expression groups of low + moderate (Low) versus high expression, and 
the combined expression groups of moderate + high (High) and low 
expression for REEP4. Mean survival times with 95% confidence intervals 
are shown for each analysis with significance values shown for each test. 
The result that REEP4 expression correlated with DFS in the opposite direction 
compared to expectations was sufficiently surprising that further analyses were 
warranted. In particular, I noted that the cohort assembled for this analysis 
included many patients treated with ER negative cancers and patients treated 
with taxane-based therapy, while my initial cohort (Chapter 3) and subsequent 
in vitro work (Chapter 4 and this Chapter) focused on ER positive cancers 
treated with epirubicin. I therefore performed Kaplan-Meier survival curves and 
log rank tests using data only from those patients with tumours that were ER 
positive and were treated with the epirubicin and cyclophosphamide (EC) 
chemotherapy regimen, since these patients were more representative of my 
previous work. Mean survival times with 95% confidence intervals were also 
calculated. This analysis was performed using three different methods. In the 
first, all three expression groups were analysed separately as in section 
5.3.4.6. In the second and third methods, the moderate expression group was 
again combined with either the low or high expression groups. The graphs 
showing Kaplan-Meier survival curves are shown in Figure 5.3.12 and mean 
survival times are shown in Table 5.3.12. 
Results showed a significant difference in DFS between the three expression 
groups of REEP4 (mean times of 4367, 3681 and 4309 days for the low, 
moderate and high groups respectively, p=0.01). Results also showed a 
significant difference in DFS when the moderate group was combined with the 
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high expression group (4367 and 3848 days for the low and high groups 
respectively, p=0.044). There was no significant difference in DFS when the 
moderate group was combined with the low expression group. However, when 
considering the Kaplan-Meier survival curves for the three separate expression 
groups (Figure 5.3.12, top panel), the moderate expression group appeared to 
have the poorest outcome in terms of DFS with both high and low expression 
groups apparently having better outcomes, leaving some uncertainty as to the 
true answer regarding how levels of REEP4 expression relates to DFS. In 
pairwise analyses of these groups, the low expression and the moderate 
expression groups, and the moderate expression and the high expression 
groups were both independently significantly different (p=0.01 and p=0.045 
respectively), hinting at a subtle dose-dependent relationship where the 
extremes of expression share good prognosis, and intermediate expression 
defined significantly poor outcomes. Although these three groups can be 
combined into two groups (Figure 5.3.12, bottom panels), these analyses 
probably do not reflect the complexity of the situation and this was 
demonstrated by the result differing depending on whether the moderate 




Three separate expression groups 
 
Low + moderate combined (Low) Moderate + high combined (High) 
  
Figure 5.3.12: Kaplan-Meier survival curves showing DFS for different 
expression groups of REEP4 where tumours were ER positive and 
treated with the EC chemotherapy regimen 
Kaplan-Meier survival analyses were performed showing DFS for low, 
moderate and high expression groups of REEP4 (top panel), combined 
expression groups of low + moderate (Low) versus high expression 
(bottom left panel), and combined expression groups of moderate + high 
(High) versus low expression (bottom right panel). Data analysed was 
from patients whose tumours were ER positive and treated with a 
chemotherapy regimen containing only EC. The x-axis shows survival 




Table 5.3.12: Mean DFS times for different expression groups of REEP4 
where tumours were ER positive and treated with the EC 































Data from ER positive tumours, treated with the EC chemotherapy 
regimen, were used to perform log rank tests to compare DFS times 
between either all three expression groups of REEP4, the combined 
expression group of low + moderate (Low) versus high expression, or the 
combined expression group of moderate + high (High) versus low 
expression. Mean survival times with 95% confidence intervals are shown 
for each group with significance values shown for each test. 
5.4 Discussion 
5.4.1 Using synthetic biotinylated miRNA mimics as bait to identify 
target mRNAs 
In Chapter 4, I attempted to identify mRNA targets of miR-26b and miR-195 
that contribute to chemoresistance by using predictive algorithms and literature 
searches. Despite identifying CCDC6 as a target of both miRNAs of interest, 
this gene did not contribute to chemoresistance as expected. Another method 
was therefore required to identify mRNA targets of miR-26b and miR-195. The 
use of synthetic biotinylated miRNA mimics as bait to capture mRNA transcripts 
has previously been described (Ørom  and Lund, 2007). This method has the 
advantage of identifying the mRNA targets that are actually bound within the 
cell type of interest – and could therefore include both those potentially 
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calculated by predictive algorithms as well as those that may bind in non-
canonical ways and are not predicted by current methods (Thorne et al., 2018). 
Synthetic biotinylated miRNA mimics have previously been successfully used 
to identify mRNA targets of miR-139-5p (Krishnan et al., 2013). Expression of 
this miRNA was deregulated in tissue samples of triple negative breast cancer, 
with down-regulation frequently observed in a cohort of invasive breast 
carcinomas. To identify the function of miR-139-5p in this context, the authors 
used a biotinylated mimic of this miRNA as bait, to perform a pulldown in order 
to identify target mRNAs in MCF7 breast cancer cells. RNA that had been 
pulled down was analysed using microarrays, instead of RNA-Seq as I have 
used. Following identification of target mRNAs, of which there were 1356 that 
were significantly enriched compared to the control sample, these were 
compared with those predicted by the predictive algorithm TargetScan, of 
which there were 346, in order to determine whether the pulldown was 
successful. Of these genes, 46 were common to the two methods, which was 
significantly more than expected by chance. These results reinforce the fact 
that predictive algorithms are limited in their capacity to predict all mRNA 
targets, and indeed may predict false targets. This may explain the limited 
success I had in identifying targets of miR-26b and miR-195 using predictive 
algorithms in Chapter 4 (section 4.3.2). Following confirmation that the 
pulldown was successful, gene set enrichment analysis was performed using 
the genes encoding the transcripts that were pulled down. These results led to 
the conclusion that miR-139-5p expression regulated metastasis but not 
proliferation, with further in vitro studies showing that expression of this miRNA 
suppressed invasion and migration of MDA-MB-231 breast cancer cells. 
In another study, the authors used this method specifically together with RNA-
Seq to identify the functions of miR-522 based on its mRNA targets as it 
allowed unbiased identification of targets without having to rely on any 
assumptions based on seed pairing (Tan et al., 2014). Targets identified by this 
pulldown method were also compared with those genes identified by 
microarray analysis that were down-regulated when miR-522 was over-
expressed. This was similar to my methodology, although down-regulated 
mRNAs were identified by RNA-Seq in my experiment, instead of microarray 
analysis. The use of RNA-Seq has the advantage of not being limited to the 
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detection of genes for which probes are present on the microarray. Following 
this comparison, mRNAs that had been pulled down were also compared with 
those predicted by five individual predictive algorithms, with the most overlaps 
found between mRNAs enriched in the pulldown and the predictive algorithm 
TargetScan. As with the previous study (Krishnan et al., 2013), the authors in 
this study (Tan et al., 2014) compared their results with those from predictive 
algorithms as a method to ensure the pulldown was successful. Using pathway 
analysis with those genes identified by the pulldown, miR-522 was found to 
regulate processes including cell cycle progression, cell survival and cell 
motility. 
In the above mentioned studies, lists of genes corresponding to the transcripts 
pulled down with the bait miRNA were compared with those provided by 
predictive algorithms as a form of quality check to ensure that the pulldown was 
successful. Further analyses were performed using the list of genes identified 
by the pulldown alone. As I had already concluded that miR-26b and miR-195 
contribute to chemoresistance in Chapter 4 (section 4.3.1), the aim of my 
experiment in this chapter was to identify individual genes that contribute to this 
phenomenon that are regulated by these miRNAs. Therefore, I compared 
genes whose transcripts had been pulled down with the bait miRNA with those 
provided by predictive algorithms not only as a quality check to ensure the 
pulldown was successful, but also as a means to shorten the list of genes of 
interest. For this reason, I also took into account those genes that were down-
regulated in the presence of the miRNAs of interest, unlike in the second study, 
where authors used this method as a second quality check (Tan et al., 2014). 
Using biotinylated miRNA mimics as bait and comparing results with these two 
other methods, followed also by literature searching, I identified two genes of 
interest as targets for each miRNA: REEP4 and PRKCD for miR-26b and ARL2 
and SEMA6D for miR-195. 
5.4.2 The roles of REEP4 and SEMA6D in chemoresponse 
Having identified potentially relevant miRNA targets, I performed a number of 
assays to determine their actual relevance in chemoresistance; these 
experiments followed a similar flow to those examining the potential targets 
studied in Chapter 4 (section 4.3.2). First, expression of potential targets was 
determined in parental and epirubicin resistant MCF7 and T47D cells, which 
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suggested SEMA6D and ARL2 as genes with potential roles in 
chemoresistance in MCF7 cells but not in T47D cells. These results reinforce 
the concept discussed in more detail in Chapter 6 (section 6.4.2.3) that 
although both of these cell lines are ER positive and represent the luminal A 
breast cancer subtype (Holliday and Speirs, 2011), they do have differential 
protein expression profiles (Aka and Lin, 2012). Short term cell viability assays 
and long term colony forming assays were then performed, using ER positive 
MCF7 cells transfected with REEP4 or SEMA6D-targeted siRNAs and 
treatment with the chemotherapeutic drug epirubicin. These two assays 
suggested a role for SEMA6D in chemoresistance, supporting the results 
obtained from the MCF7 epirubicin resistant cells. Results for REEP4 were not 
significant, but were consistent, and also suggested a role in chemoresistance. 
Results obtained for both of these genes were consistent with expectations, as 
expression of their miRNA regulators miR-26b and miR-195 was increased 
post-NAC in chemoresistant patients. As targets of these two miRNAs, 
increased miRNA expression should cause decreased expression of REEP4 
and SEMA6D, and therefore should also lead to chemoresistance. 
5.4.2.1 The function of REEP4 in cancer 
Very little is known about REEP4 specifically in the context of cancer. It was 
identified as a microtubule-binding protein six years ago as part of a known 
protein family, with the protein localised to the endoplasmic reticulum (EnR) 
(Schlaitz et al., 2013) as with the localisation of other REEP family members 
(Park et al., 2010). It has several isoforms, the largest of which is 29.4kDa 
(Saito et al., 2004, Schlaitz et al., 2013). REEP proteins contain two conserved 
hydrophobic regions in their N-terminal domain (Voeltz et al., 2006), and the 
amino acids between these two domains in REEP proteins 1-4 are positively 
charged, which represent the microtubule-binding region (Schlaitz et al., 2013). 
Investigations into the function of this protein revealed that when depleted 
together with REEP3, defects in the structure of the nuclear envelope were 
observed (Schlaitz et al., 2013). In normal mitosis, the EnR membrane aids in 
the formation of the nuclear envelope, and is cleared from mitotic chromatin 
after the nuclear envelope is formed. However, when REEP4 and REEP3 were 
depleted, aberrant association of the EnR with mitotic chromatin was observed, 
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as well as other mitotic defects. The authors concluded that REEP4, together 
with REEP3, promotes the separation of daughter nuclei through its binding 
with microtubules, thereby facilitating the process of mitosis. 
The REEP4 gene is situated on chromosome 8p, a region frequently deleted in 
several cancers including prostate and rectal carcinomas (Hornstein et al., 
2008, Doyen et al., 2014). Microarray analyses performed on samples of 
prostate cancer tissue and benign tissue revealed significant down-regulation 
of REEP4 in tumour tissue compared with healthy tissue (Hornstein et al., 
2008). Since REEP4 contributes to the fidelity of the mitotic process, one 
possible consequence for lower expression of this gene is less efficient and 
accurate mitosis, thus contributing to tumorigenesis. It may also lead to 
aberrant expression of other genes in response to inefficient and inaccurate 
mitosis, which may contribute to the chemoresistance observed in vitro in this 
chapter when REEP4 was silenced in breast cancer cells treated with 
chemotherapy. 
5.4.2.2 The function of SEMA6D in cancer 
Semaphorins are a family of signalling proteins that regulate the morphology 
and motility of many cell types, and function largely through the plexin family of 
receptors (Alto and Terman, 2017). The domain essential for signalling, the 
sema domain, is located at the N-terminus, and is also the domain that 
mediates dimerization with other semaphorin proteins (Klostermann et al., 
1998, Gherardi et al., 2004). Structurally, proximal to the sema domain is the 
plexin-sema-integrin (PSI) domain (Siebold and Jones, 2013). SEMA6D was 
first identified as a new member of the class 6 transmembrane semaphorin 
protein family almost two decades ago, with a predicted molecular weight of 
113kDa (Qu et al., 2002, Taniguchi and Shimizu, 2004, Alto and Terman, 
2017). It was detected in a variety of human tissues (Qu et al., 2002). However, 
when several cancer cell lines were tested, including those representing 
leukaemia, colorectal adenocarcinoma and lung carcinoma, no SEMA6D was 
detected, suggesting a loss of expression in cancer. Further studies in gastric 
cancer, however, revealed significantly higher protein and mRNA expression in 
gastric carcinoma tissue compared with normal gastric mucosa (Zhao et al., 
2006). Further examination revealed that the expression of both SEMA6D and 
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its receptor plexin-A1 was high in the endothelial cells (Lu et al., 2016). 
Together with the observation that when plexin-A1 and VEGFR2 were 
complexed together and SEMA6D was bound, leading to VEGFR2 being 
phosphorylated, it was concluded that SEMA6D may play a role in tumour 
angiogenesis. 
With respect to chemoresistance, there is no direct published evidence that 
SEMA6D is a contributor, but it has been noted as a target of several miRNAs 
that do confer resistance. MicroRNA expression profiling was performed on 
ovarian cancer cells that were resistant to either paclitaxel or cisplatin, and was 
compared to the parental cells (Sorrentino et al., 2008). MiR-26a and miR-30c 
were both down-regulated in both resistant cell lines compared with their 
sensitive counterparts. SEMA6D was predicted to be a target of both miRNAs 
by the predictive algorithms TargetScan and PicTar. As such, it would be 
inferred that up-regulated SEMA6D would contribute to chemoresistance. It is 
worth noting that in my results, SEMA6D mRNA was pulled down by miR-26b, 
with a fold difference of at least 100, and was predicted as a target of this 
miRNA by four different predictive algorithms. MiR-26a and miR-26b have 
highly similar sequences, and they have many mRNA targets in common 
(Trompeter et al., 2013, Hu et al., 2018). The inference that up-regulated 
SEMA6D would contribute to chemoresistance is in contrast to the results that I 
have obtained in this chapter, although it is important to note that my 
experiments were performed in breast cancer cells rather than ovarian cancer 
cells. It is also important to note, however, that no further investigations were 
performed to verify that SEMA6D was a target of miR-26a and miR-30c in the 
ovarian cancer cells. As I have shown in Chapter 4 (section 4.3.2.2), where 
CCDC6 appeared to be targeted by both miR-26b and miR-195 in MCF7 cells 
but only miR-26b in MDA-MB-175 cells, cellular context is important when 
considering mRNA targets of miRNAs. 
5.4.3 REEP4 and SEMA6D expression as prognostic factors in 
breast cancer 
Since reduced expression of both REEP4 and SEMA6D appeared to contribute 
to chemoresistance, expression of the corresponding proteins in patients was 
tested to determine if they had any prognostic and potentially therapy predictive 
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value. This potential therapy predictive value originates from the fact that in this 
cohort, all patients received adjuvant chemotherapy. However, this value 
remains only potentially predictive when considering all treatments, as no 
comparisons were made with patients who received no adjuvant 
chemotherapy. One caveat to this, is that differences could potentially be 
observed when analyses are separated between different chemotherapy 
regimens, in which case, the protein would have a therapy predictive value 
specific to that regimen.  
There were no significant correlations between expression of either protein with 
ER status, histological grade of the tumour or involvement of lymph nodes, 
which is important as it suggests that any correlation with outcome for these 
patients could be independent of known prognostic factors – and would 
therefore provide new prognostic information not otherwise available. There 
were also no significant relationships between protein expression and DFS or 
OS, although there was a trend for poorer DFS when REEP4 expression was 
higher (p=0.051). It is important to note however, that having started with 305 
patients represented on the TMAs, there were only 68 incidences of recurrence 
with corresponding REEP4 expression data available. It is possible that with a 
larger number of recurrences and therefore larger statistical power, that there 
may indeed be a significant difference in DFS between patients with low, 
moderate and high expression of REEP4. Since this analysis was performed 
using three expression groups, further analyses were performed where the 
moderate expression group was combined with either the low or high 
expression groups in an attempt to improve the statistical power. This did 
indeed lead to significant differences in DFS between the two expression 
groups, both when the moderate group was combined with the low group 
(p=0.042) and when it was combined with the high group (p=0.036). This led to 
the conclusion that REEP4 expression did have prognostic value and 
potentially therapy predictive in terms of DFS. 
However, although differences in DFS between the two expression groups of 
REEP4 were significant, the relationships between REEP4 expression and 
DFS were the opposite to expectations based on all the preceding work in the 
thesis. Since all previous work was conducted in ER positive breast cancer 
cells, and the chemotherapy agent administered was epirubicin, further 
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analyses were performed to determine whether expression of REEP4 had a 
prognostic value in accordance with expectations in this subgroup of patients. 
Once again, significant differences in DFS were observed between the three 
expression groups of REEP4 (p=0.01), and when the moderate expression 
group was combined with the high expression group (p=0.044). However, these 
analyses did not provide simple evidence of how REEP4 expression relates to 
DFS, since the moderate expression group appeared to have much poorer 
DFS than either the low or the high expression groups (verified in separate 
analyses where p=0.01 and p=0.045 respectively). It is important to note 
however, that despite performing these analyses using the subgroup of patients 
with ER positive tumours and treated with a chemotherapy regimen consisting 
only of EC, the majority of these patients were also treated with endocrine 
therapies, and some were also treated with radiotherapy. Both of these other 
forms of cancer treatment could have influenced the effect of REEP4 
expression on DFS. Therefore, this subgroup of patients, although representing 
as closely as possible the context in which all previous analyses were 
performed, did not represent the precise context of all previous analyses. 
According to the online database The Human Protein Atlas, under the 
pathology section (Uhlen et al., 2017), there is no difference in OS between 
patients with high and low expression of REEP4 (p=0.24). This database uses 
RNA-Seq data taken from TCGA datasets, with data available for 1075 patients 
for REEP4 expression. My data also shows no difference in OS between 
different expression groups of REEP4 (p=0.215). The Human Protein Atlas 
database does not provide data regarding DFS. The same result is observed 
regarding the prognostic value of SEMA6D in breast cancer, where no 
significant difference is observed in OS between the different expression 
groups (p=0.2). It is important to note, however, that The Human Protein Atlas 
database performed these analyses using RNA expression data, whereas I 
used protein expression data. This is particularly important, as mRNA and 
protein expression levels do not always perfectly correlate (Riches et al., 2015). 
A second important factor to consider is that I identified these proteins as 
targets of miRNAs, and miRNAs do not always alter mRNA expression 
(Horman et al., 2013, Wilczynska and Bushell, 2015). 
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However, in a study investigating SEMA6D expression in breast cancer, a 
difference was observed in OS (Chen et al., 2015). Data was taken from a 
TCGA dataset and expression of SEMA6D was split into three groups: low, 
medium and high. The primary aim of this study was to identify genes 
differentially expressed between the low and high expression groups and 
determine the functions of these genes. These functions included the cell cycle 
process, response to drugs and the G-protein coupled receptor (GPCR) 
pathway, of which the latter function plays an essential role in cancer 
metastasis. Contributing to the results of this analysis, was also the observation 
that FOS and FOXO1, which both contribute to oncogenesis and metastasis, 
and are also potentially regulated by SEMA6D, both having increased 
expression in the high SEMA6D expression group. Kaplan-Meier analyses 
revealed that SEMA6D expression was significantly associated with OS 
(p=0.0156), with further analyses revealing a particularly large difference in the 
triple negative subtype of breast cancer (p=0.0083). Although these data do not 
correspond with my Kaplan-Meier survival analyses results, they do support my 
results that suggest a role for SEMA6D in chemoresistance. If lower expression 
of SEMA6D results in increased chemoresistance, this could translate to 
patients with lower expression of SEMA6D not surviving as long due to more 
severe therapy failure than those with higher expression. 
5.4.4 Conclusions 
I have successfully used synthetic biotinylated mimics of miR-26b and miR-195 
as bait to pull down mRNA targets of these miRNAs. By using multiple 
methods, I selected two candidate targets of interest for each miRNA. 
Observing their expression following manipulation of miR-26b and miR-195 
expression and performing short and long term cell viability assays, I concluded 
that REEP4 is a target of miR-26b and SEMA6D is a target of miR-195, 
contributing to chemoresistance when silenced. Further analyses revealed that 
SEMA6D expression, however, had no prognostic value in terms of DFS or OS. 
REEP4 expression did have prognostic value in terms of DFS in a subgroup of 
patients with ER positive tumours, treated with the chemotherapy regimen EC. 





Chapter 6: Endocrine therapy can induce resistance to 
subsequent chemotherapy 
6.1 Abstract 
Neoadjuvant systemic therapy for breast cancer is not limited to chemotherapy, 
since some patients with ER positive tumours can receive neoadjuvant 
endocrine therapy (NAET) as an alternative. This is most commonly the case in 
patients who are relatively frail and/or suffer from co-morbidities, therefore may 
not be suitable for neoadjuvant chemotherapy or for surgery at that time. 
However, a proportion of these patients go on to have surgery and some have 
adjuvant chemotherapy. Studies on the impact of NAET on response to 
subsequent adjuvant chemotherapy have not been performed. Previous work in 
the Hughes lab has shown that NAET is associated with significant increases in 
expression of Breast Cancer Resistance Protein (BCRP) in the tumour cells. 
BCRP is a protein that acts as a xenobiotic pump and expression has 
previously been linked with chemoresistance. The aim of this chapter was to 
examine whether this increase in BCRP occurs in appropriate cell line models, 
and to assess its impact on sensitivity to subsequent chemotherapy. 
Expression of BCRP at both protein and mRNA levels (gene name ABCG2) 
was significantly increased in the ER positive cell line T47D following daily 
treatment with the endocrine therapeutic 4-hydroxy-tamoxifen (tamoxifen) for 
fifteen days (p<0.05). This pre-treatment with tamoxifen was associated with 
significantly increased resistance to subsequent treatment with the 
chemotherapeutic epirubicin (p<0.05). Cell cycle analysis using flow cytometry 
revealed no significant alterations in the proportion of cells in each cycle phase 
after this tamoxifen pre-treatment, thus eliminating reduced proliferation as a 
potential mechanism of resistance and thereby implicating the increased BCRP 
expression as the likely resistance mediator.  
These results suggest that the impact of NAET on patients’ response to  





Oestrogen receptor positive breast cancers can be treated with endocrine 
therapies, of which there are two main classes: anti-oestrogens and aromatase 
inhibitors (Lumachi et al., 2011). However, patients with ER positive tumours 
can also be treated with cytotoxic chemotherapy, or a combination of both 
(Fisher et al., 1997, Paik et al., 2006). Previous studies have noted that of the 
ER positive breast cancers, luminal A-type tumours are generally less 
responsive to chemotherapies whereas luminal B-type tumours are generally 
less responsive to endocrine therapies (Ignatiadis and Sotiriou, 2013, Gnant et 
al., 2015). 
In a subset of patients, neoadjuvant endocrine therapy (NAET) is being 
increasingly recommended instead of neoadjuvant chemotherapy (NAC) as 
previous studies have shown similar overall response rates with less 
associated toxicity (Semiglazov et al., 2007, LeVasseur et al., 2017). This 
subset of patients includes those who are elderly and/or too frail to be treated 
with chemotherapy or to undergo surgery (Barroso-Sousa et al., 2016, Spring 
et al., 2016), and also includes patients with comorbidities (Macaskill et al., 
2006). However, the consequences of administering adjuvant chemotherapy 
following NAET have not been investigated. As the use of NAET for the 
treatment of breast cancer is increasing, the incidence of such situations will 
also increase. Therefore, investigations into these possible consequences 
should be performed. 
The expression of drug efflux pumps on tumour cells is a known mechanism for 
resistance to systemic therapies (Sharom, 2008). A well known family of 
proteins with the ability to export therapeutic drugs is the ABC family, which has 
a wide variety of substrates (Massey et al., 2014). One member of this family, 
is the Breast Cancer Resistance Protein (BCRP) and the gene encoding it is 
ABCG2 (Staud and Pavek, 2005) (see section 1.4.1.1). BCRP is known to be 
associated with chemoresistance (Kovalev et al., 2013, Mao and Unadkat, 
2015); one of the first discoveries of this drug pump was in a chemotherapeutic 
drug resistant subline of MCF7 breast cancer cells that did not overexpress the 
previously known drug transporters P-glycoprotein or the multidrug resistance 
protein (Doyle et al., 1998, Doyle, 1998). ABCG2/BCRP is of particular interest 
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in the context of NAET as it has been shown to have an oestrogen response 
element in the promoter of the gene (Ee et al., 2004, Zhang et al., 2006, 
Pradhan et al., 2010), therefore expression of the protein may be influenced by 
endocrine therapies. Previous studies have shown that NAC has the ability to 
induce changes in expression of this protein in breast cancers and that these 
induced levels were predictive of survival (Kim et al., 2013a). Altered 
expression of this protein post-NAET may therefore influence the sensitivity of 
tumour cells to any subsequent chemotherapy treatments. 
Previous work in the Hughes lab had demonstrated that increased BCRP 
expression was associated with NAET for breast cancer (Figure 6.2.1A and B). 
This was further supported by analysis of patient data available from two 
separate public datasets. These datasets included data from patients treated 
with various NAET regimens where microarray analyses were performed on 
samples before and after treatment. Figure 6.2.1C shows the increase in 
ABCG2 transcript expression post-NAET relative to pre-NAET expression 
levels. As a useful control, it was also shown that in patients who received no 






Figure 6.2.1: ABCG2/BCRP expression is increased in patients post-NAET 
(Baxter et al., 2018) 
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In A and B, fifty-one matched pre- and post-NAET breast tumour samples 
were stained for BCRP (clone BXP-21, Abcam) using 
immunohistochemistry. These tumours were from patients with primary 
breast cancer that had received NAET for a period of time between one 
month and one year. These patients received no other treatment. 
Expression of BCRP was quantified in tumour cells by weighted 
histoscores using a semi-automated protocol, validated previously (Kim et 
al., 2013a). (A) Representative images of matched pre- and post-NAET 
breast tissues showing stained BCRP (brown). (B) The left panel shows 
individual histoscores for pre- and post-NAET tissue samples with lines 
connecting matched samples. The red lines indicate increases in BCRP 
expression post-NAET and blue lines indicate decreases in BCRP 
expression. The right panel shows median histoscore values with 
interquartile range. Significance was assessed using the Wilcoxon signed 
rank test. (C) ABCG2 (transcript) expression was assessed using 
microarray expression arrays in matched pre- and post-NAET breast 
cancer samples in two separate cohorts. In the Edinburgh cohort, fifty-five 
patients were treated with the endocrine therapy letrozole. The change in 
ABCG2 expression was assessed after two weeks and three months of 
treatment relative to pre-treatment expression levels. In the Houston 
cohort, ninety-four patients were treated with aromatase inhibitors (no 
information as to which) and change in ABCG2 expression was assessed 
after two weeks relative to pre-treatment expression levels. ABCG2 
expression was also assessed in thirty-seven matched diagnostic biopsy 
and surgical excision samples from patients with breast cancer who did 
not receive any neoadjuvant therapies (no T). ABCG2 expression in post-
NAET samples is shown relative to pre-NAET samples as log2-fold 
changes, with red and blue circles indicating up- or down-regulation for 
individual samples respectively. The median change in expression is 
shown by the black line, the boxes show the upper and lower quartiles 
and the whiskers show 1.5x the interquartile range. Significance of 
changes in expression was assessed using paired Wilcoxon tests. This 
figure was used in accordance with rights retained by the authors of this 
article from the publishers, Elsevier. 
6.2.1 Specific objectives 
There were three key objectives in the work described in this chapter: 
1. To determine whether increased expression of BCRP in response to 
endocrine therapy could be replicated in vitro using the anti-oestrogen 4-
hydroxy-tamoxifen and an appropriate cell line. 
2. To determine whether pre-treatment of an ER positive cell line with 4-




3. To determine whether treatment with 4-hydroxy-tamoxifen leads to an 
altered cell cycle profile that could explain any altered chemosensitivity 
rather than it relating to changes in BCRP expression. 
6.3 Results 
6.3.1 BCRP expression is up-regulated post-tamoxifen treatment in 
an ER positive breast cancer cell line 
BCRP expression has previously been shown to be significantly increased 
post-neoadjuvant endocrine therapy (NAET) in tumours taken from a cohort of 
primary breast cancer patients with ER positive tumours (Figure 6.2.1) (Baxter 
et al., 2018). As the main aim of this chapter was to determine whether NAET 
leading to increased BCRP expression could potentially lead to increased 
chemoresistance, the first objective was to identify a cell line that reproduced in 
vitro the up-regulation of BCRP seen in patients post-NAET. Therefore, the ER 
positive cell line T47D was treated with 4-hydroxy-tamoxifen (TAM), an agent 
that competitively binds the oestrogen receptor, inhibiting its activation and 
BCRP expression was investigated post-treatment at different timepoints. This 
form of tamoxifen is the more biologically active form of the drug. 
6.3.1.1 BCRP expression is up-regulated post-tamoxifen treatment within 
24 hours and is maintained for several days 
The ER positive cell line T47D was initially treated with 1µM TAM for a period 
of up to 24 hours. At various timepoints, protein was extracted for analysis of 
BCRP expression by western blot (Figure 6.3.1). BCRP expression was 
increased even after only 4 hours of TAM treatment and continued to increase 
over time to approximately 2.5 times more than in the control sample after 
seventeen hours of exposure to the drug. These results confirmed that BCRP 
expression was increased in the presence of TAM in T47D cells and therefore 





Figure 6.3.1: BCRP expression is up-regulated post-TAM treatment over a 
24 hour period 
T47D cells were treated once with 1M TAM (or vehicle control) and 
protein was extracted at the indicated timepoints. Western blots were 
performed, probing for BCRP or beta-actin used as a loading control. 
BCRP was quantified relative to actin using Image Lab software three 
separate times for each blot. One representative western blot is shown in 
the left panel, with an accompanying graph in the right panel showing 
means of three separate quantifications (+/- standard deviations). 
A second ER positive cell line was also tested. MCF7 cells were treated with 
TAM using the same method as with the T47D cells. However, BCRP 
expression decreased after 4 hours of TAM treatment and slowly returned back 
to the original levels after 24 hours of TAM treatment (Figure 6.3.2). As no 
increase in BCRP expression was observed in these cells, further experiments 





Figure 6.3.2: BCRP expression is not up-regulated post-TAM treatment 
over a 24 hour period 
MCF7 cells were treated once with 1M TAM (or vehicle control) and 
protein was extracted at the indicated timepoints. Western blots were 
performed, probing for BCRP or beta-actin used as a loading control. 
BCRP was quantified relative to actin using Image Lab software three 
separate times for each blot. One representative western blot is shown in 
the left panel, with an accompanying graph in the right panel showing 
means of three separate quantifications (+/- standard deviations). 
Next, BCRP expression in T47D cells was also analysed up to four days after a 
single dose of TAM to determine whether the rapid increase in expression seen 
previously was sustained. A similar increase in BCRP expression was 
observed to that observed over a twenty-four hour period and it was sustained 

















Figure 6.3.3: Up-regulated BCRP expression was maintained up to 4 days 
post-TAM treatment 
T47D cells were treated on Day 0 with 1M TAM (or vehicle control) and 
protein was extracted once a day. Western blots were performed, probing 
for BCRP or beta-actin used as a loading control. BCRP was quantified 
relative to actin using Image Lab software three separate times for each 
blot. One representative western blot is shown in the left panel, with an 
accompanying graph in the right panel showing means of three separate 
quantifications (+/- standard deviations). 
6.3.1.2 ABCG2 mRNA and protein expression are up-regulated post-daily 
TAM treatment for up to fifteen days 
Patients who are administered tamoxifen receive a daily oral dose of the drug 
(Clarke et al., 1998, Davies et al., 2011). Therefore, to replicate these 
conditions in vitro, T47D cells were treated daily with either of two different 
doses (1 or 5µM) of TAM for a period of up to fifteen days. ABCG2 (transcript) 
and BCRP (protein) expression were analysed by RT-qPCR and western blots 






Figure 6.3.4: Daily TAM treatment for fifteen days increases ABCG2 
mRNA and protein levels 
T47D cells were treated with either 1 or 5M of TAM (or vehicle control) 
every twenty-four hours for fifteen days. Total RNA and protein were then 
extracted and analysed by RT-qPCR (A) or western blot (B) respectively, 
with beta-actin used for normalisation. (A) Data represent means of three 
biological repeats (+/- standard error); *p<0.05. (B) One representative 
western blot is shown in the left panel. The accompanying graph in the 
right panel shows means of two biological repeats (+/- standard error); 
*p<0.05. 
Both ABCG2 mRNA and BCRP protein expression were significantly up-
regulated. This coincides with observations in patients administered NAET 
(Figure 6.2.1) (Baxter et al., 2018). The T47D cell line was therefore an 
appropriate model cell line that could be used for subsequent tests 
investigating the effect of this BCRP up-regulation on chemosensitivity. 
6.3.2 Pre-treatment with TAM leads to increased resistance to 
subsequent chemotherapy 
Having observed in section 6.3.1 that daily treatment of T47D cells with TAM 
for a period of fifteen days led to increased expression of BCRP, 
chemosensitivity assays were performed on these treated cells to determine 
whether they had become more resistant to chemotherapy – as might be 
predicted with increased expression of a chemoresistance-associated 
xenobiotic pump. Cells were treated with 1 or 5µM of tamoxifen daily for fifteen 
days as before. TAM was then removed and cells were cultured for twenty-four 
hours in fresh (drug-free) media before being assessed in chemosensitivity 
assays. Two concentrations of the chemotherapy drug epirubicin were used to 
treat these cells for twenty-four hours, and an MTT assay was performed to 































































Figure 6.3.5: T47D cells pre-treated with TAM were more resistant to 
chemotherapy 
T47D cells were treated daily for fifteen days with either 1 or 5M of TAM 
(or vehicle control) before being treated with the chemotherapy drug 
epirubicin at either 2.6M or 10M (or vehicle control) for twenty-four 
hours. Cell viability assays were then performed. The left panel shows one 
biological repeat (data represent means of three technical replicates +/- 
standard deviation). The right panel shows means of two biological 
repeats (+/- standard error), normalising to survival in the control without 
tamoxifen to allow focus on the effect of tamoxifen pre-treatment (*p< 
0.05). 
T47D cells were more resistant to epirubicin when pre-treated with TAM. In 
addition, the higher dose of TAM appeared to confer a higher degree of 
chemoresistance, which correlates with the higher induced levels of BCRP 
seen previously (Figure 6.3.4). 
6.3.3 Pre-treatment with TAM does not significantly alter the cell 
cycle profile 
Pre-treatment with TAM leads to T47D cells having increased expression of 
BCRP (Figure 6.3.4) and becoming more resistant to chemotherapy (Figure 
6.3.5). While this is an association, it does not demonstrate a causal link. One 
alternative possible explanation for the resistance observed would be that it 
could be attributed to an altered cell cycle profile induced by TAM – in 
particular, tamoxifen can induce reduced proliferation (Sutherland et al., 1983, 
Osborne et al., 1983). This may be especially important in this context if there 
is a significantly altered proportion of cells in the S phase as the 
chemotherapeutic drug epirubicin induces cell death by causing DNA damage, 
thus primarily affecting cells during DNA replication (Bell and Dutta, 2002). 
























































cycle profiles of the cells were analysed by propidium iodide (PI) staining and 
flow cytometry (Figure 6.3.6). 
 
Figure 6.3.6: TAM did not induce significant alterations in proportions of 
cells in different cell cycle stages 
T47D cells were treated daily for fifteen days with 5M of TAM (or vehicle 
control). Cells were then stained with PI and analysed by flow cytometry. 
Data were analysed using the ModFit LT software (Verity Software House) 
to determine the proportions of cells in each stage of the cell cycle. Data 
represent means of two biological repeats (+/- standard error). 
There were no significant alterations in the cell cycle profile of T47D cells pre-
treated with TAM when compared with control cells, with no suggestion of a 
difference in proportions in S phase – the cycle stage targeted by epirubicin. 
Taken in this context, these results suggested that an alteration in the cell cycle 
profile was unlikely to be the direct cause of the chemoresistance observed in 
pre-treated cells and it is therefore possible that the up-regulation of BCRP 
post-tamoxifen treatment may indeed be the cause behind this 
chemoresistance. 
6.4 Discussion 
6.4.1 Oestrogen and anti-oestrogens influence ABCG2/BCRP 
expression 
Neoadjuvant endocrine therapy is becoming more commonly used in the 
treatment of a subset of patients with ER positive breast cancers. However, 
there is as yet no evidence of there being any consequences on the sensitivity 
of remaining cancer cells to adjuvant chemotherapies. BCRP, a xenobiotic drug 
































chemotherapeutic drugs (Staud and Pavek, 2005). Previous work had shown 
that in a statistically significant number of patients treated with NAET, there is 
increased expression of this drug pump (Figure 6.2.1) (Baxter et al., 2018). 
This means there is certainly a possibility that these patients would not respond 
optimally to adjuvant chemotherapy if administered. 
I treated an ER positive cell line, T47D, with the anti-oestrogen tamoxifen to 
observe initially whether the up-regulation of BCRP could be replicated in vitro 
in order to perform subsequent chemosensitivity assays. This was successfully 
achieved even after only twenty-four hours after treatment and was maintained 
after daily exposure to tamoxifen for a period of fifteen days. This suggests that 
lack of oestrogen signalling somehow leads to increased expression of BCRP, 
which is certainly possible as putative EREs have previously been identified in 
the promoter region of the ABCG2 gene (Ee et al., 2004, Zhang et al., 2006). 
Similar increases in BCRP expression have previously been observed in the 
absence of oestrogen signalling. In a study that included the ER positive breast 
cancer cell lines T47D, which I have used in my study, and MCF7, BCRP 
expression was found to be down-regulated in response to oestrogen. This 
decrease in BCRP expression was reversed by tamoxifen. This study 
concluded that the down-regulation of BCRP by oestrogen occurred post-
transcriptionally (Imai et al., 2005). However, there is also conflicting evidence 
from other studies that have shown the opposite effects of oestrogens and anti-
oestrogens on ABCG2 and/or BCRP expression. In one such study where 
T47D were also used as in my study, expression of ABCG2 was found to be 
increased in the presence of 17β-oestradiol, which was reversed in the 
presence of 4-hydroxy-tamoxifen (Ee et al., 2004), the same anti-oestrogen 
that I have used. Similarly, both ABCG2 transcript and BCRP protein levels 
increased in response to 17β-oestradiol in MCF7 cells. This effect was 
abolished in the presence of tamoxifen. The ERE in the promoter region of the 
gene and the presence of the alpha isoform of the ER were found to be 
essential for the transcriptional activation of ABCG2 by 17β-oestradiol (Zhang 
et al., 2006). Following on from this study, the anti-oestrogen toremifene was 
found to lead to decreased expression of both ABCG2 transcript and BCRP 
protein in MCF7 cells (Zhang et al., 2010). Taken together, all of these studies 
suggest that the regulation of ABCG2 transcript and protein expression is 
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complex and can differ depending on culture conditions. This complexity has 
previously been commented on (Bailey-Dell et al., 2001, Nakanishi and Ross, 
2012) with work still ongoing in attempting to understand the regulation of this 
gene. These conflicting data may explain why in my initial experiments treating 
cells with TAM for 4-24 hours, the MCF7 cells did not show an increase in 
BCRP expression. 
It is important to note that all of the work presented in the studies above was all 
performed on cell lines in vitro, with no mentions made of observing the effects 
of anti-oestrogens in the treatment of breast cancer on ABCG2 and/or BCRP 
expression in patients, on which my study was based (Baxter et al., 2018). In 
this context, it may be worth emphasising that the regulation I see in vitro 
mirrors that in patients and may therefore be more representative. 
6.4.1.1 Other mechanisms of BCRP expression regulation 
The ABCG2 gene also has three peroxisome proliferator-activated receptor 
response elements (PPARE) (Szatmari et al., 2006) and a progesterone 
response element (PRE) (Wang et al., 2008). In a study investigating the 
effects of progesterone on BCRP expression in human placental BeWo cells, 
progesterone increased expression of this protein (Wang et al., 2006). In this 
same study, oestrogen decreased expression of BCRP. In a very similar study 
investigating the effects of oestrogen and progesterone on BCRP expression in 
BeWo cells, the opposite results were obtained: progesterone decreased 
expression of BCRP and oestrogen increased expression (Yasuda et al., 
2006). It is evident from these two studies that regulation of BCRP expression 
is a complex process that likely is dependent on numerous factors. 
MiRNAs have also previously been shown to regulate BCRP expression. As 
mentioned previously, miR-487a has been shown to regulate expression by 
targeting the 3’UTR, thus influencing the chemosensitivity of ER positive breast 
cancer cells (see section 1.4.3) (Ma et al., 2013). In a colon cancer cell line, 
miR-519c was also observed to target the 3’UTR of the ABCG2 transcript, 
leading to translational repression and eventual degradation of the mRNA (To 
et al., 2008). MiR-328 has been reported to target BCRP in ER positive breast 
cancer cells (Pan et al., 2009) and miR-520h regulates BCRP expression in 
pancreatic cancer cells (Wang et al., 2010). 
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6.4.1.2 Investigating correlations between ABCG2 expression and other 
oestrogen-regulated genes in breast tumours treated with 
endocrine therapies could clarify the regulation of ABCG2 
expression in vivo 
Previous work shown in Figure 6.2.1 (Baxter et al., 2018), together with the in 
vitro work I have performed, demonstrated increased ABCG2 transcript and/or 
protein expression post-endocrine therapy. These observations however, do 
not demonstrate a direct mechanism of endocrine therapies regulating BCRP 
expression. The Edinburgh dataset used in the analysis shown in Figure 6.2.1C 
(Baxter et al., 2018), consists of gene expression profiles of tumour samples 
taken from ER positive primary breast cancer patients, before and after 
treatment with the endocrine therapy letrozole (Miller et al., 2009). A similar 
study, the Functional Aromatase Inhibitor Molecular Study (FAIMoS), was also 
conducted, in which patients were treated with the endocrine therapy 
anastrozole, with and without the addition of the EGFR inhibitor gefitinib (Smith 
et al., 2007). In a subsequent study performed by Gao et al. using samples 
from the FAIMoS, gene expression profiles were investigated pre- and post-
anastrozole only therapy (Gao et al., 2014). It would therefore be possible 
using these datasets, to assess correlatations between ABCG2 expression and 
oestrogen-regulated genes in order to gain understanding into the mechanisms 
by which endocrine therapy affects the expression of ABCG2 in patients. 
The gene TFF1 is an oestrogen-responsive gene that is frequently expressed 
in breast tumours (Prest et al., 2002). As such, TFF1 expression would be 
expected to be down-regulated in response to endocrine therapies. With the 
observations made of increased BCRP expression post-endocrine therapy in 
Figure 6.2.1, together with my in vitro work, a negative correlation between 
TFF1 and ABCG2 would be expected. It is important to note, however, that 
despite TFF1 being considered an oestrogen-responsive gene, it has been 
observed in vitro that in the presence of tamoxifen, a small increase in TFF1 
expression occurred in MCF7 breast cancer cells (Kuske et al., 2006), rather 
than the expected decrease. In addition, an increase in expression of both 
TFF1 and ABCG2 was observed in tamoxifen resistant MCF7 cells compared 
with parental cells (Zheng et al., 2018). These results suggest the possibility 
that the regulation of TFF1 expression is not simply dependent on the presence 
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of oestrogen. Therefore, any correlation between TFF1 and ABCG2 expression 
would need to be treated with caution. 
Another oestrogen-responsive gene is that encoding PR (gene name PGR). A 
negative correlation between PGR and ABCG2 expression would again support 
the hypothesis of endocrine therapies inducing ABCG2 expression. However, 
as with TFF1, any correlation must be treated with caution, as a positive 
correlation between PGR and ABCG2 expression has previously been 
observed in untreated primary breast tumour samples (Burger et al., 2003). 
PDZK1 and GREB1 are also oestrogen-responsive genes (Xue et al., 2019) 
that have been observed to overexpressed in ER positive breast cancers 
compared with ER negative breast cancers (Ghosh et al., 2000). As oestrogen-
responsive genes, a negative correlation between the expression of ABCG2 
and PDZK1 and GREB1 individually would be expected. This would support the 
hypothesis that endocrine therapies induce ABCG2 expression. This 
expectation is supported by previous observations made of the expression of 
both PDZK1 and GREB1 being reduced in the presence of tamoxifen in vitro 
(Ghosh et al., 2000, Kim et al., 2013b). 
6.4.2 Increased BCRP expression post-tamoxifen treatment causes 
increased resistance to chemotherapy in breast cancer 
6.4.2.1 A regimen of NAET followed by adjuvant chemotherapy is very 
rare in the treatment of breast cancer 
In this study, I have shown that post-tamoxifen treatment, expression of both 
ABCG2 transcript and BCRP protein are increased compared with cells that 
were not pre-treated. I have also shown that cells pre-treated with tamoxifen 
are more resistant to chemotherapy treatment with epirubicin than their non-
treated counter parts. Unfortunately, assessing whether this observation is 
relevant clinically is difficult because the administration of tamoxifen in the 
neoadjuvant setting followed by adjuvant chemotherapy treatment is not 
standard practice in the treatment of ER positive breast cancer, although it is 
used fairly rarely. Indeed, from the initial patient cohort in which increased 
BCRP expression was observed post-NAET that my study was based on, of 
the fifty-one patients, only six received adjuvant chemotherapy. Therefore, no 
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studies have been performed to compare the outcomes of patients treated with 
NAET followed by adjuvant chemotherapy versus similar patients treated with 
adjuvant chemotherapy alone. However, with NAET becoming a more 
commonly used treatment regimen for post-menopausal patients (Chia et al., 
2010, Chiba et al., 2017), an increase in the proportion of patients treated with 
NAET followed by adjuvant chemotherapy is probable. It is therefore important 
- in future - to determine whether this therapy regimen is safe to use. 
Unfortunately, even when suitable patient cohorts are available, the follow-up 
time required for outcomes is likely to be sufficiently long that it will be many 
years before a clear answer is available. 
6.4.2.2 Increased BCRP expression causes decreased sensitivity to 
chemotherapy 
BCRP has previously been shown to be induced by neoadjuvant chemotherapy 
(NAC) and that these post-NAC expression levels predict disease free survival 
(Kim et al., 2013a). In this study, patients were treated with a regimen 
consisting of anthracyclines with or without taxanes. A more expansive study 
revealed that there was a correlation between higher BCRP expression and 
poor clinical outcomes. In this study, it was observed that when classifying 
tumour subsets into either high or low expressions of BCRP, the high 
expressing subset had a much shorter time of progression free survival than 
the low expressing group, but only if treated with anthracycline-based therapies 
(5-fluorouracil, epirubicin and cyclophosphamide) and not when treated with 
cyclophosphamide, methotrexate and 5-fluorouracil (Burger et al., 2003). This 
observation of different treatment regimens leading to different clinical 
responses highlights the fact that each treatment regimen should be 
investigated individually with respect to tumour responses as each treatment 
regimen has the potential to cause unique responses. 
The basis of my study was that previous work had shown an increase in BCRP 
expression following NAET (Baxter et al., 2018). No other such studies have 
previously been performed. There are however, a large number of studies that 
have confirmed that increased BCRP expression leads to increased 
chemoresistance. BCRP was first identified in MCF7 cells resistant to 
doxorubicin and verapamil when it was noticed that the two transporters known 
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previously to confer multi-drug resistance, P-glycoprotein and MRP1, were not 
involved (Doyle, 1998). Subsequent studies confirmed the role of BCRP in 
conferring resistance to the chemotherapeutic agent mitoxantrone in the 
placenta (Allikmets et al., 1998) and in a colon cancer cell line (Miyake et al., 
1999). Since these initial studies, BCRP has also been found to confer 
resistance to several other chemotherapeutic drugs including topotecan and 
SN-38 (Yang et al., 2000). Importantly, epirubicin, the chemotherapy drug that I 
used in this study to determine if cells pre-treated with tamoxifen were more 
resistant to chemotherapy treatment than their untreated counterparts, is also a 
substrate of BCRP (Brangi et al., 1999). It is therefore possible that the 
resistance to epirubicin displayed by the cells pre-treated with tamoxifen in my 
study is mediated by the increase in BCRP expression that occurs as a 
consequence of the tamoxifen treatment. 
6.4.2.3 Changes in cell cycle profile post-TAM treatment do not 
contribute to chemoresistant phenotype 
Anthracyclines, such as epirubicin, the chemotherapeutic drug used in this 
study, function by inhibiting topoisomerase II (Zunino and Capranico, 1990). 
Topoisomerase II enzymes function by creating transient breaks in both strands 
of DNA in order to allow the strands to unwind so that processes such as DNA 
replication and transcription can occur (Nitiss, 2009a). If topoisomerase II 
enzymes are inhibited for example by anthracyclines, the DNA can no longer 
unwind and replication cannot occur, thus inhibiting cell cycle progression. DNA 
replication occurs during the S phase of the cell cycle (Bell and Dutta, 2002). 
Therefore, a possible mechanism of resistance to epirubicin of cells after pre-
treatment with tamoxifen other than an increase in drug efflux by BCRP is that 
tamoxifen could cause fewer cells to be in S phase. This would mean that 
fewer cells would require topoisomerase II activity, thereby resulting in fewer 
active targets of epirubicin, resulting in fewer cells being affected by the 
chemotherapeutic drug and an apparent resistant phenotype. 
Previous studies have shown that treatment with tamoxifen causes reduced 
rates of proliferation of ER positive breast cancer cells (Sutherland et al., 1983, 
Osborne et al., 1983). However, the majority of these experiments have been 
performed with MCF7 cells. Evidence has shown that there can be marked 
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differences between these two ER positive cell lines such as different functional 
protein expression profiles (Aka and Lin, 2012) and differences in responses to 
oestrogens and anti-oestrogens (Karey and Sirbasku, 1988, Radde et al., 
2015). This is despite the fact that both cell lines are representative of luminal 
A-type breast cancers (Holliday and Speirs, 2011). Not only do different cell 
lines display differences, but different culture conditions have also been shown 
to give rise to different responses to drug treatments in the same cell lines 
(Reddel et al., 1985). Interestingly, it has been observed that in the absence of 
oestrogen, MCF7 cells increase expression of the ER whereas T47D cells 
decrease expression of the ER in the absence of oestrogen (Sweeney et al., 
2012). 
All the apparent differences between cell lines and within cell lines perhaps 
explain why despite previous studies showing reduced cell proliferation with 
fewer cells in S phase and a greater proportion of cells in the G0/G1 phases, I 
did not observe any significant differences in cell cycle profiles between those 
cells treated with TAM and those that were not treated. Therefore, since my 
results suggested TAM did not induce any changes in the cell cycle profile, it is 
unlikely that the chemoresistance observed in cells pre-treated with TAM was 
due to fewer cells being in the cell cycle phase most affected by the 
chemotherapy drug. Coupled with the increase in ABCG2 transcript and BCRP 
protein expression post-TAM treatment, these data suggest that the increased 
chemoresistance observed post-TAM treatment is potentially due, perhaps in 
part, to the increased expression of the xenobiotic drug transporter BCRP. 
6.4.2.4 Investigating a correlation between ABCG2 expression and 
response to endocrine therapies would indicate whether 
increased ABCG2 expression is a marker of poor prognosis 
As mentioned in section 6.4.1.2, gene expression profiles of primary breast 
tumour samples before and after endocrine therapy are available from the 
Edinburgh and FAIMoS datasets (Miller et al., 2009, Gao et al., 2014). In the 
Edinburgh study, tumour size was also measured during therapy, and patients 
were determined to be either good or poor responders based on whether there 
was a minimum of a 50% reduction in tumour size or not post-therapy (Miller et 
al., 2009). In the FAIMoS, Ki67 was measured before and after therapy, with 
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patients who had an increase in Ki67 of more than 10% post-therapy classed 
as poor responders (Smith et al., 2007). As such, correlations between ABCG2 
expression and outcome could be performed to determine whether increased 
ABCG2 expression is associated with a poor prognosis, as would be expected 
based on work presented in this chapter. However, it is important to note that 
neither the Edinburgh or FAIMoS studies reported on whether patients were 
administered adjuvant chemotherapy, which is the scenario posited in this 
chapter. Therefore, while ABCG2 expression could be correlated with response 
to the endocrine therapies, it could not be correlated with response to 
subsequent chemotherapies. 
6.4.3 Conclusions 
Previous work has shown that BCRP expression was increased in patients 
post-NAET (Baxter et al., 2018). I have successfully replicated this 
phenomenon using the ER positive cell line T47D and the anti-oestrogen 
tamoxifen. Subsequent chemotherapy treatment demonstrated increased 
resistance to this second therapy compared with non-pre-treated cells. 
Therefore, it is possible that the increase in BCRP expression post-tamoxifen 
treatment causes this increased chemoresistance. These results suggest that a 
regimen of NAET followed by adjuvant chemotherapy should be administered 
to patients with caution, and outcomes following this regimen should be 




Chapter 7: General discussion and conclusions 
7.1 The molecular mechanisms of chemoresistance in breast 
cancer 
Resistance to systemic therapies, in particular cytotoxic chemotherapy, poses a 
major obstacle to the successful treatment of breast cancer due to a number of 
factors. The first is that systemic therapies have the benefit of targeting tumour 
cells in most areas of the body simultaneously, rather than being focused to 
specific body sites at one time. This is particularly advantageous in the 
treatment of sub-clinical micro-metastases, which cannot be specifically 
targeted using local therapies when they have not yet been detected. This 
inability to detect sub-clinical micro-metastases remains an ongoing problem 
(Pantel et al., 2009). The second factor specific to cytotoxic chemotherapy is 
that this treatment option is the only fully-established choice of systemic 
therapy for certain primary breast tumours, such as those of the triple negative 
subtype, which lacks expression of any proteins targeted by the common 
targeted therapies (Foulkes et al., 2010). It is also the only choice for those 
tumours in the metastatic setting, that were previously treated with targeting 
drugs and that developed resistance (Reinert and Barrios, 2015). In such 
cases, if resistance to the cytotoxic chemotherapy arises, no alternative types 
of systemic therapy exist, other than different classes of chemotherapy drugs, 
which may not work if the tumour has developed multi-drug resistance 
(Zahreddine and Borden, 2013).  
However, it is important to note that newer targeted therapies have been 
developed and may soon be approved for primary breast cancer, potentially 
providing alternatives to cytotoxics. For example, CDK4/6 inhibitors have 
recently been approved for the treatment of metastatic, ER positive breast 
cancers in combination with endocrine therapy (Pernas et al., 2018), and the 
PARP inhibitor olaparib was recently approved by the FDA for the treatment of 
BRCA-mutated metastatic breast cancers (McCann and Hurvitz, 2018). It is, 
however, vital that we understand the molecular mechanisms of chemotherapy 
resistance in order that we may be able to identify not just novel drug targets so 
that resistance may be overcome or prevented, but also that we know which 
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successions of treatment regimens can be used successfully if resistance 
arises to the initial therapies. 
Numerous studies have demonstrated that resistance to cytotoxic 
chemotherapy is a result of numerous molecular changes, such as changes in 
the expression of miRNAs (Kutanzi et al., 2011), molecular pathway activity 
(Balko et al., 2012), and expression of xenobiotic drug pumps (Sharom, 2008). 
In this project, I have attempted to identify some of these molecular changes 
that contribute to chemoresistance during treatment of ER positive breast 
cancers with a cytotoxic chemotherapy regimen consisting of epirubicin and 
cyclophosphamide (EC). MiRNA and mRNA expression profiling was 
performed on samples taken from breast cancer patients both before and after 
neoadjuvant chemotherapy (NAC), who displayed only a partial response to the 
administered therapy, thus implying a degree of chemoresistance. Changes in 
mRNA expression that occurred during chemotherapy suggested that the 
activities of both the MAPK and the PI3K-AKT pathways were increased 
(Chapter 3, section 3.3.4.2). This result was in accordance with previous 
studies that demonstrated increased activity of these pathways in tumour cells 
resistant to chemotherapy (West et al., 2002, Leung et al., 2008, Igea and 
Nebreda, 2015). Three miRNAs were consistently dysregulated post-NAC 
(Chapter 3, section 0), with further investigations revealing expression of miR-
26b and miR-195 was associated with chemoresistance (Chapter 4, section 
4.3.1). Expression of these miRNAs had previously been associated with 
chemoresistance, although evidence was conflicting, with results suggesting 
that these miRNAs play specific roles in chemoresponse depending on context 
(Rui et al., 2010, Ujifuku et al., 2010, Yang et al., 2013, Liang et al., 2015). 
MiRNAs execute their function by manipulating gene expression post-
transcriptionally (Ambros, 2001). It would therefore follow that changes in 
miRNA expression lead to alterations in expression of their targets. REEP4  
was identified as a target of miR-26b, and SEMA6D was identified as a target 
of miR-195 (Chapter 5, section 5.3.3.1). REEP4 is a protein required for cell 
division (Schlaitz et al., 2013), whereas SEMA6D is a protein whose function 
has been linked with angiogenesis (Lu et al., 2016). While the first function 
relates directly to division and therefore DNA replication, a process that is the 
main target of the chemotherapeutic drug epirubicin (Nitiss, 2009b), the second 
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function also relates, albeit indirectly, to tumour growth as tumours require a 
blood supply to survive and grow (Tozer et al., 2005). 
Resistance to chemotherapy is not just a result of changes in gene expression 
that directly alter the effectiveness of the function of the drug. In order to 
perform their function, these cytotoxic drugs must first reach their targets. 
Increased expression of xenobiotic drug pumps whose substrates include 
cytotoxic drugs can pump these cytotoxic drugs out of the cells (Eckford and 
Sharom, 2009), thus preventing the drug from reaching its target. Increased 
expression of the xenobiotic drug pump BCRP was observed in patients 
following neoadjuvant endocrine therapy (NAET) (Baxter et al., 2018). This 
phenomenon was replicated in vitro, and resulted in an increase in 
chemoresistance following subsequent challenge with epirubicin (Chapter 6, 
sections 6.3.1 and 6.3.2). These results demonstrated that not only can 
cytotoxic chemotherapy drugs induce resistance to themselves by altering gene 
expression, but that targeted therapies such as endocrine therapies, can also 
induce resistance to cytotoxic chemotherapies. This leads back to the concept 
of multi-drug resistance (MDR), and the importance of knowing which 
successions of treatment regimens can be used successfully. The results in 
this thesis indicate that the efficacy of cytotoxic chemotherapy may be reduced 
if administered after endocrine therapy, and that this sequence of therapies 
should potentially be avoided. 
It is important to consider, however, that although I investigated increased 
BCRP expression in terms of endocrine therapy, previous studies have shown 
that not only is expression of the BCRP gene ABCG2 regulated by the 
presence of oestrogens (Ee et al., 2004, Zhang et al., 2006), it has also been 
shown to be targeted by miRNAs (Pan et al., 2009, Wang et al., 2010). With 
work presented here demonstrating altered miRNA expression contributing to 
chemoresistance being induced by cytotoxic chemotherapy, it is possible that 
ABCG2 expression, as well as that of other xenobiotic drug pumps, can also be 
induced by this form of systemic therapy. Indeed, the PI3K-AKT pathway, the 
activity of which was increased post-NAC in my work, and has previously been 
shown to confer resistance (West et al., 2002), has also been shown to be 
essential for the localisation of BCRP to the plasma membrane (Mogi et al., 
2003, Takada et al., 2005). It has also been shown that cytotoxic chemotherapy 
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drugs induced expression of the ABCG2 gene by demethylating the promoter 
(Bram et al., 2009). This resulted in a dramatic increase in transcription of this 
gene within twelve hours of treatment. 
Combining all results together, it is clear that resistance to cytotoxic 
chemotherapy is caused by multiple contributing factors, with therapies 
inducing changes in miRNA, mRNA, and xenobiotic drug pump expression, 
which in turn confer chemoresistance. This highlights the importance of 
understanding the molecular changes that occur during chemotherapy, so that 
we may be better able to treat breast cancer successfully by preventing and 
overcoming chemoresistance. This involves optimising treatment regimens, 
and knowing which therapies can be used successfully in second line 
treatments if resistance to the first line treatment develops. 
7.2 Novel targeted therapies for the treatment of 
chemoresistant breast cancers 
7.2.1 MiRNA-targeted therapies 
In this thesis, I have demonstrated that increased expression of miR-26b and 
miR-195 contribute to increased chemoresistance in ER positive breast cancer. 
It may therefore be beneficial to inhibit these miRNAs during chemotherapy 
treatment of these breast cancers, in order to potentially reduce this resistance. 
With the development of miRNA mimics and inhibitors used in vitro to 
manipulate miRNA expression in order to discover their functions, therapies 
targeting miRNAs also become potentially available. However, it was noted 
soon after the discovery of miRNAs as potential therapeutic targets that 
delivering these miRNA mimics and inhibitors in vivo to the correct locations 
was problematic (Bader et al., 2011, Braicu et al., 2019). This was due to a 
number of factors including the inherent nature of these mimics and inhibitors 
to be susceptible to nucleases, to be cleared by the kidneys, and to be taken 
up by target cells inefficiently. For this reason, numerous studies have 
investigated a number of potential delivery agents that could be used to 
transport these nucleotide sequences to their targets, as well as modifications 
to the sequences themselves.  
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As I have demonstrated in this thesis, some miRNAs have increased 
expression in cancer, and therefore require suppression. This can be achieved 
by antisense inhibition using synthetic oligonucleotides that have been modified 
so as to resist degradation, and to promote their uptake into cancer tissues 
(Esau, 2008, Lennox and Behlke, 2011). These anti-miRNA oligonucleotides 
(AMOs) primarily function by sterically blocking miRNA function. Second 
generation modifications involve the use of locked nucleic acids (LNAs) 
(Walayat et al., 2018). These nucleic acids have been modified such that a 
methylene bridge was formed between the 2’O and the 4’C atoms of the ribose, 
thus reducing the flexibility of the structure, effectively ‘locking’ it into a rigid 
conformation (Obika et al., 1997). These LNAs have been shown to increase 
the binding affinity of the AMOs to their target miRNAs, and are more resistant 
to nuclease degradation (Elmen et al., 2008). MiR-155 has been shown to have 
elevated expression in cutaneous T cell lymphoma (CTCL) (Ralfkiaer et al., 
2011). Preliminary results for a phase I clinical trial have been published in 
which patients with CTCL were included (Querfeld et al., 2016, Querfeld et al., 
2017). In this study, a LNA-modified AMO targeting miR-155 named MRG-106 
was used. Results so far have suggested that MRG-106 is well tolerated and is 
effective in reducing the effects of miR-155 over-expression. The most 
advanced LNA-modified AMO targets miR-122, also known as miravirsen 
(Janssen et al., 2013, van der Ree et al., 2016), which was successfully used in 
a phase II clinical trial. However, this trial was performed using patients with a 
chronic infection of the hepatitis C virus, rather than cancer. 
Increasing expression of specific miRNAs that are down-regulated in tumours 
could also be therapeutically beneficial. The delivery of miRNA mimics in the 
clinical setting is more developed than the delivery of inhibitors. However, such 
deliveries investigated have so far included the use of delivery agents. One 
such delivery agent involves the use of nanoparticles, of which there are many 
types (Farina et al., 2018). One of these involves the use of liposomes, which 
encapsulate the nucleotide sequences. These liposomes are largely composed 
of phospholipids, and greatly resemble cell membranes and are thus highly 
biocompatible (Bozzuto and Molinari, 2015). This also allows them to 
incorporate themselves into the cell membrane in order to deliver their 
contents. In order to minimise effects such as low specificity to cancer cells, as 
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well as off-target toxicity, surface modifications can be made such that the 
liposomes are targeted to cancer cells (Ganju et al., 2017). Such liposomes 
loaded with a miRNA mimic of miR-34 have successfully been used in a phase 
I clinical trial, which included patients who were diagnosed with one of many 
cancers, including hepatocellular cancer, pancreatic cancer and breast cancer 
(Beg et al., 2017). These liposomes were optimised to ensure the maximum 
possible time in circulation before degradation, and uptake of the contents into 
the target cells (Daige et al., 2014). This clinical trial was the first of its kind to 
successfully deliver a miRNA mimic using this formulation, named MRX34, to 
the desired target site in human patients (Beg et al., 2017). 
A second delivery agent involved the use of what were named TargomiRs, 
which are comprised of non-viable minicells loaded with a nucleotide sequence 
(MacDiarmid and Brahmbhatt, 2011, Lin et al., 2014). These minicells use a 
bacterially-derived system to deliver their contents into target cells. As with the 
liposomes mentioned previously, additions to the surface of these minicells are 
used for targeting to cancer cells. These minicells were successfully used in a 
phase I clinical trial which included patients with mesothelioma (van Zandwijk et 
al., 2017). A high proportion of mesothelioma patients have high expression of 
the epidermal growth factor receptor (EGFR) (Destro et al., 2006). For this 
reason, the TargomiR used in the clinical trial was coated with an antibody to 
EGFR, thereby targeting the minicells to the mesothelioma cells (van Zandwijk 
et al., 2017). The purpose of this clinical trial was to determine whether levels 
of miR-16 could be successfully restored, and the safe range of doses of these 
minicells that could be administered to patients. MiR-16 has a tumour 
suppressor function in mesothelioma, and has been observed to be frequently 
down-regulated (Reid et al., 2013). Results from this clinical trial were 
promising, and the possibility of additional studies using TargomiRs in 
combination with chemotherapy or immune checkpoint inhibitors was 
mentioned (van Zandwijk et al., 2017). 
Other methods have been proposed to deliver miRNA mimics and inhibitors 
efficiently to cancer cells, as well as other methods to inhibit miRNA function. 
These include miRNA sponges (Ebert et al., 2007), which are RNAs that 
contain multiple, tandem binding sites for the target miRNA, miR-masks (Wang, 
2011), anti-AMOs that bind the 3’UTR of target mRNAs, thus inhibiting binding 
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by the miRNA of interest, and adeno-associated viral (AAV) vectors (Kota et al., 
2009, Miyazaki et al., 2012), which contains the miRNA sequence conjugated 
with an expression plasmid, and is highly efficient in transducing these miRNA 
sequences into the target cell. However, these other methods have not yet 
reached the development stage where they can be tested in the clinical setting. 
7.2.2 BCRP-targeted therapies 
Since BCRP expression can be induced by both endocrine therapy (Chapter 6) 
and cytotoxic chemotherapy (Bram et al., 2009), and confers MDR (Allen and 
Schinkel, 2002), BCRP is a logical target for novel drugs that could be used to 
reverse chemoresistance (Doyle and Ross, 2003). Many drugs have been 
identified as potential inhibitors of this xenobiotic drug pump. 
Dofequidar fumarate was initially identified as a quinolone derivative that 
inhibited another of the ABC drug pumps, Pgp (Suzuki et al., 1997). It was used 
in a phase III clinical trial where patients with breast cancer were also treated 
with a chemotherapy regimen of cyclophosphamide, doxorubicin and 
fluorouracil (CAF) (Saeki, 2004). It was discovered that patients had significant 
improvements in disease free survival (DFS) and overall survival (OS) if they 
had not received prior therapies. In further in vitro and in vivo studies, 
dofequidar fumarate was used to treat chemoresistant side populations of cells, 
consisting of cancer stem-like cells, from several cancer types including breast, 
that over-expressed BCRP but not any other ABC drug pumps (Katayama et 
al., 2009). It was discovered that this drug suppressed the function of BCRP. 
When xenografts composed of irinotecan-resistant side population cells were 
treated with irinotecan together with dofequidar fumarate, tumour growth was 
significantly reduced as opposed to irinotecan treatment alone. These results 
suggest that dofequidar fumarate could also be used in combination with 
cytotoxic chemotherapy in the presence of BCRP over-expression. 
Lapatinib, a kinase inhibitor, is a HER2-targeting drug that has also been 
shown to inhibit BCRP function (Perry et al., 2010). In an in vitro study using 
several cancer cell lines including breast, significant synergy was observed 
when lapatinib was administered in combination with the cytotoxic 
chemotherapy drug SN-38, resulting in increased apoptosis. This increase in 
cell death was attributed to increased accumulation of SN-38 inside the cells. 
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Lapatinib was also shown to inhibit the efflux of a BCRP-specific substrate 
mitoxantrone. Two phase II trials investigating the combination of lapatinib with 
cytotoxic chemotherapy agents in ovarian, peritoneal and breast cancers did 
not show promising results however (Lin et al., 2011, Weroha et al., 2011). 
Excess toxicity was a major problem, and lapatinib showed only a limited ability 
to inhibit BCRP function. 
Other kinase inhibitors have also been identified as potential inhibitors of BCRP 
function. Sunitinib malate has been shown to target multiple tyrosine kinase 
receptors (Mendel et al., 2003). A phase III clinical trial was conducted to 
determine whether the addition of this drug to the chemotherapy regimen 
fluorouracil, leucovorin and irinotecan (FOLFIRI) would be beneficial in the 
treatment of metastatic colon cancer (Carrato et al., 2013). This trial had to be 
discontinued, however, due to severe adverse effects, including toxicity-related 
death. Available results demonstrated no beneficial effect of the addition of 
sunitinib malate to OS. A phase I/II trial of sorafenib in combination with 
irinotecan for the treatment of metastatic colon cancer and KRAS-mutated 
tumours did, however, show some promising results (Samalin et al., 2014).  
It seems although there are numerous potential BCRP inhibitors, the few that 
do reach the point of being tested in a clinical setting fail due to excess toxicity. 
As such, the search for inhibitors of the BCRP drug pump that can reverse 
chemoresistance is ongoing (Kathawala et al., 2017, Guo et al., 2018). It is 
possible, that as with miRNA-targeted therapies, BCRP inhibitors may be 
required to be delivered to cancer cells specifically, rather than be allowed to 
inhibit all BCRP pumps, as BCRP is expressed in a variety of healthy tissues 
that require this drug pump for normal function (Doyle and Ross, 2003). 
Previous BCRP inhibitors that failed in clinical trials, failed due to excess 
toxicity (Lin et al., 2011, Carrato et al., 2013), and it is possible that these 
toxicities may be prevented if the BCRP inhibitors were delivered specifically to 
cancer cells. 
7.2.3 Combining existing cytotoxic chemotherapies with novel 
targeting therapies 
When it was observed that HER2 expression played a significant role in the 
prognosis of breast cancer (Gschwind et al., 2004, Ross et al., 2009), HER2-
210 
 
targeted therapies were developed that significantly improved DFS and OS 
(Dent et al., 2013, Mendes et al., 2015). These HER2-targeted therapies were 
administered in combination with existing cytotoxic chemotherapy agents, as 
before the development of these agents, chemotherapy alone was still 
beneficial. This highlights the possibility of adding novel therapies to existing 
therapies to improve outcomes, creating additive or even synergistic effects. 
Since individual miRNAs do not cause tumour growth or chemoresistance 
alone, any miRNA-targeted therapies should be administered in combination 
with existing therapies.  
Preliminary studies have already been performed where miRNA-targeted 
therapy was combined with the cytotoxic chemotherapy agent paclitaxel to treat 
melanoma cells in a mouse model (Shi et al., 2014). In this study, miR-34a 
mimic was encapsulated in a lipid nanoparticle that also contained paclitaxel. 
These nanoparticles provided good protection for the miR-34a mimic and 
paclitaxel against degradation in serum. In vitro studies revealed this miRNA-
chemotherapy combination had a synergistic anti-cancer effect. In vivo studies 
showed a significant increase in inhibition of tumour growth and elimination of 
cancer cells present in the lung using the combination as compared to 
nanoparticles loaded only with paclitaxel. 
As demonstrated in section 7.2.2, all clinical trials investigating the effects of 
potential BCRP inhibitors were performed comparing cytotoxic chemotherapy 
alone with a combination of cytotoxic chemotherapy and the potential inhibitor. 
The benefit of improved efficacy of combination therapies is, however, 
accompanied by the disadvantage of more adverse side effects (Bergh et al., 
2001, Slamon et al., 2001, Beslija et al., 2003). It is therefore important that the 
correct combinations of therapies are used so as to limit adverse effects and 
maximise positive outcomes. This leads back to the importance of knowing the 
molecular changes that are induced by different therapies so that we have a 
better understanding of which combinations would be most effective. 
7.3 Conclusions 
In this thesis I have discovered several molecular mechanisms that contribute 
to chemoresistance. In particular, I identified miRNAs, miR-26b and miR-195, 
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that enhance chemoresistance, but I failed to identify the specific molecules 
downstream of these that cause these functional effects. Nevertheless, the 
miRNAs themselves present potential therapeutic targets. I also determined 
that increased expression of the xenobiotic drug pump BCRP induced by 
endocrine therapy, also confers chemoresistance, highlighting the concerns 
about the sequence of therapies of endocrine therapy followed by 
chemotherapy. In summary, it is clear from my results that resistance to 
chemotherapy is a result of multiple molecular changes that all contribute to 
overall resistance, and that novel miRNA and BCRP targeting therapies could 





Appendix A: Recipes 
A.1 Cell lysis buffer for pulldown experiment 
• 20mM Tris (pH7.5) (93362; Sigma; St Louis, USA) 
• 200mM NaCl (S3014; Sigma; St Louis, USA) 
• 2.5mM MgCl2 (M8266; Sigma; St Louis, USA) 
• 0.05% Igepal (I8896; Sigma; St Louis, USA) 
• Add fresh: 60U Superase-In RNase Inhibitor (AM2694; Ambion; Foster 
City, USA), 1mM DTT (D1532; Invitrogen; Carlsbad, USA), 1mM PMSF 
(36978; Thermo Fisher; Waltham, USA) 
A.2 Laemmli sample buffer (4x) 
• 9.6ml 1M Tris-HCl (93363; Sigma; St Louis, USA) 
• 3.2g SDS (436143; Sigma; St Louis, USA) 
• 116ml glycerol (BP229-1; Fisher Scientific; Hampton, USA) 
• 11.2ml water 
• Pinch of Bromophenol blue (ICNA04805732; VWR; Radnor, USA) 
• Add fresh on the day: 0.2M DTT (D1532; Invitrogen; Carlsbad, USA) 
A.3 RIPA buffer 
• 10mM Tris-HCl pH8.0 (93363; Sigma; St Louis, USA) 
• 140mM NaCl (S3014; Sigma; St Louis, USA) 
• 0.1% SDS (436143; Sigma; St Louis, USA) 
• 1% Triton X-100 (T8787; Sigma; St Louis, USA) 
• 0.1% sodium deoxycholate (89904; Thermo Fisher; Waltham, USA) 
• 1mM EDTA (E6758; Sigma; St Louis, USA) 
• 0.5mM EGTA (E3889; Sigma; St Louis, USA) 
• Add fresh on the day: 1mM PMSF (36978; Thermo Fisher; Waltham, 






A.4 Scott’s tap water 
• 20g sodium bicarbonate (S5761; Sigma; St Louis, USA) 
• 3.5g magnesium sulphate (MX0075; Sigma; St Louis, USA) 
• Make up to 1l 
A.5 Tris-Buffered Saline (10x) + 0.1% Tween-20 (TBST)  
• 60ml 2.5M NaCl (S3014; Sigma; St Louis, USA) 
• 20ml 1M Tris-HCl (93363; Sigma; St Louis, USA) 
• Make up to 1l 
• Check pH 7.5 




Appendix B: Commands used for analysis of RNA-Seq data 
using DESeq 
> library (“Rsubread”) 
> library (“DESeq”) 
 
> input_files <- 
c(“BAM files”) 
 
> Design <- data.frame(condition = c(“1”, “2”, “C”), 
test1= c(“y”,”n”,”y”), test2= c(“n”,”y”,”y”)) 
 
For comparing 1 target miRNA sample with control sample: 
> test2 = Design$test2 == ”y” 
> countTable2 = fc$counts[ , test2] 
> condition = factor( c(“biotin”,”scrambled”)) 
> cds2 = newCountDataSet(countTable2, condition) 
> cds2 = estimateSizeFactors(cds2) 
> sizeFactors(cds2) 
> head( counts(cds2, normalized=TRUE)) 
> cds2 = estimateDispersions(cds2, method=”blind”, 
sharingMode=”fit-only”) 
> res3 = nbinomTest(cds, “biotin”, “scrambled”) 
> write.csv(res3, file=”B2vsCon.csv”) 
> res3 = nbinomTest(cds2, “biotin”, “scrambled”) 




Appendix C: Quality assessments of RNA extracted from 









Figure C.1: Graphs showing range of nucleotide fragment lengths of 
RNA extracted from test FFPE samples 
RNA was extracted from three other FFPE tumour samples; one from a 
biopsy samples (A) and two from resection samples (B and C). The 
RNA was run on the Agilent 2200 TapeStation using the High 
Sensitivity RNA ScreenTape to determine average lengths of RNA 
fragments extracted from tissues stored as FFPE samples. The size of 
the fragments are shown on the x-axis and the quantity of fragments 




Appendix D: MiRNAs consistently changed in all five patients 
that did not meet the thresholds for fold change 
Table D.1: MiRNAs consistently deregulated post-NAC that did not meet 
the minimum or maximum thresholds for fold change in all patients 
MiRNA Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
let-7c 1.708 2.759 1.989 1.147 1.941 
miR-26a 1.718 1.18 2.83 1.544 2.686 
miR-330 1.695 1.328 1.112 1.822 >30* 
miR-335 3.147 4.941 1.156 1.547 >120* 
miR-362 1.683 1.031 1.266 2.85 >100* 
miR-483-5p 7023.331 3.336 1.127 2.27 19.93 
miR-493 >880* >110* Not detected >40* >30* 
miR-885-5p >870* 1.144 42.026 2.686 >20* 
miR-625 27.755 1.237 1.102 4.038 >10* 
miR-365 -1.18 -1.47 -4.03 -1.19 -1.66 
MicroRNAs that were consistently deregulated post-NAC across all five 
patients were identified. A minimum threshold for the fold change for each 
individual patient of 1.3 was chosen for up-regulated miRNAs and a 
maximum threshold for fold change for each individual patient of -1.25 
was chosen for down-regulated miRNAs. Fold changes marked as 
‘>number*’ are where the miRNA was not detected in the pre-NAC sample 




Appendix E: Quality assessments of library-prepared 
samples for RNA-Seq 















Figure E.1: Graphs showing populations of library prepared samples 
Library-prepared samples were analysed using the Agilent 2200 
TapeStation using the High Sensitivity DNA ScreenTape to ensure that 
only library cDNA fragments were present in the samples and no primer 
dimers were present. The x-axis shows fragment length (nucleotides) and 
the y-axis shows abundance. The ‘lower’ and ‘upper’ peaks at 25nt and 
1500nt are markers used as internal references. The left panels show 
libraries prepared from total RNA extracted from cells that did not undergo 
the pulldown process (input) and the right panels show libraries prepared 
from RNA extracted following the pulldown process (pulldown). A and B 
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